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Abstract
Conventional treatment of locally advanced non-small cell lung cancer patients
with concomitant chemo-radiation achieves poor tumor local control rates and
strongly affects the patient outcome. Although it appears essential to implement
dose intensification strategies, this remains challenging due to the proximity
of highly radiosensitive organs, which may result in unacceptable toxicities.
A potential solution would be to escalate the dose in restricted areas within
the tumor identified as potentially radio-resistant, by functional imaging (FDG-
PET), and using high conformal radiation treatment delivery and optimized tumor
motion management. This concept mainly requires an accurate definition of the
target volumes in order to spare healthy tissues. In this context, we validated a
gradient-based segmentation method for primary lung tumor definition on FDG-
PET imaging by comparison with surgical specimens. Then, in a clinical trial, we
assessed how an individualized and non-uniform es...
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mity of highly radiosensitive organs, which may result in unacceptable toxicities. 
A potential solution would be to escalate the dose in restricted areas within the 
tumor identified as potentially radio-resistant, by functional imaging (FDG-PET), 
and using high conformal radiation treatment delivery and optimized tumor 
motion management. This concept mainly requires an accurate definition of the 
target volumes in order to spare healthy tissues. In this context, we validated 
a gradient-based segmentation method for primary lung tumor definition on 
FDG-PET imaging by comparison with surgical specimens. Then, in a clinical trial, 
we assessed how an individualized and non-uniform escalated dose based on 
FDG-PET images would affect the tumor local control and the radio-induced 
toxicities. Finally, we investigated the tumor motion caused by breathing and 
studied the feasibility of the mid-position strategy in helical radiation treatment 
for lung tumors. 
La radio-chimiothérapie concomitante est le traitement de choix pour les patients atteints de 
cancer bronchique localement avancé non à petites cellules.  Cependant, le taux de récidive 
locale après un tel traitement reste élevé et affecte négativement le pronostic de ces patients. 
Bien que les stratégies d’intensification de dose paraissent essentielles, celles-ci sont limitées 
par la proximité des organes sains. Par conséquent, une augmentation de la dose sur une partie 
restreinte de la tumeur, identifiée par l’imagerie fonctionnelle FDG-PET, associée à une prise en 
charge optimale du mouvement tumoral, pourrait améliorer le contrôle tumoral local tout en 
limitant les toxicités. Cette approche nécessite une délimitation rigoureuse des volumes tumo-
raux afin d’épargner les tissus sains. C’est dans ce contexte que ce travail, scindé en trois phases, 
s’inscrit. Nous avons d’abord validé une méthode de délimitation automatique des tumeurs 
pulmonaires basée sur les gradients d’intensité dans les images FDG-PET par comparaison avec 
les pièces chirurgicales de lobectomie. Ensuite, dans le cadre d’une étude clinique, nous avons 
évalué l’impact d’une augmentation individualisée de la dose guidée par l’imagerie FDG-PET 
sur le contrôle tumoral local et sur les toxicités radio-induites. Enfin, nous avons étudié le mou-
vement tumoral lié à la respiration et intégré une stratégie, nommée mid-position, dans la pla-
nification du traitement des tumeurs pulmonaires, délivré de manière hélicoïdale.
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General introduction 
1. Epidemiology 
In Belgium, lung cancer is the second most frequent malignancy in males and the third 
in females [1], with 6783 and 2349 new cases diagnosed in 2012, respectively. It is the 
leading cause of cancer death in males and the second in females. More than half of the 
patients die within the first year after diagnosis [2]. Currently, lung cancer remains a 
major health issue due to its high incidence and its extremely poor prognosis.  
Radiotherapy (RT) holds an important place in the treatment of non-small cell lung 
cancer (NSCLC) patients. About two third of patients will receive a radiation 
treatment at least once during the course of their pulmonary illness [3].  
Due to the limited symptoms, lung cancer is mostly diagnosed at locally advanced 
stages (stage II-III, see TNM table in appendix A) and in these inoperable cases, the 5-
year overall survival is as low as 5-15%. Concurrent chemo-radiotherapy (CRT) is the 
standard treatment for inoperable or locally advanced (LA) NSCLC. However, local 
recurrence (i.e. at the primary tumor site) still occurs in about one third of patients 
even with conventional schemes [4-7]. 
2. Radiobiology   
Currently, the conventional treatment of LA stage NSCLC includes a cisplatin-based 
chemotherapy delivered concomitantly with definitive thoracic radiotherapy with a 
dose of 60 Gy in 2 Gy fractions once daily [6-8]. One of the general principles of 
radiotherapy relies on the quantitative description of the relationship between the 
delivered dose and the cell death rate. The sigmoid dose-response curve, originating 
from theoretical, experimental, and clinical data, predicts the tumor control 
probability (TCP) for a given dose. Based on this, it seems obvious to increase the dose 
to the tumor in order to limit local recurrence. However, dose escalation is rapidly 
limited by the organs at risk (OARs) surrounding the tumor. This is depicted by the 
therapeutic index, which is the ratio between the TCP and the normal tissue 
complication probability (NTCP). This ratio can be enhanced in a number of ways, 
using biological and/or physical factors, shifting either the TCP curve to the left (radio 
sensitization) or the NTCP curve towards the right (radioprotection), to gain in terms 
of tumor control while keeping toxicities as low as possible (Figure 1.1).  
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Figure 1.1 The principle of the therapeutic ratio with the green curve representing the tumor 
control probability (TCP) and the red curve illustrating the probability of normal tissue 
complication (NTCP). In an ideal radiation treatment, the TCP is maximized while the NTCP is 
minimized. However, the TCP curve is shallower than the NTCP curve. Consequently, it is essential 
to use biological and/or physical factors, in order to shift either the TCP curve to the left (radio 
sensitization) or the NTCP curve towards the right (radioprotection), to gain in term of tumor 
control while keeping toxicities as low as possible. From dkfz.de. 
Martel et al. have estimated that for NSCLC patients, the dose required to achieve a 
significant probability of tumor control (> 50%) might be as high as 84 Gy for longer 
local progression free survival (> 30 months) with standard fractionation [9]. Many 
studies have thus focused on dose escalation and on the various ways to improve the 
therapeutic index.  
Chemotherapy has been proposed since years in association with radiotherapy. The 
radiobiological benefit of concomitant CRT would stem from the inhibition of tumor 
cell proliferation by drugs during the radiation inter-fraction interval rather than from 
other identified mechanisms of interaction, i.e. modulation of deoxyribonucleic acid 
(DNA) and chromosome damage and repair, cell-cycle synchronization, enhanced 
induction of apoptosis and re-oxygenation. Several randomized trials associating RT 
and chemotherapy have been conducted and a recent meta-analysis has demonstrated 
the superiority of the concomitant CRT over the sequential one in locally advanced 
NSCLC [7]. The 5-year overall survival (OS) increases from about 10% in the 
sequential arm to 15% in the concomitant arm. Interestingly, this survival gain has 
been mainly attributed to an improvement in local tumor control.  
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The overall treatment time (OTT) over which the RT is given is also an important 
determinant of outcome. Machtay et al. have demonstrated that prolonged treatment 
time is significantly associated with poorer survival, even in concomitant CRT [10]. 
Therefore, accelerated fractionation, which is defined as an increase of the average 
dose per week above 10 Gy, given in conventional fractionation, can be used. 
Shortening the OTT may overcome tumor rapid repopulation, which takes place after 
3 to 4 weeks of radiotherapy, and corresponds to clonogenic doubling times of 3 to 3.5 
days [11]. Although early normal tissue reactions are expected to increase when using 
such a scheme, late normal-tissue damage is expected to remain constant, assuming 
that recovery from sub-lethal radiation damage between fractions is complete.  
Altered fractionation schemes that deviate from the classical 2 Gy per fraction, 5 days 
a week, have also been tested. Hyper-fractionation is the use of a reduced dose per 
fraction being delivered several times per day during a classical OTT. The therapeutic 
advantage stems from the difference in fractionation sensitivity between tumor cells 
and late-responding tissues. In clinical practice, the tumor total dose (TTD) is often 
escalated compared to classic treatment, improving tumor control rates without 
increasing the risk of late complications.  
The CHART trial combined both strategies, comparing continuous hyper-fractionated 
and accelerated RT (total tumor dose of 54 Gy, 36 fractions, thrice a day, in 12 
consecutive days) versus conventional RT (60 Gy, 2 Gy per fraction) and 
demonstrated the gain of accelerating and hyper-fractionating the treatment in terms 
of survival and local tumor control [12]. Despite the lower total dose, the 2-year 
survival was increased from 21% in the conventional arm to 30% in the CHART arm. 
Exploratory analysis revealed that this was a consequence of improved local tumor 
control. 
Hypo-fractionation is the term used for doses per fraction higher than 2 Gy with a 
reduced total number of fractions. Moderate hypo-fractionation with doses per 
fraction up to approximately 3.5 Gy is more and more used for curative radiation 
therapy. Although the TTD often needs to be decreased to avoid severe late normal 
tissue toxicities, the TCP remains quite similar thanks to the shorter OTT. There is 
growing interest in moderate hypo-fractionation for dose escalation clinical trials. 
Indeed, this scheme is convenient for the patient and helps to spare resources. 
A refinement of these concepts is the prescription of an individualized dose according 
to normal tissue dose constraints, in association with either acceleration or hyper- or 
hypo-fractionation of the treatment. The MAASTRO clinic developed such a strategy 
by delivering the highest achievable radiation dose to a patient based on localization, 
tumor size, and dose-limiting OARs, sequentially or concomitantly with 
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chemotherapy. Planning results were particularly promising in term of TCP (up to 
30% higher) while first clinical results demonstrated the feasibility of an 
individualized hyper-fractionated and accelerated scheme [13-16].  Another clinical 
study confirmed the gain in survival for stage III NSCLC patients, particularly for 
concomitant CRT with an Individualized Isotoxic Accelerated RT (INDAR) [17]. 
However, INDAR is obviously more expensive and less convenient than once-daily 
fractionation. Individualized, accelerated, and moderately hypo-fractionated RT 
should be investigated in clinical trials as dose escalation with such a scheme could 
potentially lead to late toxicities, even though better local control and survival can be 
achieved. 
3. Concepts of volumes in radiotherapy 
A successful RT relies on subsequent steps in the patient preparation and treatment 
planning. It is by nature a localized treatment and requires first accurate diagnosis 
imaging and invasive procedures (e.g. bronchoscopy, EBUS/EUS, mediastinoscopy) to 
define the exact location and extent of the tumor. After a complete staging 
determining the indication of a RT, the radiation therapy team plans the treatment in 
a process called simulation, including a careful immobilization of the patient 
(thermoplastic thorax mask), a thorough imaging planning as three-dimensional (3D) 
and four-dimensional (4D) computed tomography (CT) and marks ensuring the 
reliably alignment and position for each treatment session. Then, the most crucial step 
of the planning is the exact definition of target and non-target volumes, as discussed 
below. Eventually, dosimetrists or physicists determine the optimal beam energy and 
arrangements to best conform the tumor, preserving the OARs. 
In order to provide a standardized terminology, the International Commission on 
Radiation Units and Measurements (ICRU) published some recommendations about 
volumes in radiotherapy [18] (Figure 1.2). 
The Gross Tumor Volume (GTV) is the gross demonstrable extent and location of the 
tumor defined using clinical examination and/or multimodality imaging. 
The Clinical Target Volume (CTV) is a volume of tissue that contains a demonstrable 
GTV and/or subclinical malignant disease with a certain probability of occurrence 
considered relevant for therapy.  The notion of subclinical malignant disease includes 
the microscopic tumor spread at the boundary of the primary-tumor GTV, the possible 
regional infiltration into lymph nodes, and the potential metastatic involvement of 
other organs (e.g. brain), despite their normal appearance on clinical and radiological 
examinations.  The selection of the tissues that bear risk for microscopic infiltration 
outside of the GTV is a probabilistic assessment integrating the biological and clinical 
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behavior of the various tumor entities and the knowledge of the surrounding 
anatomy, including structures that are barriers to tissue infiltration (e.g., muscular 
fascia, bone cortex), or—on the contrary—structures that are easy conduits for tumor 
dissemination (e.g., fatty space). 
The Internal Target Volume (ITV) might be useful only in clinical situations in which 
uncertainty concerning the CTV location dominates setup uncertainties and/or when 
they are independent. An internal margin must thus be added to the CTV to 
compensate for expected physiologic movements and the variations in size, shape and 
position of the CTV during therapy related to anatomic reference points. The ITV, 
encompassing the CTV and internal margin, is considered as an optional tool in 
helping to delineate the PTV. 
The Planning Target Volume (PTV) is a geometrical concept introduced for treatment 
planning and evaluation. It is the recommended tool to shape absorbed-dose 
distributions to ensure that the prescribed absorbed dose will actually be delivered to 
all parts of the CTV with a clinically acceptable probability, despite geometrical 
uncertainties such as organ motion and setup variations. It is also used for absorbed-
dose prescription and reporting.  
The Organs at risk (OARs) or critical normal structures, i.e. non-target tissues, are 
structures sensitive to irradiation, included, at least partially, in the irradiated volume. 
They might influence the treatment planning in the aim of limiting toxicities.  
The Planning organ at Risk Volume (PRV) is a geometrical concept, i.e. a margin 
applied around serial OARs to compensate for uncertainties and variations in the 
position of the OARs during treatment, using a similar principle as for the PTV. 
 
 
 
 
 
 
 
Figure 1.2 ICRU 62.        
From Purdy et al., Semin. 
Radiat. Oncol., 2004. 
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Thoracic radiation therapy limitations 
1. Organs at risk  
1.1. Generalities 
In lung cancer, the main OARs are healthy lungs, spinal cord, esophagus, brachial 
plexus, heart, large vessels, and main bronchi.  
Despite the technical improvements in treatment planning and delivery, all target 
volumes (TVs) necessarily include a substantial amount of normal tissue. Whereas the 
Clinical and Planning Target Volumes (CTV and PTV) encompass almost exclusively 
normal parenchymal cells, even the Gross Tumor Volume (GTV) encloses blood 
vessels and normal connective tissue. Healthy tissues within the TVs are thus 
unavoidably exposed to the tumor prescribed dose while the remaining normal tissue 
(i.e. outside the TVs) receives less but potentially significant dose, depending on 
physical parameters used in treatment planning and delivering. 
Organs comprise a number of functional subunits (FSUs), i.e. units of cells that can be 
regenerated from a single surviving clonogenic cell. The clinical damages depend on 
the arrangement of the FSU, either in parallel or in series like in an electrical circuit, 
within the exposed organ. In parallel organized tissue (e.g. lungs), a critical number of 
FSU must be damaged before loss of function becomes manifest. Consequently, 
potential toxicities depend on the dose distribution throughout the whole organ 
rather than the maximum dose to a small area. In contrast, in serial organs (e.g. spinal 
cord), failure of only one FSU can cause loss of function of the entire organ. The risk of 
complications is strongly influenced by “hot spots” rather than by dose distribution 
within the organ. 
Generally, toxicities are described as early or late according to the latency time, 
respectively less or more than 90 days, of symptoms appearance after the start of the 
treatment. Early radiation effects, which develop in turnover tissues, are dominated 
by vascular and inflammatory changes as well as by hypoplasia. The latency time of 
early effects is largely independent of dose, while severity and duration are dose-
dependent. In contrast, late radiation effects involve an interactive response of 
parenchymal cells, vascular endothelium, fibroblasts and macrophages in association 
with cytokine cascade, which lead to parenchymal damage and loss of function within 
the irradiated organ. The latency time of late reactions is inversely dependent on dose. 
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For years, many studies have addressed the issue of radio-induced toxicities after RT 
for NSCLC and have tried to define some reproducible predictors of acute and late 
effects related organs. Some of them are presented in the following sections. 
1.2. Lungs 
In lungs, early pneumonitis is usually observed at 4-6 weeks after the end of RT, while 
fibrosis develops after several months to years. Rodrigues et al. demonstrated that the 
ideal parameter for estimation of the NTCP for pneumonitis from dose-volume 
histogram (DVH) has not been identified yet [19]. Nonetheless, some parameters, such 
as the percentage of total lung volume irradiated with defined doses (i.e. 5Gy, 10Gy, 
13Gy or 20Gy) [15, 20-25] are currently used while the mean lung dose (MLD), which 
does not include any critical-volume parameter, appears to be correlated well with the 
incidence of pneumonitis [26]. The European Organization for Research and 
Treatment of Cancer (EORTC) recommends keeping V20Gy below 35-37% and MLD 
lower than 20-23 Gy [27]. Some authors have also suggested to adapt lung constraints 
according to pulmonary function, i.e. the forced expiratory volume in one second 
(FEV1) and the diffusing capacity (DLCO) [15].  
1.3. Spinal cord 
Acute radio-induced myelopathy, revealed by the Lhermitte sign, occurs 
approximately 10 to 16 weeks after RT and is probably due to transient demyelination 
lesions. Its evolution is favorable with regression of symptoms after a few months to 
more than a year. It may occur at doses as low as 35 Gy in 2 Gy per fraction, i.e. well 
below usual admitted tolerance, particularly when long segments of cord are 
irradiated. On the contrary, the late myelopathy develops months to years after the 
irradiation. This complication is rare but extremely severe and is associated with a 
poor prognosis (i.e. sensitive, motor and sphincter disorders). Two main syndromes 
are described. The first, occurring 6-18 months after RT, is mostly limited to 
demyelination and necrosis of the white matter, whereas the second, occurring 1 to 
more than 4 years after RT, is mostly a vasculopathy. The main risk factors are the 
TTD as well as the dose per fraction received by the spinal cord. Surprisingly, spinal 
cord still presents a volume effect for irradiation of very short lengths (<1cm) while it 
is less pronounced for lengths above 2cm, i.e. the spinal cord tolerates a high radiation 
dose as long as few millimeters are irradiated. This suggests the migration of 
surviving clonogenic cells to the edge of the irradiated field, explaining also the partial 
repair of RT-induced subclinical damage after several years. The clinically accepted 
maximum tolerance dose for spinal cord is approximately 50 Gy, given in 2 Gy per 
fraction, even if it is probably too conservative. Indeed, using conventional 
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fractionation, the estimated risk of myelopathy is <1% and <10% at 54 Gy and 61 Gy, 
respectively [28]. 
1.4. Esophagus 
The symptoms of severe esophagitis (≥ grade3) typically occur 4-8 weeks from the 
start of RT. Late esophageal damage, i.e. stricture and dysphagia, develops 3-8 months 
after the end of RT. Concurrent chemotherapy or hyper-fractionation increases the 
rate of severe acute esophagitis up to 30% [29, 30]. The most robust dosimetric 
parameter might be the mean esophagus dose (MED), with less than 15% esophagitis 
of grade ≥ 3 for MED below 28 Gy [29]. In addition, consistent data demonstrated that 
esophagitis of grade ≥ 2 increased to more than 30% as V70 exceeds 20%, V50 exceeds 
40% and V35 exceeds 50% [29, 31]. Any hot spot should also be avoided, especially in 
the era of IMRT. Nonetheless, exceeded esophagus constraints should not prevent the 
patient from receiving a curative intent CRT because esophagitis of grade 3 or 4 
usually heals rapidly without late effects (<1%) [27]. 
1.5. Heart 
Radiation damage to the heart can involve the pericardium, myocardium, valves, and 
coronary vessels. The latency of RT-associated cardiac effects ranges from months 
(pericarditis and arrhythmia) to decades (coronary artery disease or myocardial 
infarction). The risk of cardiac events is probably related to both dose and irradiated 
volume. Pericarditis is the most common cardiac effect and it is generally 
asymptomatic although approximately in 20% of cases it develops into chronic 
and/or constrictive pericarditis. Radiation-induced cardiomyopathy, such as 
congestive heart failure, is increased by the additional exposure to anthracycline-
based chemotherapy. Late damage to the pericardium and myocardium is 
characterized by diffuse interstitial fibrosis, perivascular fibrosis and loss of 
cardiomyocytes. Perfusion myocardium defects are detected as early as 6-24 months 
after RT and their incidence is strongly correlated with the volume of the left ventricle 
exposed in the RT field. Most perfusion defects are encompassed within an isodose 
line of 45Gy in the RT plan [32, 33]. Importantly, even though endothelial dysfunction 
is the primary pathological cause of the radio-induced coronary artery disease, other 
cardio-vascular factors such as age, smoking and hyperlipidemia appear to act as 
accelerating factors [33, 34]. Radiation can also impair aortic and mitral valves but 
most of the time, lesions are asymptomatic. The heart conduction system is the least 
commonly involved. One of its serious manifestations is complete atrio-ventricular 
block with required pacemaker implantation.  
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Most of the data concerning cardiac toxicities come from RT in breast cancer or 
lymphoma. In the field of lung cancer, where an increased rate of heart disease has 
been observed [34], dose-volume data are scarce and arise only from retrospective 
analysis. Especially, RTOG 0617 and IDEAL CRT trial demonstrated some evidence of 
negative association between overall survival and heart volume receiving more than 5 
Gy (V5Gy) and heart volume receiving doses of 65-75 Gy or left ventricule volumes 
receiving 1-5 Gy, respectively [35, 36]. Nonetheless, further studies are required to 
better understand the radiation effects on heart structures and to define reliable 
predictors of toxicities.  
1.6. Tracheo-bronchial tree and large vessels 
Tracheo-bronchial tree and large vessels are considered less radiosensitive than lung 
parenchyma. Even though no constraint has been applied to these organs in 
conventional treatment, bronchial stenosis or fistula with hemoptysis are becoming 
novel and often threatening recognized side effects. These mediastinal organs are 
particularly dose limiting in centrally located tumors treated with intensified dose 
strategies (stereotactic body radiation therapy or dose escalation). Several authors 
suggest a dose-relationship for radiation induced stenosis and fistula [37-39]. High-
dose RT appears to cause a fibrosing mediastinitis with extrinsic compression of 
airways, which develops as early as 2 months and up to several years after RT. The 
EORTC recommends keeping doses to the central bronchi below 80Gy in conventional 
concurrent CRT [27]. 
1.7. Brachial plexus 
Brachial plexus is a dose-limiting OAR for apex-located tumor. Symptoms of radiation-
induced brachial plexopathy are mainly pain together with sensitive and motor 
disorders; they appear usually 1 to 4 years after treatment, even if some of them can 
be diagnosed up to 20 years after treatment. Physiopathology reveals demyelination 
damages, microvasculature alteration, and fibrosis of surrounding tissues and of 
nervous structures themselves. The brachial plexus is considered as a serial organ, 
very sensitive to high doses per fraction. Based on old patient series and techniques, 
its classically tolerated dose is approximately 60 Gy [40]. However, Hall et al. have 
demonstrated that, in head and neck cancer radiation treatment, brachial plexus 
receives doses considerably higher than 60 Gy [41]. Actually, brachial plexus tolerance 
is difficult to assess due to uncertainties in location and organ delineation, as well as 
to the lack of DVH parameter data, especially for NSCLC treatment. 
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2. Tumor motion and other geometric uncertainties  
Geometrical uncertainties are inherent in any radiation treatment. Many factors can 
impact the precision of the radiation dose delivered. As previously discussed, 
radiotherapy includes several steps from the initial consultation and simulation to the 
daily treatment delivery. Each step involves some degree of potential error, usually on 
the order of a millimeter. But larger error can occur when most errors are in the same 
direction. This can affect the adequate coverage of the tumor, resulting in cold spots 
with potentially poorer LC or in unexpected dose and hot spots in surrounding normal 
tissue. Quantifying these uncertainties is a particular subject of concern in lung 
cancer, where the tumor moves during the breathing. Rigorous margins have thus to 
be chosen to ensure correct target dose coverage. 
2.1. Description of geometrical errors 
Geometrical uncertainties may jeopardize the radiation treatment. With IMRT, the 
impact of these uncertainties could be more severe compared to conventional 
treatment due to the better dose conformation. These potential geometric 
uncertainties and variations have to be assessed in order to measure their impact on 
dose to the CTV and to the OARs.  
They can be categorized in two groups: 
(1) The treatment execution error, random error or day-to-day variation, is 
different for each fraction but constant within a fraction. It is estimated by averaging 
one or more measurements made during a single fraction. Its uncertainty is computed 
by taking the standard deviation (SD) of this error over many fractions (σ). The 
sources of random uncertainties are setup error and organ motion on the treatment 
machine, poor reproducibility of the treatment machine, and errors in daily correction 
procedure [42].  
(2) The treatment preparation error, or systematic error, is different for each 
patient, but identical for all fractions of one patient. This error is estimated by 
averaging measurements made during multiple fractions of a single patient treatment. 
Its uncertainty is estimated by computing the SD of this error for many patients (Σ). 
The sources of systematic uncertainties are “frozen” setup error and organ motion on 
the planning CT image, artifacts on planning CT related to physiological motion, errors 
in CTV and OARs delineation, multi-modality registration errors, poor reproducibility 
of the planning procedure, and differences in patient anatomy between imaging and 
treatment [42]. 
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Tumor motion, baseline shift, and setup errors include both random and systematic 
components.  
Breathing consisting in the muscular contraction and relaxation of the diaphragm and 
intercostal muscles generates thoracic and abdominal motion. In the case of lung 
cancer, the parenchymal tumor moves with amplitude up to 2 cm, especially for 
tumors located in the lower lobe and for cranio-caudal motion direction [43, 44]. The 
trajectory of the tumor is usually not rectilinear and possible hysteresis can make it 
look like a loop. Moreover, motion does not only affect the primary lung tumor. 
Mediastinal and hilar lymph nodes, together with upper abdominal organs, also 
undergo the effects of motion. Consequently, respiratory motion can introduce 
significant uncertainties [45, 46] in the entire process of RT from imaging and 
treatment planning to daily treatment delivery. 
The baseline shift is an inter- and intra-fraction variation of the average tumor 
position relative to the bony structures (Figure 1.3 and 1.4). The physiologic process 
causing baseline variations are not well understood. Its potential shift seems to 
correlate with motion amplitude, suggesting it might be due to diaphragm motion, 
difference in stomach filling, stress status or heartbeat characteristics [47]. 
 
 
Figure 1.3 Intra-fraction baseline variation. The graph shows the average tumor position (red 
line) in the superior-inferior direction in function of time, notably between the different sequential 
beams of a radiation treatment. From Sydney.edu. 
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Figure 1.4 Illustration of the inter-
fraction baseline shift. The tumor has 
moved between fractions with respect 
to the bony anatomy. From Van 
Rooijen C. et al., IJROBP, 2012. 
 
 
  
 
 
The setup error corresponds to variations in patient positioning and alignment of the 
therapeutic beams during the treatment planning through all treatment sessions. The 
setup uncertainties depend on the patient-immobilization devices, the application of 
quality-assurance programs, the skill and experience of the technologists or nurses, 
and the use of image-guidance systems or other uncertainty-reduction techniques. 
The delineation step is by far the largest source of error (Figure 1.5). It depends on the 
radiation oncologist experience and appreciation, the tumor location (peripheral 
versus central), the planning CT image quality, the window level used for contouring, 
etc. Several studies have demonstrated the high rate of inter- and intra-observer 
variability in GTV delineation for NSCLC tumors [48-55]. 
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Figure 1.5 Inter-observer variability in lung tumor delineation. From Steenbakkers et al., IJROBP, 
2006. 
 
2.2. Effects of errors on the dose 
The treatment execution deviations lead to a blurring of the dose distribution (Figure 
1.6) while treatment preparation deviations lead to an unknown shift or sometimes 
more complex distortion of the cumulative dose distribution relative to the CTV 
(Figure 1.7).  
Systematic errors have more impact on dose distribution than random errors. 
Consequently, margins accounting for systematic errors are much larger than random 
error margins [42].  
Chapter 1 
34 
 
 
Figure 1.6 Effect of treatment execution errors. 
 
 
 
Figure 1.7 Effect of treatment preparation errors. 
 
2.3. CTV to PTV margin recipe  
The definition of safety margins around the visible tumor (GTV) and the microscopic 
invasion (CTV) is mandatory to include uncertainties and avoid deviation from the 
prescribed dose in the CTV. Van Herk et al. have proposed the dose-population 
histogram concept, which describes the probability for a patient in a population to 
receive a certain cumulative CTV dose [42]. Population-based margins concept stems 
from the fact that, even with Image Guided Radiation Therapy (IGRT) or even if they 
can be quantified, there will always remain uncertainties that cannot be corrected for 
individual patients, e.g. definition of TVs, unfeasibility of daily planning for dealing 
with tumor/anatomy changes or deformations. 
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The PTV margin is affected by each aforementioned error, i.e. variations in CTV 
position, size, shape and variations between patient and beam positioning, as well as 
by dosimetric uncertainties (i.e. penetration of the beam). 
Consequently, Van Herk et al. analytically computed probability distributions of the 
minimum cumulative CTV dose and then derived a margin rule [42]: 
 
 
 
where Σ and σ denote the standard deviations of the systematic and random errors, 
respectively. Subscripts TM, BL, SETUP, D and p refer to tumor motion, baseline shift, 
patient setup variability, delineation uncertainty, and penumbra width, respectively. 
The coefficients in the formula ensure that the CTV receives at least 95% of the 
prescribed dose for 90% of patients. The coefficient of the systematic errors 
determines the confidence level or the percentage of patient population properly 
treated with a given prescription dose. A confidence level of 90% is generally 
considered as acceptable. On the other hand, the coefficient of the random errors 
determines the minimal isodose covering correctly the CTV. As a minimum CTV dose 
of 100% of the nominal dose cannot be achieved and would require an infinite margin, 
one should define clinically acceptable probabilities for the clinical goal, and 95% 
seems a good compromise. In the formula, σp denotes the SD of the dose gradient or 
penumbra, for which Sonke et al. have suggested a value of 3.2 mm for a photon beam 
in the water and 6.4 mm in the lung [47]. 
The penumbra represents the region at the edges of a radiation beam, where the dose 
falls off rapidly, and is usually specified by the lateral width of isodose levels (e.g. 
90%-20%) (Figure 1.8). Related to scattered beam from tissues and treatment head, it 
is influenced by many factors, such as field size, depth, transmission through the jaws 
of the machine and energy of the beam. The penumbra contributes to blurring the 
dose distribution and can be harnessed in the computation of margins for random 
errors [56].  
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Figure 1.8 Isodose lines in the central plane (a) from an 80 SSD cobalt-60 beam and (b) from a 6 
MV linear accelerator. The penumbra is tighter for the 6 MV beam. From Handbook of 
radiotherapy physics, Theory and Practice, 2007. 
Importantly, as formalized in the equation above, the SDs of all treatment execution 
and preparation variations have to be squared before being summed because internal 
and external error sources are usually uncorrelated. 
Noteworthy, some simplifications have been introduced in the recipe and adjustments 
should be made accordingly. Actually, it was assumed that the patient population was 
homogeneous, that RT included many fractions, that CTV was spherical and that 
probability distributions were normal. In addition, tumor rotations and shape 
variations have been ignored, isotropic errors were used for computation, the 
different sources of errors were assumed to be statistically independent and a shift 
invariant dose distribution was considered [42]. Notwithstanding, the validity of the 
margin recipe for clinical plans was demonstrated using Monte Carlo (MC) simulation 
methods [57]. 
The PTV is probably not the only tool to allow sufficient dose coverage of the CTV. 
Indeed, margin recipes are well established for rigid motion but issues still remain 
when it comes to rotations, deformations, changes in biology, delineation errors and 
non-uniform dose. The integration of TCP and NTCP model parameters as well as 
geometric uncertainties directly in the optimization process could lead to better 
treatment plan [58]. 
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Improving the therapeutic index 
1. Better defining the targets 
As already mentioned, improving the therapeutic index involves intensification of the 
dose to increase the tumor control probability, while keeping toxicities as low as 
possible. However, this approach requires an accurate selection and definition of 
target volumes as a first step. 
1.1. Multimodality imaging for gross tumor volume definition 
1.1.1. CT imaging 
The main role of imaging in RT planning is to provide an accurate and reproducible 
delineation of the true tumor volume. Nowadays, CT is the reference imaging modality 
for the treatment planning of NSCLC. 
CT imaging is based on the fundamental principle that the differential attenuation of 
the X-ray beam by the various crossed tissues depends on the differences in tissue 
densities. Practically, the helical CT consists of an x-ray tube, a collimator and a 
receptor including several detectors. The X-ray tube rotates around the patient while 
the detectors measure the intensity of transmitted radiation (Figure 1.9). The 
transmitted intensity profiles obtained at different angles allow axial CT slices to be 
reconstructed. 
CT is widely available, conveys essential anatomical information, has a high spatial 
resolution (about 0.5 mm) and also gives information about the electronic density of 
the tissues allowing dose calculation in RT planning. Nevertheless, it offers poor soft 
tissue contrast between the primary tumor and the surrounding normal tissues. It can 
present artifacts due to metallic material, breathing motion (i.e. in lung or upper 
abdomen) or beam hardening when traversing thick and/or bony structures like the 
spine/ribs. These limitations could affect the actual definition of target volumes. 
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Figure 1.9 Principle of computed 
tomography. The table moves 
continuously as the x-ray source and 
detectors rotate, producing a helical 
scan. From Brenner DJ et al., NEJM, 
2007.  
1.1.2. FDG-PET imaging 
In that regard, positron emission tomography with the radiotracer [18F]-fluoro-deoxy-
glucose (FDG-PET) used in combination with structural imaging, such as CT, can 
improve this task by providing then a combination of anatomical and functional 
information about tumors. Currently, FDG-PET is used for tumor staging, tumor 
response prediction before treatment, tumor response assessment after therapy, and 
detection of early recurrence in NSCLC. In addition, FDG-PET has some advantages 
over CT. First, it offers higher sensitivity and specificity than CT for the detection of 
primary tumors and mediastinal lymph nodes. Second, FDG-PET modifies significantly 
the size, location, and shape of the primary GTV, leading to the opportunity of 
adapting treatment planning or patient’s management. Third, FDG-PET decreases 
dramatically the inter-observer variability of CT-based delineation, even when 
contouring protocols are available. Finally, with an appropriate radiotracer, PET 
allows potentially for the identification of tumor sub-volumes that are suspected of 
being radio-resistant, and could therefore beneficiate from dose escalation. 
1.1.2.1. Principle of PET 
The basis of PET is the injection of radiopharmaceuticals labeled with positron 
emitting radioisotopes allowing annihilation coincidence detection. The positron 
emitted from the nucleus of the radioisotope travels a short distance in a random 
direction before meeting with an electron from the tissue. Their annihilation produces 
two 511 keV photons, which are emitted in opposite directions at nearly 180° of each 
other. The almost simultaneous detection (in a short coincidence window) of two 
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annihilation photons by two opposite detectors defines a line of response (LOR) 
(Figure 1.10). The number of recorded coincidence events is proportional to the 
activity concentration. Parallel LORs from all angles are assembled into projections, 
which are then processed by iterative algorithms to reconstruct a 3D image that 
renders the distribution of the activity inside the patient. 
 
 
Figure 1.10 Positron emission, annihilation and creation of a line of response. From 
ANSTO.gov.au. 
1.1.2.2. PET features and limitations 
Accuracy of PET imaging depends on several physical factors. Some of them can be 
modeled in reconstruction; some others are taken into account by applying 
corrections on data prior to reconstruction. Imperfect corrections are potential 
limitations to image quality and jeopardize the interest of integrating PET into 
planning radiation treatment. 
 Erroneous LOR assignments stem from both scattered and random 
coincidence events. A scattered coincidence is produced when one (or both) 
of the detected photons deviates from its trajectory by Compton scattering 
prior to its detection, whereas a random coincidence is the detection of two 
photons that are not arising from the same annihilation event. These 
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unwanted coincidences lead to image contrast degradation and incorrect 
quantitation and their estimation adds statistical noise to the signal (Figure 
1.11). 
 
Figure 1.11 Types of coincidences. From depts.washington.edu. 
 Attenuation is caused by the loss of true events, i.e. loss of coincidences. It is 
related to scattering and absorption of photons in the imaged subject 
him/herself. This results in an inaccurate estimation of the tracer 
distribution. Attenuation correction is usually performed using an additional 
transmission scan to measure attenuation factors for a PET alone device 
(leading to increased noise in the image) or using the attenuation map of the 
CT for a combined PET/CT system (with potential bias in the resulting image, 
i.e. different energy and acquisition time between both imaging modalities). 
 Spatial resolution of PET images is by far lower that of CT images. It is 
estimated by measuring the point spread function (PSF), which describes the 
response of the imaging system to a point source, i.e. the signal intensity as a 
function of the distance. The PSF is distributed as a Gaussian function with the 
spatial resolution expressed as the full width at half maximum (FWHM) of 
this distribution (Figure 1.12). The spatial resolution of current PET systems 
ranges from 4 to 7 mm.  
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Figure 1.12 The spatial resolution of a PET image is estimated by measuring the point 
spread function, which describe the response of an imaging system to a point source. The 
PSF is distributed as a Gaussian function with the spatial resolution expressed as the full 
width at half maximum of this distribution. As shown, the smaller the FWHM, the better 
is the spatial resolution. 
 The partial volume effect (PVE) results from the poor spatial resolution of the 
PET image, which leads to blurred images. A secondary cause is the sampling 
of the radiotracer distribution in a voxel grid, also called the tissue fraction 
effect, i.e. the pixels covering the edges of the source measure a mixture of 
both source and background signals (Figure 1.13). The PVE affects the 
quantification of the activity in objects smaller than twice or thrice the FWHM 
of the system. In this case, part of the object signal spills out into surrounding 
areas and the object looks larger and dimmer than it is actually. 
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Figure 1.13 The partial volume effect affects the quantification of the activity 
distribution in an object. Especially, the measured image (D) of the activity distribution 
(A) results from a mixture of spilling out (B) and spilling in (C). Consequently, the 
measured image looks larger and dimmer than it is actually. From Soret et al. JNM, 2007. 
 The statistical noise is the random variation in the pixel intensity of the 
reconstructed image. Increasing the injected tracer dose to the patient, the 
acquisition duration or the detection efficiency can reduce the image 
statistical noise. It can also be reduced by image filtering, but at the cost of a 
reduced spatial resolution. However, even with all optimized features, the 
number of detected events is much lower than in CT imaging and 
reconstructed PET images suffer from high level of noise. 
 In combined PET/CT systems, breathing can generate artifacts since 
acquisition duration between PET and CT is different. As a result, structures 
located in the lower chest and the upper abdomen are acquired in a mean 
respiratory position during PET imaging or as a snapshot of a particular 
breathing position during CT. 
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1.1.2.3. Physiologic distribution of [18F]-FDG tracer  
In the field of oncology and radiation therapy planning, FDG is the most widely used 
tracer. [18F]-FDG is an analogue of glucose with the positron-emitting radioactive 
isotope fluorine-18 substituted for the normal hydroxyl group at the 2' position in the 
glucose molecule (Figure 1.14). After intravenous injection, FDG is distributed in the 
body like glucose. It is incorporated into the tumor cell via a glucose transport protein 
(i.e. mainly GLUT-1) and is phosphorylated by hexokinase. However, FDG cannot be 
further metabolized and is consequently trapped in cells. Tumor cells show an 
increased anaerobic glycolysis resulting in an up regulation of GLUT-1 and 
hexokinase, which together with physiologic trapping leads to an accumulation of 
FDG. This accumulation is affected by tumor blood flow, activity of glucose 
transporters and hexokinase, and by cellular glucose consumption. As a result, FDG is 
not a specific tracer of tumor cells detection, as it can also be detected in inflammatory 
cells, in normal brain tissue, muscles, myocardium, musculature of the bowel, brown 
fat tissue and, in urinary tract, when it is excreted. 
 
Figure 1.14 A radioactive label called fluorine 18 (18F) is produced in a cyclotron. The 18F replaces 
a hydroxyl group in the glucose molecule resulting in fluorodeoxyglucose. 
1.1.2.4. Standardized uptake value 
In clinical practice, the standardized uptake value (SUV) is commonly used for semi-
quantitative evaluation of the FDG uptake in tumors. It is calculated as follow: 
 
Nonetheless, this semi-quantitative index suffers from major simplifications. First, the 
temporal evolution of the FDG uptake and the unmetabolized FDG are neglected. 
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Second, it is assumed that normal tissue uses a quantity of FDG proportional to the 
patient weight, i.e. no distinction between lean body mass and body fat. Finally, the 
formula neglects glycaemia level and ignores the metabolic difference between 
glucose and FDG.  
Actually, the SUV provides an uptake index (i.e. not a measure of the glucose metabolic 
rate) and depends on many physiological, technical, and physical factors.  
The SUV can be significantly affected among other things by image noise, low image 
resolution, reconstruction algorithm, attenuation correction, the kind of PET scanner 
used, time point of acquisition, lean body mass, blood glucose concentration, and user 
biased region of interest (ROI) selection.  
Consequently, standardization of SUV is mandatory to compare measures performed 
in different centers. Protocols describing all aspects of the examination have been 
proposed, like patient preparation, tracer administration, dose standardization, image 
reconstruction and processing, guidelines for data analysis and standard quality 
control process [59]. 
FDG-PET/CT is being used increasingly to evaluate tumor response in addition to 
diagnosis and staging of tumors. The FDG uptake can be assessed visually or using a 
(semi) quantitative assessment, such as SUV (i.e. normalized to body weight) or SUL 
(i.e. SUV normalized to lean body mass (LBM)). Because large changes in body weight 
may occur during the course of the treatment, SUL should preferably be calculated 
alongside SUV, as follows: 
 
   
where LBM is calculated according to the formula of James et al. [60], i.e. 
  
 
and   
  
where BW is the body weight expressed in kilogram, while height is expressed in 
centimeter. 
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In the context of the evaluation of response to therapy, the extent and intensity of the 
FDG uptake have to be documented and compared to prior measurements. The EORTC 
firstly suggests the use of SUVmax as criteria for assessing tumor response [61]. 
Although SUVmax is widely used in clinical practice, easy to measure and less sensitive 
to PVE, it is strongly affected by statistical fluctuations since it is based on only one 
pixel. As a result, Wahl et al. proposed the so-called PERCIST criteria, using a 3D peak 
spherical volume of interest (VOI) of 1 cm3, centered on the pixel with the maximum 
value, i.e. SULpeak [62]. Reporting relative change in SUV or SUL during therapy 
represents the most robust parameter, classifying response into complete or partial 
metabolic response, and stable or progressive disease. 
1.1.2.5. Integration of PET in RT planning  
As already mentioned, conventional concomitant CRT for LA stages NSCLC achieves 
poor tumor local control rates. Available data support the dose intensification 
strategies. However, increasing the radiation dose in the whole target volume might 
potentially impair the surrounding healthy tissues. In that regard, functional imaging 
could help us to determine some sub-volumes suspected to be radio-resistant, which 
would require an additional radiation dose to obtain tumoricidal effect.  
The NKI and MAASTRO groups have demonstrated that FDG-PET can provide 
sensitive and accurate molecular information to guide selective boosting. 
Firstly, a high pre-treatment FDG uptake within the tumor correlates with poor tumor 
local control and survival [63-66]. Secondly, the high FDG uptake within the tumor 
remains at the same location during a course of RT or CRT [14]. Thirdly, the stable 
FDG uptake within the tumor is identifiable based on only one pre-treatment FDG-
PET/CT [64, 67, 68]. Finally, high FDG uptake voxels in the pre-treatment FDG-PET 
have a higher probability to contain residual metabolic disease after therapy. As a 
consequence, these areas could probably beneficiate from dose escalation [69].  
Although FDG-PET imaging seems to be a promising tool for guiding selective 
boosting, its integration in RT planning remains technically complex especially for the 
accurate definition of the tumor boundaries. Currently, several delineation methods 
have been suggested, relying mainly on either manual contouring [70-75] or 
automatic threshold-based segmentation [49, 74-94]. However, the main pitfalls for 
PET delineation stem certainly from the rather low resolution and signal-to-noise 
ratio of the images. Manual delineation is hindered by image blur, which can lead to 
inaccurate TV delineation. On the other hand, automatic threshold-based 
segmentation suffers from the fact that the optimal threshold depends on the size, the 
shape, and contrast to the background of the target, which are not known a priori or 
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difficult to estimate. In addition, theory shows that a threshold value can recover the 
true target boundary only if the target is spherical, the target and background activity 
are uniform, and the PSF isotropic and constant through the whole field of view; this is 
not the case in the reality. To overcome the inherent limitations of these approaches, a 
segmentation method that exploits the image gradient information has been 
developed in our lab. The gradient-based segmentation includes two main steps. First, 
a pre-processing step reduces statistical noise and resolution blur in order to sharpen 
the image gradient (Figure 1.15). Afterwards, the watershed transform algorithm 
detects the gradient magnitude peaks and generates the object contour (Figure 1.16). 
This method has been validated on both phantoms and head and neck cancer patients 
[95]. In NSCLC, the validation of this gradient-based segmentation technique on 
pathological specimens was still lacking.  
 
 
Figure 1.15 The image processing reduces statistical noise and resolution blur in order to sharpen 
the image gradient. 
 
Figure 1.16 The watershed transform algorithm detects the gradient magnitude peaks and 
generates the object contour (J. Lee). 
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2. Better defining and preserving OARs 
Usually, a classical predefined dose is prescribed for all LA NSCLC patients, i.e. 60 to 
66 Gy in 2 Gy per fraction once daily. This standard scheme leads to poor tumor local 
control and survival in a number of patients, who could tolerate higher dose without 
increasing toxicities. The MAASTRO clinic has suggested prescribing the dose based 
on normal tissue constraints instead of a classic predefined prescription. This 
individualized isotoxic strategy has been shown feasible [13-15, 96] and increases the 
fundamental therapeutic ratio. Moreover, prediction models for radiation-induced 
acute dysphagia and dyspnea have been proposed to assist in treatment decision-
making [97, 98].  
Although some OARs constraints are well defined, data are lacking or equivocal for 
some of them. In addition, analyzed data arise from 3D-CRT and classical 
fractionation. Few studies report risk of toxicity from hypo-fractionation schemes and 
no dose-volume based analyses have been published. We also need standardization to 
obtain coherent recommendations. First, OARs delineation is critical in daily practice 
as well as in clinical trials. Currently available atlases from RTOG, EORTC and SWOG 
may guide to define the OARs with less variation and generate more reliable and 
consistent dosimetric data [99]. Second, uniformity is required when using dosimetric 
parameters. Confusedly, the mean lung dose is defined on the basis of either the whole 
lungs volume or the lungs volume minus the GTV, minus the CTV or minus the PTV, 
which can lead to large variability in the assessment of lungs tolerance. Third, toxicity 
assessment should be based on only one standard international grading system. 
Finally, recommended and common dosimetric parameters as well as early and late 
toxicities should be registered and shared for the constitution of large international 
and multicenter database. 
The current recommended or used dosimetric parameters for each organ are 
presented in Table 1.1. 
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OARs Constraints  Values Authors 
Lungs MLD FEV1/DLCO>50% <19Gy Van Baardwijk et al. 
  FEV1/DLCO40-50% <15Gy Van Baardwijk et al. 
  FEV1/DLCO <40% <10Gy Van Baardwijk et al. 
   <20-23Gy EORTC and QUANTEC 
   <20Gy RTOG 0617, MAASTRO 
 V20Gy  <35-37% EORTC 
   < 37% RTOG 0617 
   <30% QUANTEC 
Esophagus MED  <28Gy EORTC and QUANTEC 
   <34Gy RTOG 0617 
 V70Gy  <20% QUANTEC 
 V50Gy  <40% QUANTEC 
 V35Gy  <50% QUANTEC 
   <80% MAASTRO 
Heart D100%  <30Gy  QUANTEC 
 D33%  <60Gy RTOG 0617 - Emami et al. 
 D66%  <45Gy RTOG 0617 - Emami et al.  
 D100%  <40Gy RTOG 0617 -  Emami et al. 
 Dmean  <46 Gy MAASTRO 
Pericardium Dmean  <26Gy QUANTEC 
 V30Gy  <46% QUANTEC 
Spinal cord Dmax  <54Gy EORTC 
   <50.5Gy RTOG 0617 
   <52Gy QUANTEC 
   <53Gy MAASTRO 
 D1cc  <50Gy QUANTEC 
Mediastinal 
organs 
Dmax  <80Gy EORTC 
Dmax  <96Gy PET boost trial 
Dmax  <76 Gy MAASTRO and KULeuven 
Brachial plexus Dmax  <60Gy Emami et al. 
 Dmax  <66Gy MAASTRO 
 
Table 1.1 OARs dosimetric parameters currently used. 
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3. Better delivering the dose 
3.1. From 2D conventional RT to Intensity Modulated RT (IMRT) 
Since a few decades, technological innovations have greatly improved treatment 
delivery and outcome. Historically, two-dimension (2D) conventional radiotherapy 
was limited to generate dose distributions in a single or a few planes of the patient’s 
target volume, leading to unsatisfactory and heterogeneous dose distributions to both 
TVs and normal tissues. Rectangular shaped radiation fields encompassing the 
presumed tumor location were roughly defined using skin or bony landmarks 
according to planar radiographs.  
Several advances in the field of image data acquisition, computer science and 
development of new machines and accelerators have led to high precision radiation 
techniques, such as 3D conformal radiotherapy (3D-CRT). Computerized treatment 
planning and 3D CT acquisition of the patient’s anatomy allowed to precisely define 
the tumor and created shaped dose distribution that closely conform to the target 
volume while minimizing the dose to critical normal tissue. In 3D-CRT, multiple 
beams are usually used to better conform the tumor but the radiation intensity 
remains uniform within each beam, even if intensity profile can be slightly modified 
by using wedges or compensators to offset contour irregularities and produce more 
uniform composite dose distribution.  
In the 90’s, the refinement of 3D-CRT has ultimately led to Intensity Modulated 
Radiation Therapy (IMRT) (Figure 1.17). IMRT refers to a radiation therapy technique 
in which non-uniform fluence is delivered to the patient from some different angles in 
order to optimize the composite dose distribution, i.e. to deliver a high dose to the TVs 
and a low dose to OARs with a sharped dose fall off. A Multi Leaf Collimator (MLC) 
geometrically shapes the field, where intensity is modulated, allowing to create 
homogeneous concave dose distributions for complex shaped TVs or when an OAR is 
closely juxtaposed. The optimal fluence profiles are determined through inverse 
planning, where number, energy and direction of treatment beams are chosen, 
adjusted and optimized to satisfy predefined dose criteria to TVs and dose constraints 
to OARs. An additional advantage of IMRT over 3D-CRT is its ability to intentionally 
generate inhomogeneous dose distributions within TVs, inhomogeneities that are 
notably required in Simultaneous Integrated Boost (SIB) or dose painting strategies. 
Since its emergence, IMRT has spread to most radiotherapy departments with rapid 
implementation for a wide range of indications.  
Although from a planning point of view, IMRT clearly has the potential to improve 
dose delivery in NSCLC, especially for centrally located tumors, reports on its clinical 
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use and comparison with 3D-CRT remain scarce. Several issues including the effect of 
tumor and organ motion, the risk of pneumonitis and/or secondary malignancy 
resulting from low radiation doses, and the optimal planning algorithm remain 
unanswered and require further analysis. However, based on available data, IMRT 
seems promising with a clear impact on volumes irradiated at high dose and 
dosimetric parameters allowing a potential way for dose escalation. In addition, 
survival and progression free survival are at least similar to 3D-CRT technique [21, 
100-107]. 
TomoTherapy, similar to helical CT, delivers intensity modulated, rotational radiation 
therapy using a fan-beam. It allows treatment delivery by continuous gantry rotation 
and treatment couch translation. In addition to full IMRT technique, the advantage is 
its ability to provide accurate verification of the delivery using megavoltage CT (MV-
CT) images. 
 
 
Figure 1.17 Two-dimensional RT consists of radiation beams delivered to the patient from one or 
several directions, e.g. parallel opposed beams antero-posterior, postero-anterior or lateral beams. 
This results in rectangular shaped radiation fields encompassing the presumed tumor location. 
Using a three-dimensional representation of the patient anatomy, 3D-CRT sculpts the radiation 
beams to the shape of the tumor. Intensity modulated radiation therapy delivers radiation beams 
from different angles. At each of these angles, the intensity of the radiation is varied and the beam 
shape is changed to closely conform to the target volume while minimizing the dose to critical 
normal tissue. 
3.2. A step forward with Image-Guided RT (IGRT) 
The accurate knowledge of the TVs and OARs location is of utmost importance for the 
correct dose delivery. This is even more important in the era of IMRT because dose 
distribution is more conformal than in 3D-CRT. Image Guided Radiation Therapy 
(IGRT) is defined as an external beam radiation therapy with positional verification 
using imaging prior to treatment delivery. However, guiding the placement of the 
treatment field is not a new concept. Treatment field was firstly verified using surface 
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and skin marks, and then portal images using gamma-ray (i.e. gammagraphy) were 
used. Currently, the acquisition of electronic portal imaging (EPID) with two 
orthogonal radiographs allows patient setup verification based on bony landmarks 
before the session. In contrast, the acquisition of a cone-beam CT (CB-CT) or MV-CT 
allows patient alignment based on soft tissue visualization (i.e. tumor and/or bony 
based matching) before the session. The adjustment of the patient and beam position 
can be performed either online, i.e. before or during the treatment process, or offline, 
i.e. after determination of the best patient position through accumulated data 
gathered during first treatment sessions. IGRT is especially indicated in case of 
moving target, complex positioning, potential tumor shrinkage or expansion, tumor 
shape or anatomy changes and is thus mandatory for hypo-fractionated RT, dose 
painting strategies and adaptive RT. Finally, the exact knowledge of the tumor 
location allows clinicians to reduce safety margins, thus reducing the volume of tissue 
irradiated, and/or potentially to escalate the dose. 
4. Better integrating tumor motion 
4.1. Tumor motion: an issue in thoracic RT 
As already mentioned, the breathing leads to organs, lung primary tumor and 
mediastinal lymph nodes motion. This is a complex and asynchronous motion, 
including translation, rotation and deformation of the image voxels, which introduces 
errors in the entire process of RT from imaging and treatment planning to daily 
treatment delivery. 
As a consequence, it appears essential to integrate it in the RT processes either in 
treatment planning and/or in treatment delivery according to the chosen method. 
4.2. Three-dimensional CT (3D-CT) and the conventional PTV margin 
Careful acquisition of images of the patient anatomy is the prerequisite for a correct 
RT planning. For years, free-breathing 3D-CT has been the reference imaging modality 
for treatment planning of NSCLC patients. However, it is merely a snapshot of the 
tumor and of the whole patient anatomy at some point of the respiratory cycle. As a 
result, it suffers from geometric distortions of the tumor volume by interplay effect 
between advancing image plane and internal organ motion, leading to blurring, 
duplication, overlapping and truncature artifacts (Figure 1.18). Moreover, 3D-CT does 
not provide any information on the actual tumor position and shape, on the amplitude 
range, on the complex trajectory (i.e. hysteresis) or on the baseline position of the 
tumor. In order to include uncertainties related to intra- and inter-fraction tumor 
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motion and patient setup in RT planning, a generic and isotropic PTV margin based on 
population statistics has to be applied around the CTV. 
 
 
Figure 1.18 CT imaging performed in free breathing can suffer from geometric distortions. From 
Yamamoto et al., IJROBP, 2008. 
4.3. Time-resolved four-dimensional CT (4D-CT): a definite innovation 
4D-CT scanning techniques have been developed to reduce geometric uncertainties 
inherent to 3D-CT images. 4D-CT consists in the synchronization of a low-pitch CT 
data acquisition with the respiratory signal, which is generated either from a 
pneumatic elongation belt, from magnetic sensors or from infrared markers placed on 
the patient chest or epigastric area. From this dataset, breathing CT images can be 
prospectively or retrospectively sorted according to either phase or amplitude of the 
respiratory signal (Figure 1.19). 4D-CT allows a precise and individual quantification 
of tumor and organ motion. In particular, the radiation oncologist can assess the 
various positions, the amplitude, the baseline and the trajectory of the tumor. 
Nonetheless, the patient breathing during the planning 4D-CT might not be 
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representative of the breathing during treatment and the correlation between internal 
tumor motion and the external recorded signal could became unreliable, i.e. in case of 
irregular breathing or baseline shifts. The reproducibility of the breathing pattern is 
critical and can be increased by using audio and video coaching during the planning 
imaging as well as during each treatment session. It has been shown that using audio 
coaching decreases the respiratory rate variability whereas video coaching reduces 
amplitude and baseline shift uncertainties [108]. In addition, a CT imaging is required 
prior to each treatment session to validate and/or adapt the correlation between the 
external respiratory signal and the internal tumor motion. In that regard, setup 
correction protocols should consider imaging features in order to perform correct 
matching between planning CT and daily CB-CT or MV-CT, i.e. a bony-based or tumor-
based matching [109].  
 
 
Figure 1.19 Schematic overview of the 4D-CT image sorting principle.  
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4.4. Integration of 4D data into treatment planning 
Various approaches to incorporate 4D-CT data in treatment planning have been 
reported, including respiratory synchronized techniques and margin based strategies. 
4.4.1. Respiratory synchronized techniques 
In these techniques, the breathing pattern is obtained from an external or internal 
signal, which is correlated to the internal tumor motion. Integrating information on 
tumor motion into the treatment planning process allows to minimize tumor motion 
contribution in the PTV margin. However, it generally involves advance equipment, 
education and training in the use of complex technology, and the implementation of a 
dedicated quality assurance program. 
4.4.1.1. Breath-hold  
The deep inspiration breath-hold consists in an attempt for the patient to 
reproducibly and deeply inhale during imaging session and treatment delivery. In 
contrast, the Active Breathing Control (ABC) assists the patient breath-hold by using a 
valved spirometer blocking at a predefined relative lung volume level and airflow 
direction, i.e. moderate or deep breath-hold. These techniques aim at decreasing 
tumor motion and potentially shifts a significant volume of lung tissue outside the 
treatment field [110]. However, the poor patient compliance can lead to a lower 
reproducibility and the reduction of lung density might overestimate the dosimetric 
coverage if an inappropriate dose calculation algorithm is used [111]. 
4.4.1.2. Abdominal compression 
An abdominal compression plate can be used to limit diaphragmatic motion and force 
a shallow breathing. Although amplitude tumor motion should be reduced, it has been 
demonstrated that this gain is limited to lower lobe tumors [112]. For other tumor 
locations, the abdominal compression provides only a minor benefit or even induces 
unwanted effects such as larger or erratic tumor motion and resulting margins. This 
technique may also be unsuitable for obese patients or those with poor respiratory 
function. 
4.4.1.3. Gating 
In gating technique, the patient breathes freely but the tumor is irradiated within a 
predefined portion of the patient breathing cycle, i.e. the gating window. Radiation is 
generally delivered during exhalation because exhalation takes longer than inhalation 
and corresponds to the most stable part of the cycle, thus improving the 
reproducibility. As a result, delineation of TVs and treatment planning are performed 
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on a particular frame of the 4D-CT corresponding to the end exhalation phase. During 
treatment, patient breathing is recorded either externally (e.g. infrared or skin 
markers, pressure belt) or internally (e.g. fiducials, fluoroscopy) to determine when 
the beam should be on and off. In an idealized gated approach, margin from CTV to 
PTV could be very small, as systematic errors due to breathing are significantly 
reduced and the margin becomes insensitive to patient-specific motion [113]. 
Nonetheless, a real gated treatment requires an online monitoring of the tumor 
position and assumes precise and real time tumor localization as well as prompt 
linear accelerator reaction to the gating signal, all conditions that are difficult to meet. 
Moreover, imprecise correlation between actual tumor motion and its surrogate can 
lead to uncertainties and poor treatment outcome if margins are too tight. Finally, a 
gated treatment requires additional equipment in the treatment room and increases 
the session duration. However, the application of guided voluntary breath-hold at a 
predefined position in the breathing cycle by using visual feedback and audio 
assistance and/or an increase in dose rate could significantly reduce this time [114, 
115]. 
4.4.1.4. Tracking 
The tracking technique is the real-time delivery of radiation with simultaneous 
tracking of the tumor, usually by using internal or external surrogate. This requires a 
dedicated device which is able to identify the tumor in real time, to anticipate the 
tumor motion, i.e. compensate for system lag (< 0.5 seconds [116]), to reposition 
beam in real time and to adapt dosimetry for changing target and critical structure 
locations. Basically, using ionizing or non-ionizing (e.g. electromagnetic transponders) 
imaging modalities, implanted fiducials or target position surrogates are localized. 
After image acquisition, data are processed and the beam has to be realigned either by 
moving the beam (i.e. MLC tracking, gimbaled linac head or robot-mounted linac) or 
by moving the patient (i.e. repositioning of the couch). Finally, a “time-resolved 
dosimetry” is required to assess the target coverage and OARs sparing. In an idealized 
tracking system, safety margins are significantly reduced and the delivery treatment 
time is faster than in gated treatment. However, uncertainties can accumulate through 
each step of the process, especially in the determination of the tumor position (i.e. 
accurate tumor prediction models) or in the relationship between the target and its 
surrogate (i.e. efficiency of MLC or gimbals tracking [115, 117, 118]), potentially 
resulting in considerable and unexpected safety margins.  
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4.4.2. Margin based strategies 
These strategies aim at covering the entire tumor trajectory derived from 4D 
information, such as the ITV technique or take advantage of the geometrical time-
weighted mean tumor position derived from the mid-position CT, extended with 
appropriate margin. 
4.4.2.1.  Internal Target Volume (ITV) strategy 
The ITV encompasses all tumor positions during the breathing cycle. Therefore, the 
ITV concept aims to provide 100% dose coverage to the CTV during the whole cycle, 
i.e. considering tumor motion as a systematic error. This method tends to 
overestimate the safety margins as the tumor spends only a fraction of time at each 
position of the breathing cycle, and thus may lead to unnecessary irradiation of 
healthy tissues. Nevertheless, ITV approach is widely used because it is easy to 
determine, either automatically using non-rigid registration or manually on all phases 
of the 4D-CT. 
4.4.2.2. Mid-position (MidP) strategy 
The MidP represents the exact time-weighted average position of the tumor and all 
other internal structures during the breathing cycle (Figure 1.20). This average 
position can be automatically generated using 4D-CT data and non-rigid registration 
applied to each phase of the 4D-CT [119, 120]. As a result, the systematic error due to 
hysteresis is eliminated and motion is integrated in the Van Herk probabilistic margin 
recipe as a random error. In that regard, correct dose coverage can be obtained, even 
if the tumor is not fully within the PTV during a small part of the breathing cycle, 
thanks to the wide penumbra in lung parenchyma [121, 122]. The MidP concept 
presents several advantages. First, it can be applied to both primary tumor and 
regional lymph nodes. Second, it achieves smaller PTV margin than the ITV approach 
(and similar margin compared to gated treatment), resulting in smaller irradiated 
volume. Finally, it affects only the target volumes definition, and leaves all other 
aspects of planning unchanged; MidP is a simple method requiring no additional 
equipment in the treatment room, or complex 4D features in the treatment planning 
station (TPS) [113]. However, it uses a 4D-CT scan whose phases are non-rigidly 
registered. Unfortunately, no commercial implementation of MidP exists at the 
moment, which hinders adoption in clinical routine. 
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Figure 1.20 Schematic overview of the margin based strategies for moving tumors treatment.  
From Wolthaus et al., Med Phys, 2008. 
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Conventional treatment of LA-NSCLC patients with concomitant chemo-radiation 
achieves poor tumor local control rates and strongly affects the patient’s outcome 
with an overall survival rate at 5 years of approximately 15%. It has been 
demonstrated that improved loco-regional tumor control strongly influences survival 
of NSCLC patients. Moreover, given the relationship between local tumor control and 
dose, it appears essential to implement dose intensification strategies. However, this 
remains challenging due to the proximity of highly radiosensitive organs, which may 
result in unacceptable toxicities. In that regard, escalating the dose uniformly over the 
whole tumor is arduous as demonstrated by the RTOG 0617 trial, which has failed to 
show any survival gain from dose intensification (74 Gy versus 60 Gy). A potential 
solution would be to escalate the dose in restricted areas within the tumor using high 
conformal RT delivery and optimized tumor motion management. In this context, 
functional imaging could allow the identification of potentially radio-resistant sub 
regions within the tumor, notably using FDG-PET, as a surrogate of tumor burden. 
This imaging technique benefits from a wide and long-term clinical experience and 
provides higher sensitivity and specificity than CT for the detection of primary tumor 
and mediastinal lymph nodes. Moreover, it offers a good signal to background ratio 
and is able to modify the size, location, and shape of the primary GTV for NSCLC, 
leading to the opportunity to adapt the treatment planning or patient’s management. 
Finally, FDG-PET decreases the inter- and intra- observer variability of CT-based 
target volumes delineation. 
Target volumes definition:  
concept and validation with pathology (Chapter 3) 
The FDG-PET based selective boosting concept mainly requires an accurate selection 
and rigorous definition of the target volumes in order to spare as much as possible the 
healthy tissues. Although promising, the integration of FDG-PET in the treatment 
planning remains technically complex, especially for the accurate definition of the 
tumor boundaries. Currently, PET-based delineation methods rely on either manual 
contouring or automatic threshold-based segmentation. To overcome the inherent 
limitations of these approaches, a segmentation method that exploits the image 
gradient information has been developed in our laboratory. This algorithm has been 
first validated on phantoms and then on head and neck cancer patients. In NSCLC, the 
pathological validation of this gradient-based segmentation technique is still lacking. 
As a result, we designed a first study aiming at validating FDG-PET imaging as an 
accurate tool to define the tumor and identify tumor sub-volumes considered as 
radio-resistant. We validated a gradient-based segmentation method for GTV 
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delineation on FDG-PET images in NSCLC with surgical specimen, in comparison with 
threshold-based approaches and CT images. 
Dose escalation based on FDG-PET (Chapter 4) 
Besides the ability of FDG-PET to accurately define the actual GTV, it provides 
sensitive and accurate molecular information to guide a selective boosting. As already 
mentioned, a high pre-treatment FDG uptake within the tumor correlates with poor 
tumor local control and survival [63-65]. This high uptake is identifiable from one pre-
treatment FDG-PET/CT and it remains at the same location during the course of RT 
[14, 67]. Moreover, a dose prescription based on OARs constraints instead of a fixed 
prescribed dose has been shown feasible with promising results in terms of toxicity 
and outcome [13-15, 96]. Based on these assertions and on the validation of a 
gradient-based method for the GTV definition on PET imaging with the surgical 
specimen, we designed a clinical trial to assess how an individualized escalated dose 
based on FDG-PET images would affect the tumor local control and the chemo-radio-
induced toxicities.  
Validation of the mid-position concept (Chapter 5) 
Our third study investigated the tumor motion caused by breathing, which is another 
key issue in thoracic radiotherapy. It can be accounted for in the treatment plan by 
drawing an ITV that encompasses all tumor positions during the breathing cycle. 
Nonetheless, this widely used technique turns out to be overly conservative in terms 
of dose coverage and impedes dose escalation. In contrast, the mid-position (MidP) 
corresponds to the time-weighted average position of the tumor during the 
respiratory cycle. The knowledge of the average position is completed with the 
definition of specific margins to account for both motion and other geometrical 
uncertainties, according to the formalism of the margin recipe developed by M. Van 
Herk in NKI Amsterdam. Currently, MidP has never been implemented for helical 
TomoTherapy of moving lung tumors, nor compared to ITV for this treatment 
modality. In this context, we designed a study to assess the potential gain of MidP over 
ITV in terms of margin and PTV reduction, as well as in term of OARs dosimetric 
advantage. Finally, using a 4D Monte Carlo model, we assessed the plan quality and 
more particularly, the potential impact of intra-fraction motion and treatment 
delivery mechanics on tumor dose coverage when margins are reduced. 
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Introduction 
Radiotherapy is one of the most important treatment modalities for locally advanced 
or unresectable non-small cell lung cancer (NSCLC). However, conventional radiation 
regimens still lead to high local recurrence rates that strongly affect the patient’s 
outcome. Although dose intensification strategies, such as concomitant chemo-
radiation, altered and dose-escalated schemes have been shown to improve the tumor 
local control and survival [13, 15, 123-125], their clinical implementations remain 
problematic. The proximity between the target volumes (TVs) and highly 
radiosensitive organs, such as the lungs, spinal cord, esophagus and heart, might 
result in unacceptable short- and long-term toxicities when dose intensification is 
considered. Therefore the recent development of additional techniques such as 
intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT) and 
stereotactic radiation therapy (SRT) offers new perspectives by providing high 
precision in radiation dose delivery. They require however a thorough selection and 
delineation of the TVs, particularly the gross tumor volume (GTV), to avoid 
inadequate dosage of these TVs and/or organs at risk (OARs). 
Nowadays, computed tomography (CT) is the reference imaging modality for the 
treatment planning of NSCLC. It is widely available, conveys essential anatomical 
information, and also indicates the electronic density of the tissues used for dose 
calculation. Nevertheless, it offers poor soft tissue contrast between the primary 
tumor and the surrounding normal tissues in cases of lung parenchyma changes (i.e. 
fibrosis, atelectasis, pleural effusion, poststenotic pneumonia), contiguity between the 
primary tumor and mediastinal nodes, and tumor located close to the mediastinum or 
chest wall. Alternatively, positron emission tomography with 18F-fluorodeoxyglucose 
(FDG-PET) is a functional imaging modality that provides higher sensitivity and 
specificity than CT for the detection of primary tumor and mediastinal nodes [126]. In 
radiation therapy, FDG-PET has already been shown to significantly modify the size, 
location, and shape of the primary GTV for NSCLC, leading to the opportunity to adapt 
the treatment planning or patient’s management [70, 76-80, 127-129]. Likewise, FDG-
PET dramatically decreases the inter-observer variability of CT-based delineation, 
even when contouring protocols are available [48-55, 72, 73, 81, 82, 130, 131]. Finally, 
with an appropriate tracer, PET allows the identification of tumor sub-volumes that 
are suspected of being radioresistant, in which case a targeted dose escalation [14, 64, 
68, 69, 132, 133] could improve tumor control probability and overall survival [65, 
134]. 
Although promising, the integration of FDG-PET in the treatment planning remains 
technically complex, especially for the accurate definition of the tumor boundaries 
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[135]. At the moment, several delineation methods were suggested relying mainly on 
either manual contouring [70, 72-75, 130] or automatic threshold-based 
segmentation [49, 74-94, 136]. To overcome the inherent limitations of these 
approaches, a segmentation method that exploit the image gradient information has 
been developed in our lab and validated on both phantoms and head neck patients 
with pathology specimens [95]. In NSCLC, the pathological validation of this gradient-
based segmentation technique is still lacking. The few studies conducted in this field 
only concerned conventional threshold-based segmentation approaches, and suffered 
from important methodological issues, such as image acquisition in free breathing 
mode, or the lack of true volumetric assessment of tumors with the surgical specimen 
[85, 87, 88, 90, 136-138]. In this context, the present study aimed to compare the GTV 
delineation on CT and FDG-PET by using this novel segmentation method as well as 
the classical techniques described in the literature and to validate the results with 
surgical specimen in NSCLC. The originality of the study lays in its methodology, 
which addresses tumor motion by using gated imaging acquisitions, relies on an 
innovative segmentation technique, and compares the delineated volumes in a 3D 
mode to pathology specimens. 
Materials and methods  
1. Patient Selection 
Ten patients (mean age 66 years; range 54-85) with histologically proven NSCLC stage 
I-II were prospectively enrolled in this study between October 2008 and February 
2010. From these 10 patients, 6 had squamous cell carcinoma (SCC) and 4 had an 
adenocarcinoma (ADC). All patients were exclusively treated by lobectomy, excluding 
thus atypic resections and pneumonectomy. One patient had pre-operative 
chemotherapy. The patients and their primary tumor characteristics are summarized 
in Table 3.1. This study was approved by the local Ethical Committee, and informed 
consent was obtained from all patients. 
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Table 3.1 Patient and primary tumor characteristics 
 
Patient  
No 
Gender Age 
(years) 
Tumor 
localization 
Tumor 
type 
Histologic 
grade 
cTNM Stage pTNM Change in 
lung 
          
1 Female 85 LU ADC 2 T2aN0M0 Ib T2aN0M0 No 
2 Male 66 RM SCC NA T1aN0M0 Ia T1aN0M0 No 
3 Male 59 RU SCC 2 T1bN0M0 Ia T0N0M0 No 
4 Male 66 RU ADC 2 T1bN0M0 Ia T1aN0M0 No 
5 Female 54 LU ADC 2 T2aN0M0 Ib T2aN0M0 Yes† 
6 Male 62 LU SCC 2 T2aN0M0 Ib T2aNoM0 No 
7 Male 69 LL SCC 2 T1aN0M0 Ia T1bN0M0 No 
8 Male 64 LU ADC 3 T1aN1M0 IIa T1aN2M0 No 
9 Male 73 LL ADC 2 T1bN0M0 Ia T1bN2M0 No 
10 Female 62 RL ADC 2 T2aN0M0 Ib T1aN0M0 Yes 
Note: LU: left upper, RM: right middle, RU: right upper, LL: left lower, ADC: adenocarcinoma, SCC: 
squamous cell carcinoma. 
Atelectasis, †BOOP (Bronchiolitis Obliterans Organizing Pneumonia),  7th Edition IASLC TNM 
Staging Classification. 
2. Image acquisition 
All patients successively underwent a contrast-enhanced (CE) CT, a 4D respiratory-
correlated CT, and a respiratory-gated FDG-PET on a combined PET-CT camera 
(Gemini TF, Philips Medical system, Cleveland, OH, USA). The image acquisitions were 
performed the day before surgery during a single session. The total acquisition time 
for all scans was approximately 35 minutes. For all acquisitions, the patients were 
immobilized in a forearm support (Posiboard-2, Med Tec, Cablon Medical system, The 
Netherlands) in a supine, head first and arms overhead position.  
The CE-CT acquisition started 35 seconds after an injection of 70 ml of iodinated 
contrast intravenously at a rate of 2.0 ml/sec (Iottexol, Omnipaque 350, HealthCare, 
Diegem, BE). The image acquisition was performed using a slice thickness of 2.0 mm, a 
reconstruction interval of 2 mm and a pitch of 0.94. The tube voltage and current were 
set at 120 kV and 200 mAs, respectively. Axial images were reconstructed using a 
matrix of 512 x 512 pixels, corresponding to a voxel size of 0.48 x 0.48 x 2 mm3 in the 
x, y and z directions, respectively. The longitudinal field of view (FOV) typically 
covered the entire pulmonary region, from the supraclavicular fossa to the upper 
abdomen, and the axial FOV was set at 500 mm. The image data sets were transferred 
to the treatment planning system (Elekta CMS Computerized Medical Systems 
Software - Focal v4.40). 
The 4D respiratory-correlated CT had the same parameters as the CE-CT, except for 
the low pitch value of 0.08 and the axial FOV of 600 mm. The respiratory signal was 
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generated from a pneumatic elongation belt placed on the epigastric area 
(Medspira/Mayo Clinic Breath HoldTM, Interactive Breath-Hold Control System, Mayo 
Clinic Medical Devices, USA). From this dataset, 10 phase-binned breathing images 
were retrospectively reconstructed, covering thus the entire breathing cycle. 
For gated FDG-PET, the patients were fasted for at least 6 hours and normal blood 
glucose levels were confirmed before tracer injection. Images were obtained between 
60-120 minutes after injection of an average dose of 8.1 mCi (range 5.7-9.8 mCi) of 
FDG. The acquisition of the breathing signal was performed with the same respiratory 
device as the 4D-CT. After correction for decay, random, scatter, and attenuation, 
images were reconstructed with the iterative algorithm 3D LOR-OSEM (line of 
response ordered-subset expectation maximization) using only 20% of the breathing 
cycle’s duration centered on the end of the expiratory phase, with a transverse FOV of 
180 mm (one bed position centered on the primary tumor). The acquisition time was 
multiplied by 5 to compensate for the gating procedure and to avoid loss of statistics. 
The attenuation correction was performed by means of the averaged images of the 4D 
respiratory-correlated CT. The images were first reconstructed with a matrix of 288 x 
288 x 90 voxels and a voxel size of 2 x 2 x 2 mm. The same acquired data was also 
used to reconstruct images with a matrix of 144 x 144 x 45 voxels and a voxel size of 4 
x 4 x 4 mm. The resolution of the PET images measured in the center of the FOV with a 
punctual source led to a full width at half maximum (FWHM) of approximately 7.7 
mm.  
3. Processing of the Surgical Specimen 
The surgical specimen was processed according to the method described in [86] for 
laryngeal tumors, which was adapted to the peculiarities of NSCLC.  
The first step consisted in collecting the fresh lobe just after lobectomy in the 
operating room. Next, the lobe was immediately inflated with liquid gelatin (Gelatin 
15%, BDH Prolabo, Leuven, BE) until being uniformly filled. The surgical specimen 
was then slightly cooled with ice to solidify the gelatin and placed inside a polystyrene 
box containing four parallel and equally spaced wooden sticks, longitudinally placed 
between the corners. The box was then filled with gelatin, frozen at -20°C for at least 
four hours, and thereafter at -80°C for two days. CT images of the frozen specimen 
were acquired on the Gemini TF PET-CT camera, with a slice thickness of 2 mm. Next, 
the box was cut with a carpentry band saw (EBS 3601; Elu, Köln, Germany) into 
transverse parallel slices of an average thickness of 4 mm. Afterwards, both sides of 
each slice were digitized with a flatbed scanner, and images were stored in tag image 
file format (TIFF) with a resolution of 150 x 150 pixels per inch. The digitized slices 
Target volumes definition: Concept and histology validation 
 
69 
 
were semi-automatically aligned using the wood rods as markers (home-made 
software), and eventually stacked to assemble the 3D volume of the surgical specimen.  
The CT images of the whole box served to adjust the slice thickness of the 3D 
assembly, in order to compensate for the loss of material caused by the saw teeth. In 
practice, the CT image and the 3D assembly were manually registered. The rigid-body 
registration parameters and the slice thickness of the 3D assembly were alternately 
and iteratively updated until a good visual agreement was found. On average, the loss 
of material was evaluated at 0.6 mm per slice. Corrections of the resolution in the Z 
direction were thus applied to ensure the best fit between both imaging modalities. 
The slice thickness of the 3D assembly ranged from 2.28 to 2.35 mm, with an average 
of 2.3 mm.  
Eventually, this methodology yielded a three-dimensional image of the surgical 
specimen that was used for further comparisons with conventional CT and PET 
imaging modalities. 
4. Delineation of GTV (Figures 3.1 and 3.2) 
The primary GTVs were delineated on each transverse section of all considered 
imaging modalities by two operators (MW and XG).  
The GTVs on CT images (GTVCT) were manually outlined on the planning workstation 
without knowledge of the FDG-PET results. Two fixed-display window settings were 
used:  the lung window (width, 1700 HU; center, -300 HU) (GTVCTLW) and the 
mediastinal window (width, 600 HU; center 40 HU) (GTVCTMW). In complex cases, the 
delineation of GTVs was done with the help of an experienced radiologist in the field 
of thoracic oncology (EC). 
The GTVs on FDG-PET imaging (GTVPET) were automatically segmented on the two 
sets of reconstructed images with voxel sizes of 2 mm (GTVPET2) and 4 mm (GTVPET4) 
using four different methods with homemade software (IMREviewer). Firstly, we 
applied the gradient-based method on denoised and deblurred PET images 
(GTVPETW&C), as described in [95]. Then, we used the fixed thresholds of the maximal 
standardized uptake value (SUV) at 40% (GTVPET40%) and 50% (GTVPET50%). Finally, we 
applied the adaptive thresholding method based on the source to background ratio 
(GTVPETSBR) [83, 86]. 
The GTVs on the surgical specimen (GTVmacro) were defined from the visualization of 
gross tumor infiltration on each digitized slice with the help of an experienced 
pathologist (BW). 
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5. Image co-registration (Figures 3.1 and 3.2) 
All images obtained from CT, FDG-PET and surgical specimens were transferred to the 
IMREviewer software. PET and CT images were rigidly registered with those from the 
surgical specimen using manual translations and rotations in x, y and z directions 
until visual agreement was obtained. In this regard, it is noteworthy that the lobe as it 
appeared on the specimen images had a slightly different shape than on the pre-
lobectomy CE-CT images, because in vivo and ex vivo mechanical constraints were not 
the same. Consequently, the rigid registration between the CT imaging and the 
surgical specimen was globally adjusted for the specimen orientation but locally 
optimized in the vicinity of the tumor. All volume contours were transferred to the CT 
images for comparison. 
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Figure 3.1 Overview of the tumor delineation and image registration between CT, FDG-PET, and 
the macroscopic specimen of a well defined tumor. Volumes are displayed in transverse, coronal, 
and sagittal planes. The fusion represents the transfer of the three volumes on CT. The outlines 
show the GTVs delineated on each imaging modality: CT with the mediastinal window (red line), 
FDG-PET reconstructed with a voxel size of 2 mm3 using the gradient-based method (blue line), 
macroscopy (yellow line), and the lung contour (green line). GTVs do not significantly differ 
between the various imaging modalities. 
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Figure 3.2 Overview of the registration between CT, FDG-PET and the macroscopic specimen of a 
poorly defined tumor surrounded by BOOP. In comparison with Figure 3.1, CT largely 
overestimates the true tumor volume as defined on the macroscopic specimen, while FDG-PET 
provides a more accurate estimation of this later one. 
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6. Statistical Analysis 
GTVs delineated on macroscopic, CT and FDG-PET images with the different 
segmentation methods were quantitatively analyzed for all patients. 
The analysis was twofold. A first volumetric analysis was conducted with the raw 
volumes expressed in ml. The second analysis considered a logarithmic 
transformation to reduce the magnitude of both skewness and kurtosis of the volume 
distributions. The main purpose of this transformation is to obtain nearly Gaussian 
distributions, as most statistical tests rely on this assumption. The identity ln(a) – 
ln(b) = ln(a/b) shows that comparing logarithmic transformed values equals 
considering the logarithm of their ratio. The analysis focused on ln(GTVX) – 
ln(GTVmacro), where GTVX can be any of the considered GTVs and GTVmacro is the 
ground truth. Zero indicates a perfect volume equality (ratio equal to 1). A positive 
value means that the technique overestimates the macroscopy, and a negative value 
results from an underestimation. In both analyses, the mean value and standard 
deviation were calculated. The impact of the imaging modality and the segmentation 
method on tumor volume assessment was estimated by ANOVA. In addition, the 
groups were compared with a pairwise Student t-test. 
The same two analyses were also repeated after excluding a patient subgroup. Out of 
the ten patients, two had noticeable changes to the lung parenchyma surrounding the 
tumor. One had an extensive BOOP (Bronchiolitis Obliterans Organizing Pneumonia) 
and the second a basal atelectasis. We called this subgroup “poorly defined tumors” 
(PDT). As these modifications of parenchyma might significantly affect the delineation 
on CT, they were secondarily excluded for the sub-analysis.   
While until here only volumes were considered, a matching analysis was also 
performed and the Dice’s similarity index (DSI) was calculated to estimate the 
discrepancies between the different GTVs. The DSI indicates the overlapping ratio 
between the GTVmacro and the various GTVs obtained at imaging. A DSI equal to one, 
means a perfect match between both volumes whereas a DSI equal to zero, means two 
disjoined volumes. 
All the statistical calculations were performed with NCSS software 2004© (Number 
Cruncher Statistical System, Kaysville, UT, USA), p-values < 0.05 were considered 
statistically significant and all tests were two-sided.  
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Results 
The GTVs delineated with the considered imaging modalities are reported in Table 
3.2. The mean and standard deviations of the raw GTVs are provided as well. As 
detailed in the statistical analysis section, they were computed after logarithmic 
transformation of the volumes in order to process data distributions that were closer 
to normality. Means and standard deviations of transformed volumes are illustrated in 
Figure 3.3 with error bars (mean +/- 1 SD).  
Table 3.2 Raw GTVs (ml) measured on the different imaging modalities, along with averages and 
standard deviations. 
Patient No Macro CT PET 2mm PET 4mm 
            
  LW MW 
PET 
W&C  
PET  
SBR  
PET  
40%  
PET  
50%  
PET  
W&C  
PET  
SBR  
PET  
40%  
PET  
50%  
 aaaaaaa aaaaaa aaaaaa aaaaaaa aaaaaaa aaaaaaa aaaaaaa aaaaaaa aaaaaaa aaaaaaa aaaaaaa 
1 13.8 26.0 22.0 7.4 9.9 10.4 7.3 9.7 10.1 12.9 9.0 
2 1.7 2.5 1.6 2.3 2.4 2.4 1.8 2.7 3.2 3.2 3.0 
3 3.6 8.0 6.1 2.4 2.9 3.1 1.9 2.8 5.0 7.5 4.2 
4 1.1 3.4 1.0 3.0 6.2 8.0 4.0 3.4 6.3 8.6 6.0 
5 29.5 288.9 267.0 48.5 51.8 51.9 31.5 58.5 66.8 78.2 54.7 
6 45.5 51.0 43.1 42.3 25.9 26.6 12.9 50.0 47.3 51.3 35.3 
7 7.3 10.8 7.1 8.4 9.0 8.9 7.1 N/A N/A N/A N/A 
8 1.8 2.6 1.6 1.5 1.3 1.4 0.9 1.8 2.1 2.6 1.8 
9 5.1 8.2 5.9 5.8 5.0 4.9 3.1 4.0 6.8 7.2 5.1 
10 3.5 26.7 20.1 5.9 7.3 7.3 5.5 4.7 7.3 7.8 6.1 
Mean for all patients 11.3 42.8 37.6 12.7 12.2 12.5 7.6 15.3 17.2 19.9 13.9 
SD for all patients 14.8 87.8 81.7 17.4 15.6 15.6 9.1 22.3 23.2 26.5 18.4 
Mean without PDF 10.0 14.0 11.0 9.1 7.8 8.2 4.9 10.6 11.5 13.3 9.2 
SD without PDF 15.0 16.8 14.6 13.7 7.9 8.1 4.0 17.6 16.0 17.1 11.73 
Abbreviations: N/A: Non available; Patient No: patient number; PDF: poorly defined tumors. 
With all patients taken into consideration, CT led to a large overestimation of the true 
tumor volume as defined on the macroscopic specimen, both with the mediastinal and 
lung windows (ANOVA, p<0.001), although the paired analysis only revealed a 
significant difference for the latter one (Student t-test, p=0.10 and p<0.005, 
respectively). On the other hand, GTVs delineated on FDG-PET did not differ from 
GTVmacro, except for GTVPET4-SBR and GTVPET4-40% that were significantly larger (Student 
t-test, p<0.05). GTVPET2-50% was the only volume that was on average smaller than 
GTVmacro, but this difference was not statistically significant (Student t-test, p=0.46). 
Interestingly, moving from PET images with 2mm³ voxels to 4mm³ voxels resulted in 
larger GTVs on average, independently of the segmentation method used (ANOVA, 
p<0.001). For this reason, only data corresponding to PET images with 2 mm³ voxels 
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are shown in Figure 3.3. As one can see, FDG-PET globally outperformed CT and 
showed the smallest SD. The gradient-based method achieved the best results, with 
the lowest average error and smallest standard deviation (0.14 ± 0.49). This confirms 
the robustness of this approach on a case-by-case basis, compared to usual threshold-
based techniques.  
Removing the 2 patients who presented parenchyma densifications surrounding the 
tumor from the data altered the analysis results. Here, CT achieved a close estimation 
of the macroscopy, particularly when the mediastinal window was selected, with 
average raw volumes of 10, 14, and 11 ml for GTVmacro, GTVCTLW and GTVCTMW, 
respectively. The logarithmic transformation led to means and standard deviations 
that are equal to 0.11 ± 0.25 and 0.54 ± 0.32 for CT with mediastinal and lung 
windows, respectively. Hence, mediastinal window showed a reduction of 
overestimation compared to the lung window (Student t-test, p=0.002 and p=0.28 for 
CTLW and CTMW, respectively) and also reached the smallest standard deviation among 
all imaging modalities. For FDG-PET, the results did not differ from those observed for 
the whole group, the best results being provided again by the gradient-based method 
(GTVPETW&C).  
Regarding the matching analysis, there was no statistical difference between the 
different imaging modalities and delineation methods (ANOVA, p=0.59). The average 
DSI values were comparable with 0.58 and 0.62 for the CTLW and CTMW respectively, 
0.68, 0.66, 0.66 and 0.63 for the PETW&C, PETSBR, PET40% and PET50% with a 2 mm voxel, 
respectively, and 0.66, 0.64, 0.62 and 0.65 when images with a 4 mm voxel size were 
used. 
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Logarithmically transformed GTVs 
without the subgroup "poorly defined tumors"
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Figure 3.3 Comparison between the mean volumes determined on each imaging modality for all 
patients (a) and for the subgroup excluding the ‘‘poorly defined tumors” (b). Volumes are 
presented as mean ± 1SD of logarithmic differences between the various GTV and GTVmacro. 
Differences and SD tending towards zero means that the imaging modality and delineation 
technique are reliable and robust to assess the macroscopy. Regarding the whole group of patients 
(left panel (a)), FDG-PET segmented by the gradient-based method (PETW&C) provided the closest 
and more robust estimation of the pathology. When only considering the ‘‘well defined tumors” 
(right panel (b)), CT reached an accurate estimation of the macroscopic specimen, which was even 
better when the mediastinal window was selected. 
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Discussion 
Overall, we showed that FDG-PET outperformed CT for the delineation of primary 
tumor volumes in NSCLC, as previously observed in HNSCC patients [86]. We also 
confirmed the superiority of the gradient-based segmentation, compared to usual 
threshold-based delineation, both in terms of raw volumes and logarithmically 
transformed ones. However, the added value of FDG-PET was more pronounced in 
cases of tumors surrounded by densifications of the lung parenchyma (atelectasis, 
BOOP). In other cases, the high natural contrast between the tumor and air allowed an 
estimation of the tumor volume on CT accurate enough for clinical use, even more if 
the mediastinal window was selected.  
In comparison with previously published studies addressing the pathological 
validation of PET-based contouring in NSCLC, methodological aspects were performed 
in highly controlled conditions. Firstly, the validity of the pathologic specimen as “gold 
standard” relies on the accuracy of the whole procedure. In this respect, our work is 
based on the method previously developed and validated by Daisne et al. in laryngeal 
carcinomas [86]. The major advantages of this approach are that (i) the freezing 
procedure causes very limited tissue retraction compared to other fixation 
techniques, and (ii) the registration between CT and digitized images of the surgical 
specimen prevented from any distortion related to the slicing procedure. This leads to 
a reliable three-dimensional representation of the pathologic specimen. Interestingly, 
a three-dimensional assessment has been shown to provide a better estimation of the 
true tumor volume than measurements of one, two, or three sectional diameters [51, 
85, 88, 90, 136, 137], since the relationship between the volume and the diameter 
along any direction is not linear except for strictly spherical objects [48]. To our best 
knowledge, only Stroom et al. performed a volumetric analysis between usual imaging 
and pathology findings [87].  
Secondly, our study was the first to deal with the tumor motion during the images 
acquisition. In lung tumors, the long acquisition time required for PET imaging 
generates additional motion blur within images, with apparent loss of image contrast, 
increase of tumor size and decrease in activity [139, 140]. These artifacts caused by 
respiratory motion degrade the qualitative and quantitative accuracy for diagnosis 
purposes. In addition, they can also strongly affect the tumor delineation procedure, 
whatever the segmentation method used. This issue can largely be addressed by using 
4D PET-CT acquisition, as described in [141]. In our study, PET images were 
reconstructed at the end-expiratory phase of the breathing cycle, which is the most 
stable [43, 142-144]. This guaranteed the most accurate target delineation by 
avoiding unwanted motion-induced blur. In order to keep acquisition statistics and 
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the signal to noise ratio (SNR) to reasonable levels, the acquisition time was 
prolonged accordingly. 
Regarding PET image, the gradient-based method has been used in this study as a 
robust alternative to the threshold-based approaches. Indeed, the simple method that 
selects a fixed threshold of activity failed to provide an accurate estimation of the 
tumor volume. In summary, thresholds of 40% of the maximal activity led to an 
overestimation of the macroscopy, while a value of 50% underestimated it, with 
considerable variations on an individual basis for both approaches (Table 3.2, Figures 
3.1 and 3.3). These findings confirm previously published data in NSCLC patients. 
Stroom et al. showed that a threshold of 42% overestimated the pathology [87]. Yu et 
al. determined that a cut-off of 31% ± 11% of the SUVmax provided the best estimate, 
which corresponded to a range from 15% to 55% according to individual patients 
[136]. Wu et al. used several fixed thresholds varying from 20 to 55%, and found that 
the value of 50% best correlated with the pathology, but CT remained superior to PET 
for this task [85]. In addition, some studies pointed out that the threshold for 
accurately recover the actual volume, substantially differs with the size, shape, 
heterogeneity, and background uptake of the tumor, questioning thus the use of a 
single threshold [74, 75, 84, 91, 92, 145]. Consequently, the adaptive threshold relying 
on the SBR appeared to be a valuable alternative [83]. However, this method did not 
improve the accuracy of the PET segmentation compared to fixed thresholds, and 
tended to overestimate the pathological specimen in our results. This confirms the 
data from Schaefer et al., showing that the SBR-based method led to an overestimation 
up to 28% of the PET over the CT-based GTV [94]. In contrast, Van Baardwijk et al. 
observed a slight underestimation of the macroscopic specimen when using this 
technique, although a good correlation was obtained [90]. 
Compared to thresholding approaches, the gradient-based method better deals with 
the inherent shortcomings of PET images, such as their low SNR and resolution. The 
method includes specific preprocessing steps to reduce statistical noise and resolution 
blur, which both preclude the accurate detection of the tumor boundaries. Denoising 
and deblurring sharpen the image gradient in a principled way, making it easier to 
detect peaks of gradient magnitude with algorithms such as the watershed transform 
[95]. This method was first validated in our center on phantom and HNSCC patient 
materials, and was shown to outperform the SBR method in a laryngectomy series 
[95]. Our data confirm the superiority of this approach also in NSCLC, since it 
provided a closer estimation of the pathological specimen than the threshold-based 
techniques, not only on average but also on case-by-case basis. The last observation is 
clinically important, as any misestimation of the target volume for a given patient 
might jeopardize the treatment outcome. Consequently, we believe that the gradient-
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based method should be used as the reference segmentation method in the field of 
PET-driven delineation in NSCLC patients. 
Although CT has been long-past considered as the reference imaging modality for the 
delineation of primary tumor in lung, it suffers from a low contrast resolution in cases 
of tumors associated with fibrosis, atelectasis, pleural effusion, post-stenotic 
pneumonia, or tumors located close to the mediastinum or chest wall. In such 
situations, consequential overestimations of the true volume can occur, as seen in the 
present study with the two patients suffering from BOOP and atelectasis, and large 
inter-observer variations have been reported due to image interpretation difficulties 
[48-50, 53-55, 81]. In the other cases, the air offers a high natural contrast in 
peripherally located tumors, and CT remains an appropriate modality imaging in 
these tumor locations. However, the window setting should be carefully selected 
before manual delineation, since these parameters are known to influence the image 
interpretation. In that regard, the radiotherapy group of the EORTC recommended 
some years ago the use of a lung window for the delineation of the primary lung 
tumor [146], based on previous phantom measurements [147, 148]. Although this 
recommendation is nowadays widely accepted and followed, most recent clinical 
studies have illustrated that its use typically led to an overestimation of the surgical 
specimen [85, 87, 88, 149]. In addition, data of Grills et al. showed that the volumes 
delineated with the mediastinal window were closer to the pathology findings 
compared to those defined with the lung one [149]. Obviously, the available clinical 
data based on patient material, including our own results, seems to indicate that the 
mediastinal window would be more appropriate. In this context, we recommend using 
mediastinal window for CT-based GTV delineation of primary NSCLC, even if the 
contradictory results from patient and phantom measurements preclude any 
definitive conclusion.   
The collected data has potential limitations. Firstly, we assume that the surgical 
specimen is the ground truth. However, uncertainties persist about the volume of the 
macroscopic tumor despite each step of the procedure has been controlled carefully. 
Actually, we consider that the freezing procedure does not involve any consequential 
modification based on the assertion of Daisne et al. who observed very little or no 
tissue distortion after the same procedure on macroscopic laryngeal pieces [86]. Then, 
we estimated that the box slicing was performed regularly, although small deviations 
were observed. Finally, the 3D volume reconstruction of the digitized slices was 
processed by semi-automated tools that allowed for less variability. 
Secondly, the lobe deformation might preclude the adequate assessment of GTV, and 
might impact the matching analysis. Albeit the lobe was filled with gelatin until it was 
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uniformly inflated as assessed by manual palpation and visual check, the lobe shape 
significantly differed from its in vivo status. However, we assumed that the GTV is a 
non-deformable rigid tissue, relying on previous investigations on the potential 
deformation of the lung lobe after surgery [87, 150]. This assumption excludes the use 
of any deformable registration algorithms, if artificially-induced volume and shape 
modifications of the tumor on the surgical specimen want to be avoided. Furthermore, 
such algorithms could encounter technical difficulties in case of different contrasted 
images, such as CT or PET and pathology images. However, optimizing rigid 
registration at the tumor level was a difficult task, and the resulting small translation 
gap between the various GTV may partially explain the relatively low DSI observed in 
our study.  
Thirdly, since the tumors sample came from a surgical series, the size of our tumors 
set is relatively small with an average volume of 11.3 ml, which corresponds to a 
sphere of 28-mm diameter. We can assume that the partial volume effect (PVE) is 
relatively substantial since the sizes of some tumors are less than 3 times the FWHM 
considering individual patients. The PVE could explain the differences observed 
between the GTVPET reconstructed with voxels size of 2 and 4 mm. In fact, the GTVPET4 
seems to give a larger tumor than the GTVPET2 because of the relatively low spatial 
resolution of the imaging system and the tissue fraction effect. As a result, part of the 
tumor signal spills out into surrounding areas and the image is larger but dimmer 
compared to the actual tumor, hence overestimating it in size and underestimating it 
in intensity value. Basically, the parameters of image reconstruction should favor a 
high spatial resolution, in order to decrease the PVE [151].  
Fourthly, the present study concerns surgical cases. Consequently, tumors have small 
sizes and peripheral location. The extrapolation of our data to central location or 
larger tumors seems feasible given that FDG-PET is more relevant in case of poorly 
defined tumors (i.e. tumors located next to the mediastinum or larger tumor inducing 
pneumonia or atelectasis). As a result, FDG-PET could be useful more often in 
radiotherapy intent NSCLC patients.  
Finally, the small sample of patients decreases the power of the statistical tests. In 
consequence, some irrelevant tests could reach a level of significance for a larger 
cross-section and notably, would display some significant differences among the 
segmentation methods used.  
In conclusion, in regard to these results, we suggest to use FDG-PET images 
segmented by a gradient-based technique for the delineation of the primary tumor in 
NSCLC, surely when they are poorly identifiable on conventional CT. For well-defined, 
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peripherally located tumors, the CT with mediastinal window remains a clinically 
acceptable alternative to FDG-PET. 
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Introduction 
Concomitant chemo-radiation (CRT) for locally advanced (LA) stages non-small cell 
lung cancer (NSCLC) achieves poor tumor local control (LC) rates, which negatively 
affects the patient’s outcome with a 5-year loco-regional failure rate of about 30% [7]. 
Available data show that increasing tumor LC improves survival, even in LA NSCLC [7, 
152]. These evidences support dose intensification strategies [7, 153-157]. 
Escalating the dose uniformly over the whole tumor remains challenging, and may 
result in unacceptable toxicities due to the proximity of radiosensitive organs. 
Although the RTOG 0617 study failed to show any survival gain from dose 
intensification (74 Gy versus 60 Gy), pursuing validation of dose escalation makes 
sense, considering radiobiological evidence [23]. Indeed, several factors may explain 
this unexpected failure, like unadapted organs at risk (OAR) constraints in three-
dimensional (3D) and IMRT planning and dose escalation on whole target volume 
(TV), causing late cardiac and pulmonary toxicity and death. The extended overall 
treatment time (OTT) in the 74 Gy arm [158] or less optimal target volume coverage 
in order to meet constraints could also explain the higher local failure rates. 
In that regard, dose escalation schemes based on functional imaging might improve 
the therapeutic ratio. [18F]-fluoro-deoxy-glucose positron emission tomography (FDG-
PET) provides better soft tissue contrast between the tumor and normal tissues than 
computed tomography (CT), thereby improving the definition of the gross primary 
tumor volume (GTV) [159]. Furthermore, local recurrence or progression typically 
occurs within geometrically stable high FDG uptake regions of the primary tumor, 
providing a rationale to guide selective dose intensification [14, 63, 64, 67, 69, 160].  
Moderate accelerated hypo-fractionation schedules might also improve the LC. 
Shortening the OTT reduces the effect of accelerated repopulation during the course 
of radiotherapy (RT) [10, 11, 13, 161]. Moreover, a dose prescription based on normal 
tissue constraints instead of a classic fixed prescription has been shown feasible, with 
promising results in terms of toxicity and outcome [13, 14, 16, 96]. This approach 
makes sense in case of moderate hypo-fractionation scheme, where particular 
attention is paid to radiosensitive organs to avoid late normal tissue injury. 
Modern RT technologies like intensity modulated radiation therapy (IMRT) and image 
guided radiation therapy (IGRT) contribute to accurate delivery of selective boost 
doses to metabolically active regions in the tumor [162]. Nonetheless, if advanced 
delivery techniques allow steeper dose gradients, tumor motion management 
becomes even more critical in the process. The conventional Internal Target Volume 
(ITV) can adequately address this issue. 
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For all these reasons, we designed a clinical trial to assess the feasibility of an 
individualized and accelerated FDG-PET boost prescription delivered with IMRT in LA 
NSCLC patients. The study also aimed to assess the impact of this prescription on the 
tumor LC and chemo-radiation-induced early and late toxicities with a 2-year follow-
up (FU). 
Materials and methods 
1. Patient selection 
Thirteen patients with histologically proven stage II-III NSCLC were prospectively 
enrolled from November 2010 to February 2013. The diameter of their FDG-PET 
positive primary tumor had to exceed 3 cm, since smaller tumors have relatively 
better LC. Patients had no bulky lymph nodes (LN) involvement (average LN diameter 
of 13.3 ± 5.5mm).  All patients were fit for sequential or concomitant CRT (i.e. ECOG-
performance status ≤ 2). Patients with prior thoracic radiation or poor lung function 
(FEV1 or DLCO <30% of predicted age-adjusted normal values) were not eligible. 
Patients were recruited from 2 different hospitals. The Local Ethical Committees 
approved the study and all patients gave their informed consent. 
2. Image acquisition 
Before irradiation (average 14.9 days), all patients underwent a contrast-enhanced 
computed tomography (CE-CT) in free breathing, a four-dimensional (4D)-CT and a 
4D-FDG-PET on an EANM-accredited PET/CT camera (Gemini TF, Philips Medical 
System, Cleveland, OH, USA). Patients were immobilized with a customized 
thermoplastic mask (CIVCO Medical Solutions, Iowa, USA) in supine treatment 
position.  
The CE-CT acquisition started 35 s after intravenous injection of 70 ml of iodinated 
contrast at a rate of 2.0 ml/s (Iohexol, Omnipaque 350, GE Healthcare, Diegem, BE). 
The acquisition typically covered the thoracic region from the supraclavicular fossa to 
the upper abdomen. CT images were reconstructed in 2 mm slice thickness, and 
transferred to the treatment planning system (Elekta Computerized Medical Systems 
Software – Focal v4.40). 
The 4D-CT had the same parameters as the CE-CT, except for the lower pitch (0.08). 
Patients were audio-coached to regularize breathing [108]. The 4D-CT scans were 
binned retrospectively into 10 equally distributed temporal phases, for motion 
management purposes.  
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The 4D-FDG-PET images were acquired 60 to 120 min after injection of an average 
activity of 8.04 mCi of FDG in patients fasting for 6h and with normal glycaemia (<140 
mg/dl). The scans were binned in 5 equally distributed temporal phases to create the 
4D PET sequences. The acquisition duration was 15 min per bed position, to 
compensate for 4D gating and keep sufficient statistics. After correction for decay, 
random, scatter, and attenuation, images were reconstructed by iterative 3D LOR-
OSEM, with a transverse field of view of 180 mm (one bed position) centered on the 
region of interest. Attenuation correction involved the averaged 4D-CT. The image 
matrix was 288 x 288 x 90 isotropic voxels (2 x 2 x 2 mm3). 
3. Definition of organs at risk and target volumes 
3.1. CT images processing 
The OARs, i.e. lungs, esophagus, spinal cord, bronchus, trachea, large vessels, heart 
and brachial plexus were manually delineated on the CE-CT. A 5 mm margin around 
serial organs was added to obtain the corresponding planning organ at risk volume 
(PRV). 
The GTV on CT images included the primary tumor (GTVT-CT) and the pathologic 
lymph nodes (GTVN-CT), i.e. PET positive and/or histologically proven. GTVT-CT and 
GTVN-CT were manually delineated on the CE-CT using a mediastinal window (width, 
600 HU; center, 40 HU), as shown in a previous study [159]. 
A 5 mm margin defined the clinical target volumes (CTVT-CT and CTVN-CT) around both 
GTVs, to account for potential microscopic extensions. The CTVs were manually 
corrected for anatomical barriers, i.e. large vessels, bone, pleura and esophagus when 
organs were not clinically invaded on the available CT and PET-CT images.   
Internal tumor motion due to breathing was estimated in the 4D-CT scan and an ITV 
was automatically generated [163]. 
The planning target volumes (PTVT-CT and PTVN-CT) resulted from isotropic 5 mm 
expansions of both ITVs. 
3.2. PET images processing 
The metabolically active region within the primary tumor (GTVPET) was automatically 
and accurately segmented on each temporal phase of the 4D-FDG-PET, using a 
validated gradient-based method [95, 159]. The union of these 5 GTVsPET defined the 
ITVPET. No CTV margin was used. Finally, the PTVPET was obtained by adding a 5 mm 
isotropic expansion to the ITVPET. 
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All contours drawn on PET were transferred to the CE-CT images for planning. 
4. Treatment planning  
A total dose of 62.5 Gy was prescribed to PTVT-CT and PTVN-CT and delivered in 25 
once-daily fractions of 2.5 Gy. The dose per fraction was then individually increased to 
the PTVPET (maximum dose of 4.8 Gy per fraction), until a predefined dose constraint 
was reached for any organ [15, 16, 20, 22, 24, 29, 34, 153, 164-166]. This was 
performed using a simultaneous integrated boost (SIB) with either helical IMRT or an 
intensity-modulated arc therapy (IMAT) technique (11 and 2 patients, respectively). 
Treatment was delivered in an accelerated scheme of 5 weeks to minimize the effect 
of accelerated repopulation.  
Treatment plans were made on either TomoTherapy V. 4.2.1 or Eclipse AAA v.10.0.28 
Treatment Planning System (TPS). All TomoTherapy plans used a 2.5 cm field width, a 
pitch of 0.287 and a planned modulation factor of 2.0. RapidArc plans relied on MLC 
120 HD and a calculation grid size of 0.25.  
Treatment plan quality evaluation involved constraints to TVs and OARs. Acceptability 
criteria for TVs were: D50 equal to prescription for PTVCT and PTVPET, D95 above 95% 
of prescription, D99 above 90% of prescription and D2 below 105% of prescription for 
the PTVPET.  
The physical dose constraints for the OARs [15, 16, 20, 22, 24, 29, 34, 153, 164-167], 
were normalized for the prescribed dose (i.e. 62.5 Gy given in 25 fractions) and 
equivalent doses in 2 Gy per fraction (EQD2) using the appropriate α/β ratios (i.e. α/β  
= 2 for spinal cord and brachial plexus, and α/β = 3 for lungs, esophagus, large vessels, 
bronchus, and heart) were calculated with the linear quadratic (LQ) model. Table 4.1 
summarizes all OARs constraints. 
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Table 4.1 Dose constraints for organs at risk. 
Organs at risk α/β Constraints  EQD2 
Lungs – GTV 3 MLD FEV1/DLCO > 60%   < 19 Gy 
   FEV1/DLCO 40-60%   < 15 Gy 
   FEV1/DLCO < 40%   < 10 Gy 
  V20 Gy    < 30% 
  V13 Gy    < 40% 
  V10 Gy    < 45% 
  V5 Gy total    < 65% 
  V5 Gy contralat    < 60% 
Esophagus 3 V40 Gy    < 50% 
  V50 Gy    < 30% 
  V70 Gy    < 20% 
  Dmean    < 34 Gy 
Spinal cord 2 D2    < 50 Gy 
Brachial plexus 2 D2    < 60 Gy 
Large vessels 3 D2    < 94 Gy 
Bronchi 3 D2    < 94 Gy 
Whole heart 3 Dmean    < 46 Gy 
  V40 Gy    < 50% 
Abbreviations: MLD, mean lung dose; FEV1, forced expiratory volume in 1 second; DLCO: diffusing 
capacity for carbon monoxide; Dx, dose received by x percent of the organ at risk volume; VxGy, 
volume of the OAR receiving x Gy; EQD2, equivalent dose in 2 Gy fraction. 
5. Treatment delivery and follow-up (FU) 
RT started at day 22 (first day of cycle 2) of cisplatin/etoposide or 
cisplatin/vinorelbine chemotherapy regimen for concomitant scheme, and after 6 
cycles of gemcitabine and cisplatin induction chemotherapy for sequential scheme (1 
patient).  
On-line verification was performed prior daily treatment using mega-voltage CT (MV-
CT) or cone-beam CT (CB-CT) for set-up correction. 
Each patient was seen before treatment (baseline consultation), weekly during RT, 2 
weeks, 1 month, 2 months after RT, then every 6 months until 2 years. Consultations 
consisted of history, physical examination, and evaluation of potential toxicities. 
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6. Toxicities 
Acute (i.e. less than 90 days after the start of RT) and late (i.e. more than 90 days after 
the start of RT) chemo-radiation induced toxicities were scored at each consultation 
according to common terminology criteria for adverse events (CTCAE) v.4.0. 
7. Tumor response assessment 
Tumor response was assessed with FDG-PET/CT at 2, 6, 12, and 24 months after RT. 
Measurements were blinded and performed by different experienced operators, 
depending on the image modality. 
Local failure was defined as a recurrence in the primary tumor. Regional failure was 
defined as a mediastinal LN recurrence occurring either in field (i.e. initially involved 
nodes) or out of field. Distant failure was considered for recurrence in any distant LN 
or organs. All recurrences were stated based on the FDG-PET imaging and no proven 
histology was required. 
Metabolic tumor response or recurrence was assessed using PET Response Criteria in 
Solid Tumors (PERCIST) [62, 168], which recommends using SULpeak. 
Moreover, tumor response was also assessed anatomically according to Response 
Evaluation Criteria in Solid Tumors (RECIST) [169] and metabolically with the 
classical maximum standardized uptake value (SUVmax) [61].  
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8. Statistical analysis 
The various descriptive data (target volumes and doses) were presented with their 
mean and standard deviation.  
Progression-free survival (PFS) and overall survival (OS) medians and 95% 
confidence interval (CI) were estimated using the Kaplan-Meier method.  
PFS was defined as the time from the date of first RT to the earliest to the date of the 
event documented based on the PERCIST results. Patients with no recurrence (local, 
regional, or distant as appropriate) or alive at the time of analysis were censored at 
the date of last tumor assessment.  
OS was defined as the time from the date of first RT until date of death. For patients 
alive at the date of analysis, time to death was censored at the time of last FU. 
All statistics were computed with SAS 9.3 (Statistical Analysis System, NC, USA). 
Results 
1. Patient and tumor characteristics 
Table 4.2 summarizes characteristics of patients and primary tumors. Mean age was 
63.3 ± 8.9 years. Six patients had central tumors whereas 7 had peripheral tumors. 
Seven patients had adenocarcinoma while 6 had squamous cell carcinomas. Mean 
primary tumor diameter at baseline was 49.3 ± 15.0 mm. Mean PTV of the primary 
tumor at baseline was 262.4 ± 205.1 ml on CT and 108.6 ± 94.9 ml on PET. Mean 
SULpeak of the primary tumor at baseline was 7.35 ± 2.70. Evolution of SULpeak, SUVmax 
and longest diameter of the primary tumor are shown in Table 1 and Figure 1 of the 
appendix B.  
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Table 4.2 Patient and primary tumor characteristics. 
Pat 
No 
histology cTNM  location Age 
(years) 
GTVCT 
(ml) 
GTVPET 
(ml) 
PTVCT 
(ml) 
PTVPET 
(ml) 
SULpeak 
baseline 
Dose 
(Gy) 
Dose/# 
(Gy) 
1 SCC T3N3M0 RU – 
central 
59 61.6 14.6 490.9 64.1 9.77 75 3.0 
2 SCC T4N2M0 LU – 
central 
68 181.0 78.9 655.2 215.2 11.08 70 2.8 
3 SCC T4N2M0 RM – 
central 
45 65.7 21.3 390.0 100.5 3.92 75 3.0 
4 SCC T3N2M0 LU – 
central 
58 89.3 53.1 372.5 200.4 8.40 75 3.0 
5 SCC T3N2M0 RU – 
central 
75 36.4 16.9 262.6 69.5 5.47 75 3.0 
6 ADC T4N2M0 LL – 
periph 
69 174.1 80.6 587.8 300.2 9.62 65 2.6 
7 ADC T3N2M0 RU – 
periph 
56 63.4 31.7 241.7 114.1 4.28 77.5 3.1 
8 ADC T3N2M0 RU – 
periph 
59 277.2 193.3 661.2 342.4 7.35 65 2.6 
9 ADC T2aN2M0 RU – 
periph 
69 8.1 4.4 84.3 42.8 5.07 120 4.8 
10 ADC T2bN1M0 RL – 
periph 
72 34.0 23.4 185.1 78.4 10.14 75 3.0 
11 SCC T1bN2M0 RU – 
periph 
66 7.3 5.65 62.3 25.6 9.87 100 4.0 
12 ADC T2N3M0 RU – 
periph 
74 6.7 6.20 111.0 51.7 3.19 110 4.4 
13 ADC T3N3M0 RU – 
central 
54 65.1 20.7 342.7 110.9 7.40 80 3.2 
Abbreviation: Patient No, Patient number; SCC, squamous cell carcinoma; ADC, adenocarcinoma; 
RU, right upper; LU, left upper; LL, left lower; RL, right lower; RM, right middle; central, centrally 
located, based on RTOG criteria; periph, peripherally located, based on RTOG criteria; GTVCT, gross 
tumor volume on CT images; GTVPET, Gross Tumor Volume on PET images; PTVCT, Planning Target 
Volume on CT images; PTVPET, Planning Target Volume on PET images; SULpeak, lean body mass 
normalized SUV; Dose: prescribed dose to the PET positive area within the tumor. 
2. Dose escalation level 
The mean prescribed dose to the PTVPET reached 82.1 ± 17.9 Gy for all patients, with 
values of 89.2 ± 24.0 Gy, and 75.0 ± 3.2 Gy for peripheral and central tumors, 
respectively. The corresponding EQD2 with a α/β ratio equal to 10 (i.e. for tumor) 
were 90.8 Gy, 100.8 Gy, and 81.3 Gy, respectively. The main limiting organ was the 
lung (8 patients, 62%) although brachial plexus was also limiting for apex-located 
tumors (2 patients, 15.4%). Figure 4.1 shows two dose distribution profiles for a 
central and a peripheral tumor. 
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Figure 4.1a Coronal plane of planning FDG-
PET/CT in patient 3 presenting a squamous cell 
carcinoma of the right middle lung classified as 
cT4N2M0. 
Gross and planning target volumes are 
represented with GTVPET in orange, PTVPET in 
red, GTVCT in light blue and PTVCT in dark blue.  
This centrally located tumor received a boost 
dose of 75 Gy on the metabolically active area 
(PTVPET) while the remaining tumor received 
62.5 Gy (PTVCT). The isodose lines are 
represented with in red, the 71.3 Gy isodose 
(95% of 75 Gy), in green, the 59.4 Gy isodose 
(95% of 62.5 Gy), in blue, the 18.2 Gy isodose 
(corresponding to 20 Gy EQD2) and finally, in 
white, the 4.6 Gy isodose (corresponding to 5 Gy 
EQD2). 
 
Figure 4.1b Coronal plane of planning PET/CT 
in patient 11 presenting a squamous cell 
carcinoma of the upper right lung classified as 
cT1bN2M0. 
Gross and planning target volumes are 
represented with GTVPET in orange, PTVPET in 
red, GTVT-CT in light blue, PTVT-CT in dark blue, 
GTVN-CT in light green and PTVN-CT in dark 
green. 
This peripherally located tumor received a 
boost dose of 100 Gy on the metabolically active 
area while the remaining tumor received 62.5 
Gy. The isodose lines are represented with in 
red, the 95.0 Gy isodose (95% of 100 Gy), in 
green, the 59.4 Gy isodose (95% of 62.5 Gy), in 
blue, the 18.2 Gy isodose (corresponding to 20 
Gy EQD2) and finally, in white, the 4.6 Gy 
isodose (corresponding to 5 Gy EQD2). 
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3. Toxicities 
Acute and late toxicity rates are reported in Table 4.3. 
All patients experienced acute grade 1 and 2 fatigue, cough, esophagitis and 
hematological toxicities while 9 patients (69.2%) presented grade 1 and 2 weight loss. 
Acute grade 3 toxicities included esophagitis (23.1%), dyspnea (23.1%), fatigue 
(30.8%), dermatitis (15.4%), anorexia (15.4%), and nausea (7.7%). No grade 4 acute 
non-hematological toxicity was reported. In all patients but one (patient 3), radio-
induced symptoms had resolved within 2 months after treatment (6 months for 
respiratory symptoms). 
Concerning late toxicities, 5 patients presented grade 1 pulmonary fibrosis (38.5%), 4 
patients developed grade 2 pneumonitis (30.8%) but no late pulmonary toxicities of 
grade ≥ 3 occurred. One patient (7.7%) with a central tumor (patient 3) experienced 
grade 3 esophageal stenosis associated with a grade 4 dysphagia, a grade 4 
pericarditis, as well as a bronchial fistula and a fatal grade 5 hemoptysis. An additional 
patient (P4) died from a grade 5 hemoptysis. 
Two patients required unplanned hospitalization during or after the chemo-radiation 
treatment. Patient 3 (P3) was first hospitalized for a febrile neutropenia in the second 
week of radiation treatment. At the end of CRT, he was readmitted for hydration and 
parenteral alimentation in the context of a grade 3 acute esophagitis and dysphagia 
associated with tube feeding intolerance. Two weeks after the end of CRT, this patient 
presented with an aphagia due to an extrinsic compression of the esophagus by 
necrosis of mediastinal lymph nodes. A stent was placed. Five months later, he was 
admitted in intensive care unit for a pericarditis associated with a pericardial 
tamponade and hemoptysis treated by pericardial drainage and embolization, 
respectively. He died finally from a massive hemoptysis 8 months after the end of CRT. 
An additional patient (P11) was admitted for a febrile neutropenia in the last week of 
CRT. 
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Table 4.3 Number of patients experiencing acute and late toxicities. 
 Maximum toxicity grade* 1 2 3 4 5 
Acute Fatigue 13 9 4 0 0 
 Weight loss 9 4 0 0 0 
 Anorexia 6 1 2 0 0 
 Esophagitis/dysphagia 12 7 3 0 0 
 Nausea 8 1 1 0 0 
 Cough 11 3 0 0 0 
 Dyspnea 12 6 3 0 0 
 Pneumonitis 2 4 0 0 0 
 Retrosternal thoracic 
pain§ 
9 4 3 0 0 
 Hemoptysis 2 0 0 0 0 
 Dermatitis 8 5 2 0 0 
 Febrile neutropenia 0 0 2 0 0 
 Anemia 12 8 0 0 0 
 Leucocytopenia 7 8 1 2 0 
 Lymphopenia 6 10 11 5 0 
 Neutropenia  5 4 2 3 0 
 Thrombopenia 7 2 1 1 0 
Late Esophageal stenosis ‡ 0 0 1 0 0 
 Dysphagia ‡ 0 0 0 1 0 
 Bronchial fistula ‡ 0 0 1 0 0 
 Pericarditis ‡ 
Hemoptysis ‡ 
0 
0 
0 
0 
0 
0 
1 
0 
0 
2 
 Pulmonary fibrosis 5 0 0 0 0 
* defined according to CTCAE v.4.0. 
§ due to esophagitis. 
‡ P3 developed several late complications including dysphagia, esophageal stenosis, bronchial 
fistula, perdicarditis and a fatal hemoptysis. 
4. Recurrence analysis 
Median FU for living patients was 29.28 months (95%CI: 21.25-40.56). At the end of 
FU, 7 patients were still alive (53.8%) while 6 patients died (46.2%). Four distant 
progressions and 2 grade 5 toxicities (hemoptysis) led to 6 deaths.  
Table 4.4 report patterns of relapse, whereas the appendix B provides all survival 
tables and figures as well as overall, local, regional and at distance PFS.  
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Local progression occurred in 2 patients (15.4%) at 6 and 12 months, respectively. In 
both cases, local recurrences were not isolated and happened simultaneously (1 
patient) or after regional and distant recurrence (1 patient).  
Regional recurrence occurred in 6 patients (46.2%). Four patients (30.8%) developed 
out-of-field regional recurrence while 1 patient (7.7%) had simultaneously an in-field 
and out-of-field regional recurrence and the last one (7.7%) experienced in-field 
recurrence. All but one were associated with either local (1 patient) or distant (4 
patients) recurrence.  
Distant recurrence occurred in 6 patients (46.2%), as cerebral, liver, distant LN or 
lung metastases.  
Table 4.4 Patterns of relapse. 
Recurrence Number of patients (%) 
No 6    (46) 
Yes 7    (54) 
Local tumor failure 2    (15) 
     Isolated  0      (0) 
     Non-isolated 2    (15) 
Regional nodal failure 6    (46) 
     Isolated 1      (8) 
     Non-isolated 5    (38) 
Distant failure 6    (46) 
     Isolated 3    (23) 
     Non-isolated 3    (23) 
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Discussion 
Our study demonstrated the feasibility of individualized dose escalation based on 
FDG-PET in LA NSCLC patients. The boost on FDG-avid regions reached 82 Gy on 
average for all patients, with values of 89 Gy and 75 Gy for peripheral and central 
tumors, respectively. We showed with a minimum 2-year FU no isolated local 
recurrence in our cohort. Acute toxicities were mild and no late toxicity was recorded 
except two grade 5 toxicity for centrally located tumors. We also demonstrated that 
distant recurrence remains a critical issue.  
All methodological aspects of the dose escalation trial were carefully programmed. 
Firstly, dose was escalated non-uniformly within the tumor, allowing for higher dose 
prescription, while keeping toxicities as low as possible (see Figure 4.1). Secondly, all 
patients but one received concurrent CRT in an accelerated way without treatment 
interruption and with perfect FU compliance. Thirdly, each treatment was planned 
and optimized meticulously with respect to OARs constraints in a step-by-step dose 
escalation fashion. Fourthly, treatments were delivered in helical IMRT or IMAT to 
obtain sharp dose distributions, and using SIB to keep identical OTT. Finally, 4D 
imaging was acquired in strict conditions for each patient and TVs were delineated 
accurately with methods validated on NSCLC patients [154, 159, 170]. 
In our cohort, P1 and P6 had non-isolated local recurrence at 6 and 12 months, 
respectively. Both patients had large (T3-T4) and poorly differentiated primary 
tumors with high FDG uptake at diagnosis, as well as poor response to the first course 
of chemotherapy. P1 received a boost on metabolically active areas of 75 Gy and P6, a 
dose of 65 Gy, which corresponded to low dose escalation levels limited by lung 
constraints.  
Our local tumor control results compared favorably to those from conventional CRT, 
even though most multicenter randomized trials do not study tumor LC as a primary 
endpoint. In a radiation dose escalation studying LC, Kong et al. demonstrated that 
progression was initially observed at local site alone in 37% and at distant sites only 
in 46% [153]. 
Regarding regional recurrence, several studies have demonstrated that involved 
nodes irradiation (i.e. omitting elective nodal irradiation) is safe with less than 5% of 
isolated nodal failure [171-175]. De Ruysscher et al. showed that selective mediastinal 
node irradiation based on FDG-PET resulted in low isolated nodal failure rates, with 
only 1 patient (2%) developing isolated out-of-field regional recurrence and 2 
patients (4.5%) presenting a non-isolated out-of-field regional recurrence [170]. 
However, the incidence of out-of-field regional failures was higher in our series 
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(38.5%), and mainly in the sub-clavicular area (3 out of 5 patients). Despite the 
potential role of incidental irradiation of uninvolded mediastinal areas close to the 
PTV, the sub-clavicular area does not beneficiate from this effect for these three 
patients.  For the other patients, the LN recurrences were located far away from the 
RT field and these areas did not beneficiate from any incidental irradiation. 
As in most trials, the main pattern of recurrence remains distant metastases, which 
raises the issue of systemic treatments. In that regard, systemic targeted therapies 
appear as a promising strategy and combination with RT could favorably affect the 
patient’s outcome [176, 177], as shown in head and neck cancer. 
Acute and late toxicity rates were comparable to conventional schemes except for two 
patients who died from a grade 5 hemoptysis. The first patient (P3) had a central 
tumor, classified cT4N2M0 by invasion of the esophagus and bronchial tree, and 
encasement of the pulmonary artery (grade 3 pulmonary artery involvement 
according to [178]). The prescription to the PTVPET was 75 Gy (i.e. 90 Gy EQD2 with 
α/β ratio of 3 for OARs). The patient experienced at third week of RT a grade 3 
esophagitis requiring a feeding tube and morphinic drugs. Five months after the end 
of CRT, the patient developed bronchial and esophageal fistulas complicated by 
mediastinitis and pericarditis. We retrospectively checked all constraints to the 
esophagus, bronchial tree, and great vessels, which did not exceed recommended 
values but with a recording of esophagus maximal dose of 76.72 Gy (corresponding to 
92.1 Gy EQD2 with α/β ratio of 3). No local recurrence was observed in spite of 
multiple bronchial/esophageal biopsies and pericardial effusion analysis. We 
hypothesized that radio-necrosis and rapid shrinkage of the tumor post CRT took 
away the bronchus and esophagus walls, causing lethal hemorrhage few weeks later. 
After this adverse event, we modified inclusion criteria to exclude tumors classified as 
T4 by invasion of mediastinal organs [179, 180]. Therapeutic options for these 
patients are very limited, and most die eventually from local complications if no 
curative treatment is given. 
Additionally, P4 deceased also from hemoptysis 5 months after CRT. We classified this 
hemoptysis as a grade 5 toxicity although the event appears rather early after the CRT. 
This centrally located tumor was classified as cT3 versus cT4N2M0 by suspicious 
esophagus invasion. At diagnosis, the tumor involved the main left bronchus and the 
left pulmonary artery involvement was scored as grade 3 (encasement) according to 
[178]. The prescription to the PTVPET was 75 Gy. Again, all constraints complied with 
OARs recommendations for esophagus and mediastinum organs. Actually, it is very 
difficult to make the difference between an adverse event and a local progression. In 
this regard, the primary tumor showed a net reduced metabolism on FDG-PET 
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imaging performed 2 months after CRT and it was considered as a stable disease 
according to RECIST at 4 months on an unplanned CT scan. Incidence of massive 
hemoptysis is relatively high in central tumor treated by conventional external RT 
(10%), especially, as in P4, when endobronchial tumor extends into the upper left 
main bronchus (lying next to left pulmonary artery), encases the left pulmonary 
artery and when hemoptysis already occurs prior to radiotherapy [38].  
Regarding these two patients died from hemoptysis, it is possible that constraints on 
large vessels, bronchial tree and esophagus should be revised for centrally located 
tumors encasing or involving some mediastinum organs. 
The main limitation is the limited number of patients included in our trial, which was 
designed as a feasibility study. The main center recruited fewer stage III NSCLC 
patients than expected, particularly after excluding central T4 tumor with invasion of 
mediastinum organs. Consequently, another center joined the trial later on to increase 
the number of patients, but recruitment remained low. 
A second limitation of our trial is that we used the conventional ITV approach, 
according to a planning study demonstrating its safety for TomoTherapy [163]. 
However, ITV overestimates safety margins, leading to unnecessary irradiation of 
healthy tissues. In the context of dose escalation especially, the mid-position approach 
can significantly reduce the PTV and irradiated volumes. Mid-position was proven to 
be feasible and safe in helical delivery for LA stage NSCLC patients [181], but was not 
yet available in our center at the time of the trial. 
Finally, although the small cohort demonstrates the feasibility concept, we cannot 
formally generalize our results due to the limited number of recorded events. 
Randomized studies with more patients, comparing conventional treatment with 
escalated dose radiation therapy, are still needed, especially after the counterintuitive 
results of RTOG 0617 [35]. Final results of the randomized PET boost trial are awaited 
to determine the toxicity of dose escalation and report on tumor control and survival 
of dose intensification strategy [166]. Especially, they are studying the theoretical 
concept developed by Niemerko et al. [182, 183] whereby tumor LC depends more on 
the mean radiation dose to the tumor than on the maximal dose, provided the minimal 
dose reaches a critical threshold. Patients are randomized accordingly, between a 
selective (i.e. based on FDG-PET) and a non-selective (i.e. heterogeneous but higher 
mean dose) dose re-distribution within the tumor [166]. 
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Conclusions 
These results suggest that a non-uniform and individualized dose escalation based on 
FDG-PET in IMRT delivery is feasible. The dose can be further increased for peripheral 
tumors, compared to central ones. Although acute and late toxicities were comparable 
to conventional scheme in peripheral tumors, two patients (15%) with centrally 
located tumors died from fatal hemorrhage. Centrally located tumors with direct 
invasion of mediastinal organs must thus be treated cautiously to avoid late toxicities.  
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Introduction 
Helical TomoTherapy is an appealing irradiation modality to treat unresectable locally 
advanced stage II-III as well as inoperable stage I non-small cell lung cancer (NSCLC) 
patients. Indeed, it combines an advanced technique of intensity-modulated radiation 
therapy (IMRT), leading to highly conformal dose distributions, with an accurate 
imaging device for patient positioning, based on megavoltage computed tomography 
(MVCT). These features allow target volumes to be irradiated with sharp dose 
gradient, and thus help deliver high dose while sparing healthy surrounding tissues. 
However, tumor motion caused by breathing may jeopardize treatment quality.  In 
that regard, on-line management of respiratory tumor motion requires dedicated 
methodologies and techniques, like breath hold, gating [184], or tracking [185], which 
are not yet available in TomoTherapy systems [163]. Thus, treatment plan robustness 
against breathing motion still relies on the definition of specific volumes, like an 
internal target volume (ITV) or the mid-position (MidP), which are expanded with 
safety margins. 
The ITV approach is widely used in clinical practice [44, 116, 186]. The ITV 
encompasses all tumor positions during the breathing cycle and can be determined 
from a four-dimensional computed tomography (4D-CT). A planning study with four-
dimensional (4D) Monte Carlo (MC) has demonstrated that an expanded ITV can be 
safely applied in TomoTherapy [163]. In particular, interplay effect between beam and 
tumor motions did not significantly affect the delivered dose distributions. However, 
the ITV approach is known to overestimate the safety margins, and thus may lead to 
unnecessary irradiation of healthy tissues [113, 187].  
The MidP, on the other hand, involves a volume that corresponds to the time-
weighted mean position of target volumes during the breathing cycle [113]. This 
approach provides several theoretical advantages over the ITV and partly overcome 
the issues encountered with the ITV. First, by using a 4D-CT, it eliminates the 
systematic error that would otherwise occur with a fast 3D CT that is merely a 
snapshot at some point of the respiratory cycle, possibly polluted by artifacts. In 
contrast with the ITV approach, the random uncertainty about tumor motion is added 
in quadrature to the other random geometric uncertainties in the formula for the 
Planning Target Volume (PTV) margin calculation proposed by Van Herk et al. [42]. As 
a result, this approach allows the margins to be significantly smaller and therefore 
comparable to those obtained with gated radiotherapy [113]. Furthermore, the MidP 
approach allows the treatment planning and delivery workflow to remain the same as 
in other approaches based on margins. 
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To our best knowledge, MidP has never been implemented for helical TomoTherapy of 
moving lung tumors, nor compared to ITV for this treatment modality. In this context, 
we designed the present study to assess the potential gain of MidP over ITV in terms 
of margin and PTV reduction. As a second objective, we investigated whether these 
volumetric changes in the PTV actually lowered the irradiation of the organs at risk 
using clinically relevant dosimetric parameters. Finally, we also computed motion-
corrected dose distributions for both scenarios using a previously validated 4D Monte 
Carlo (MC) model based on TomoPen [163]. The latter was used to assess the plan 
quality, especially the potential impact of intra-fraction motion and treatment delivery 
mechanics on tumor coverage when margins were reduced. 
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Materials and methods 
Figure 5.1 illustrates the complete workflow from image acquisitions to treatment 
planning. 
 
Figure 5.1 Workflow depicting the definition of target volumes and organs at risk for ITV and 
mid-position strategies from the image acquisition to the treatment planning. 
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1. Patient selection 
Fifteen NSCLC patients were retrospectively included in the present study. Among 
these, 8 patients had stage I NSCLC treated with stereotactic body radiation therapy 
(SBRT), while the remaining 7 patients had locally-advanced stage II-III NSCLC treated 
with simultaneous integrated boost (SIB) IMRT in the framework of a dose escalation 
protocol. The internal review board approved this study and all patients gave their 
informed consent. 
2. Image acquisition 
Prior to treatment, all patients underwent a planning imaging session either on a big 
bore CT scanner (Aquilion LB, Toshiba medical system corporation, Japan) or a 
combined PET-CT scanner (Gemini TF, Philips Medical system, Cleveland, OH, USA). 
For all acquisitions, patients were immobilized in a thermoformed plastic mask 
(CIVCO Medical Solutions, Iowa, USA).  
A contrast-enhanced CT (CE-CT) from the entire thoracic region was acquired in free 
breathing mode for the purpose of delineation, and reconstructed in 2 mm-thick 
slices. Next, a 4D-CT was acquired and patients were audio-coached to regularize their 
breathing and thus reduce 4D-CT image artefacts [120, 188]. In this acquisition mode, 
the CT scanner automatically set the optimal helical pitch according to the patient’s 
breathing period measured from either a pressure belt (Medspira/Mayo Clinic Breath 
HoldTM, Mayo Clinic Medical Devices, USA) or magnetic sensors (Nomics©, Liège, 
Belgium). The 4D-CT datasets were retrospectively binned into 10 equally distributed 
temporal phases, for motion management purposes. Finally, an average CT was 
computed by averaging all 10 phases.  
For the SIB group, 4D-FDG-PET images were also acquired 60 to 120 min after 
injection of an average activity of 8.04 mCi of FDG in patients fasting at least for 6h 
before examination. The breathing signal was recorded with the same devices as the 
4D-CT. After correction for decay, random, scatter, and attenuation, images were 
reconstructed with the iterative algorithm 3D LOR-OSEM using a window of only 20% 
of the breathing period and centered on the end of the expiratory phase. The images 
had a transverse FOV of 180mm (one bed position centered on the region of interest). 
The attenuation correction was performed using the averaged 4D-CT.  
3. Motion estimation 
Internal motion due to breathing was estimated with the 4D-CT images. First, the CE-
CT and the end-exhale phase of the 4D-CT were non-rigidly registered using a log-
domain diffeomorphic Morphon algorithm (see Appendix C for more details). This 
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method is based on the matching of the local phase (i.e. lines and edges) at different 
scales and is therefore insensitive to contrast differences between the CE-CT and the 
4D-CT. Next, this registration algorithm was run to map the end-exhale phase of the 
4D-CT with the other phases, yielding 9 non-rigid transformations [119]. The latter 
were used in two different ways: first, to compute the deformation between the 
reference phase and the mean position of the anatomy along the respiratory cycle, 
which will further be applied to the CE-CT-based target volumes (TVs) to generate 
their corresponding MidP volumes and, second, to propagate these contours on all 
other phases of the respiratory cycle, the union of all deformed TVs forming an 
individual ITV. The deformed contours were visually checked on all phases, to assess 
registration accuracy. For the SIB group, the combined PET/CT acquisitions allowed 
MidP PET images to be computed in a straightforward way, just by applying the non-
rigid deformations to the PET component. 
4. Definition of Target Volumes and Organs at risk 
For both the ITV and MidP, Figure 5.1 illustrates the workflow for the definition of the 
target volumes (TVs) and organs at risk (OARs). It comprises the following steps: 
1) OARs, Gross Tumor Volume (GTVCT) and Clinical Target Volume (CTVCT) of primary 
tumors and lymph nodes were manually delineated on the CE-CT. As there is no CTV 
extension for the SBRT group (i.e. CTVCT = GTVCT), the GTV will be noted CTV in the 
rest of the text, for the sake of clarity [189, 190]. Additionally, for the SIB group, a 
GTVPET, corresponding to the boost region, was automatically segmented on PET 
images using a previously validated gradient-based method [95, 159]. 
2) The corresponding ITVCT and ITVPET were generated using non-rigid registration, 
like previously described.  
3) Then, the internal structures were computed in their mid-position, using the 
transformation vectors from deformable registrations as described earlier. The 
resulting TVs were noted GTVCT-MidP, CTVCT-MidP and GTVPET-MidP. 
4) The PTV margins were drawn using the formalism proposed by Van Herk et al. 
In the last step, the margin thickness formula combines different types of geometric 
uncertainties and can be written as  
 
where Σ and σ denote the standard deviations of the systematic and random errors, 
respectively. Subscripts TM, BL, SETUP, D and p refer to tumor motion, baseline shift, 
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patient setup variability, delineation uncertainty, and penumbra, respectively. The 
coefficients in the formula ensure that the CTV receives at least 95% of the prescribed 
dose for 90% of patients. All standard deviations, except ΣTM and σTM, were set in 
agreement with the literature, while also taking into account the specificities of 
TomoTherapy and the handling of operators in our treatment unit [47, 191, 192]. 
These values were similar for ITV and MidP. In the particular case of penumbra, its 
width σp for helical TomoTherapy was computed as follows. Dose profiles in 
transverse and longitudinal directions at 5 cm depth for a 5x5 cm2 field were obtained 
with TomoPen MC simulations in a 0.33g/cm3 density phantom. The computed profile 
was fitted with the sum of two Gaussians according to Witte et al. [121]. The effect of 
couch motion on dose distributions can be approximated as a convolution of the beam 
with a square response with width SW width, SW being the slice width. The standard 
deviation related to the couch motion equals . The total standard deviation was 
computed, leading to σp adapted for lung density and TomoTherapy delivery. In the 
end, σp equalled 4.6 mm and 4.3 mm in LR and AP directions. For the SI direction, it 
corresponded to 4.3 mm and 9 mm for the 1 cm or 2.5 cm slice widths, respectively. 
Last but not least, standard deviations related to tumor motion were individually 
estimated, depending on the considered margin strategy: 
 For the ITV, the tumor motion uncertainties are implicitly included in the ITV 
margin, which encompasses the CTV deformed onto the different respiratory 
phases of the 4D-CT [193]. Both ΣTM and σTM were therefore set to 0 [113]. 
 For the MidP, ΣTM was fixed to 0.5 mm, which corresponds to the residual 
error of deformable registration [113], whereas σTM was particularized 
according to the amplitudes of tumor motion measured in the 4D-CT along 
each axis [113, 192]. 
Table 5.1 provides volumetric information for the GTVs and CTVs, their motion along 
each axis, as well as the PTV margins for both ITV and MidP approaches. It is 
noteworthy that primary tumor and lymph nodes move differently but, for the sake of 
clarity, Table 5.1 does not report this information. 
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Table 5.1 GTV and CTV with their corresponding motion amplitudes and PTV margins for both 
ITV and MidP approaches. Patients 1-8 correspond to the SBRT group (i.e. GTV=CTV) and patients 
9-15 correspond to the SIB treatment group.  
Pat. 
no 
CTV 
T-CT  
(cc) 
CTV 
N-CT  
(cc) 
GTV 
PET   
(cc) 
LR 
motion  
(mm) 
AP 
motion 
 (mm) 
SI 
motion  
(mm) 
PTVMidP  
LR  
margins    
(mm) 
PTVMidP  
AP  
margins     
(mm) 
PTVMidP  
SI  
margins     
(mm) 
PTVITV  
LR  
margins     
(mm) 
PTVITV  
AP  
margins     
(mm) 
PTVITV  
SI 
margins 
(mm) 
1 2.8 - - 1.7 7.5 8.0 5.7 10.2 10.0 5.5 8.7 8.5 
2 4.8 - - 5.3 8.1 8.5 6.3 10.0 9.9 5.5 8.7 8.5 
3 12.2 - - 0.8 0.6 2.0 5.7 8.8 8.7 5.5 8.7 8.5 
4 2.5 - - 3.2 3.3 10.8 6.2 9.5 9.6 5.5 8.7 8.5 
5 10.5 - - 5.2 11.8 30.0 6.3 11.0 20.9 5.5 8.7 8.5 
6 5.2 - - 2.1 7.5 10.3 5.8 9.8 10.9 5.5 8.7 8.5 
7 10.9 - - 1.4 2.4 7.5 5.7 8.9 9.1 5.5 8.7 8.5 
8 3.5 - - 2.2 3.8 24.6 5.8 9.1 18.3 5.5 8.7 8.5 
9 183.8 - 88.7 1.3 1.5 2.1 5.7 8.8 8.4 5.5 8.7 8.2 
10 122.1 66.8 61.0 0.4 2.3 2.0 5.7 8.9 8.4 5.5 8.7 8.2 
11 29.3 34.1 8.9 1.0 3.7 4.2 5.7 9.1 8.6 5.5 8.7 8.2 
12 212.0 38.4 57.3 0.3 1.7 0.7 5.7 8.8 8.3 5.5 8.7 8.2 
13 319.9 24.5 187.5 0.4 1.3 5.9 5.5 8.7 8.7 5.5 8.7 8.2 
14 99.0 29.5 39.6 1.2 2.4 5.4 5.7 8.9 8.7 5.5 8.7 8.2 
15 137.6 - 63.6 1.0 4.3 12.0 5.7 9.2 10.1 5.5 8.7 8.2 
Abbreviations: CTVT-CT and CTVN-CT, Clinical Target Volume of the primary tumor and the lymph 
nodes on CT images, respectively; GTVPET, Gross Tumor Volume of the primary tumor on PET 
images; LR, left-right; AP, anterior-posterior; SI, superior-inferior; PTVMidP and PTVITV margin, 
Planning Target Volume margins derived from the mid-position and the Internal Target Volume 
approaches, respectively. 
5. Treatment planning 
For each patient, two treatments were planned, either with an ITV or a MidP.  
For the SBRT group, a dose of 54Gy in 3 fractions to the PTV was prescribed, except 
for two patients who received 60Gy and 48Gy in 4 fractions due to the proximity 
between their tumor and critical mediastinal structures. For the SIB group, a dose of 
62.5Gy was prescribed to the PTV of the primary tumor defined on CT images (PTVT-
CT) and the PTV of the lymph nodes defined on CT images (PTVN-CT), and delivered in 
25 fractions of 2.5Gy. Simultaneously, a higher dose was individually prescribed to the 
PTVPET based on the maximal tolerance of each organ at risk [13]. These doses were 
prescribed to 95% and 50% of the PTV for SBRT and SIB treatment groups 
respectively, according to RTOG 0236 and 0618 trials and ICRU83 recommendations 
[18, 189, 194-196]. 
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Treatment plans were performed on a research version of the TomoTherapy 
Treatment Planning System (TPS). Its new dose engine, performing computations on a 
general-purpose graphical processing unit, showed excellent agreement with former 
versions running on conventional central processors, and was previously validated for 
heterogeneous media on phantoms and patient cases [197, 198]. For SBRT patients, 
treatment plans were generated using a fine dose grid, a 1 cm field width, a pitch 
ranging from 0.172 to 0.215, and a planned modulation factor (ranging from 1.2 to 
1.5) adapted in order to obtain a gantry period below 60 sec (required by the TPS) 
and a treatment time short enough to keep the patient setup variability as low as 
possible. For SIB treatment patients, all plans were generated using a 2.5 cm field 
width, a pitch of 0.287 and a planned modulation factor of 2.0.  
Treatment planning was performed on the average CT. Although the CE-CT acquired 
in free breathing offers the optimal contrast for delineation purpose, it only 
represents a snapshot of the patient’s anatomy at a given time point, and may suffer 
from motion-related artefacts. On the contrary, the average CT represents a voxel-
wise average of the ten 4D-CT phases and therefore adequately renders the mean 
geometry and density of the patient [199-201]. 
The evaluation of treatment plan quality relied on constraints to TVs and OARs. In the 
SBRT group, constraints on the PTV were set as follows in an overlapping mode: D95 
equals the prescription dose; D99 above 90% of the prescribed dose; D2 within a range 
of 110-140% of the prescribed dose according to RTOG recommendations [196, 202, 
203]. Constraints to the OARs were also set according to these trials [196, 202, 203]. 
In the SIB group, the acceptability criteria for TVs, in an overlapping mode, were: D50 
equals prescribed dose for both the PTVCT and PTVPET, a D95 above 95% of the 
prescribed dose, a D99 above 90% of the prescribed dose and a D2 below 105% of the 
prescribed dose for the PTVPET. The physical dose constraints for the OARs, taken from 
the literature [15, 20, 22, 24, 29, 34, 153, 164-167], were normalized for the 
prescribed dose (i.e. 62.5Gy given in 25 fractions) and equivalent doses in 2Gy per 
fraction (EQD2) using the appropriate α/β values were calculated with the LQ-
model for each parameter. 
6. MC simulations with TomoPen 
In the case of dynamic IMRT delivery, patient and beam motions may interfere, 
potentially resulting in a distortion of the dose distributions, i.e. the so-called 
interplay effect [204]. Dose distributions were computed using a previously validated 
4D MC model based on TomoPen, in order to assess the impact of intra-fraction tumor 
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motion on tumor coverage, with and without the interplay effect [205-208]. TomoPen 
was used to: 
1) Recompute the 3D dose distributions, comparable to the planned dose 
generated with TomoTherapy’s TPS and denoted 3D MC planned doses 
hereafter. 
2) Compute 4D dose distributions for every 4D-CT data set, with or without 
beamlet-phase correlation, that is, with interplay simulation (4D MC IS) or no 
interplay (4D MC NI) [163, 209].  
The 4D MC model was previously described in [163]. The simulated dose maps with 
and without interplay were compared with MC dose distributions computed on the 
average CT used for planning.  
It is noteworthy that the 4D MC doses include the effect of motion, in contrast to the 
3D MC planned dose. As a consequence, 4D MC doses must be assessed with smaller 
volumes whose margins account for all uncertainties but tumor motion. In other 
words, GTVs and CTVs are expanded differently, isotropically and with ΣTM = 0 and σTM 
= 0, into volumes called  and , to be compared to the PTVs in the 3D 
MC doses.  
Finally, the impact of tumor motion and interplay on tumor dose coverage was 
quantified by comparing the different dose-volume histogram (DVH) metrics obtained 
for the 3D MC planned dose and the 4D MC doses with and without interplay. Firstly, 
Dmean, D99, D95, and D2 were computed for the 3D MC planned dose distribution in the 
PTVs. Secondly, these metrics were computed for 4D MC dose distributions with and 
without interplay on the modified GTV and CTV volumes (  and ). 
Basically, the various DVH metrics in the PTV for the 3D MC planned dose 
distributions were compared to the same metrics in the  and  drawn 
on the 4D MC dose distributions with and without interplay. Afterwards, DVH metrics 
for 4D MC doses with or without interplay were compared to single out the potential 
interplay effect alone. 
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7. Statistical evaluation  
PTVs expanded from the MidP and ITV were compared in terms of volumes. 
Dosimetric parameters (mean +/- standard deviation) for TVs and OARs were 
computed and compared between the MidP and ITV treatment plans. Likewise, plan 
conformity indexes were calculated and compared between plans.  The Paddick 
conformity index is defined as   where TVPI is the target volume 
(TV) within the prescribed isodose volume (PI). Dice’s similarity index is defined as 
. A perfect plan would have TVPI = PI = TV and therefore CIPaddick = 1 
and DSI = 1 [210-212].   
All the statistical calculations were performed with NCSS software 2004© (Number 
Cruncher Statistical System, Kaysville, UT, USA), p-values lower than 0.05 were 
considered statistically significant and all tests were two-sided. Doses and volumes 
were pairwise compared between ITV and MidP using either Student t-tests when 
data were normally distributed, or Wilcoxon signed rank tests for non-Gaussian 
distributions. 
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Results 
1. Volumetric analysis 
The PTVs expressed in cc are reported in Table 5.2. The PTVs expanded from the ITV 
were on average 1.2 times larger than those obtained with the MidP. This difference 
was statistically significant for both the SBRT and the SIB groups (t-test, p<0.001 and 
p=0.027, respectively).  
Table 5.2 PTV corresponding to the primary tumors, lymph nodes and PET-based boost expressed 
in cc for mid-position and ITV plans for all patients. The ratios between ITV and MidP derived PTV 
are also presented.  
Patient no PTVT-CT (cc) PTVN-CT (cc) PTVPET (cc) 
  MidP ITV ratio MidP ITV ratio MidP ITV ratio 
SBRT 1 24.6 33.3 1.36 - - - - - - 
 2 33.9 48.2 1.42 - - - - - - 
 3 52.8 57.9 1.10 - - - - - - 
 4 20.3 31.7 1.56 - - - - - - 
 5 84.5 95.1 1.13 - - - - - - 
 6 38.6 50.5 1.31 - - - -  - 
 7 48.2 63.2 1.31 - - - - - - 
 8 36.5 46.2 1.26 - - - - - - 
 mean 42.4 53.3 1.31 - - - - - - 
 SD 20.2 20.1 0.15 - - - - - - 
SIB 9 396.6 443.7 1.12 - - - 212.7 214.5 1.01 
 10 270.4 295.6 1.09 210.0 251.7 1.20 120.7 128.3 1.06 
 11 90.6 109.1 1.20 140.6 184.3 1.31 29.0 37.8 1.30 
 12 533.9 627.8 1.18 153.3 194.6 1.27 72.3 72.8 1.01 
 13 591.0 668.5 1.13 97.7 122.2 1.25 312.2 337.3 1.08 
 14 259.4 313.7 1.21 118.5 147.4 1.24 66.5 74.1 1.11 
 15 358.9 459.4 1.28 - - - 105.0 126.9 1.21 
 mean 357.3 416.8 1.17 144.0 180.0 1.25 131.2 141.7 1.11 
 SD 171.1 196.0 0.06 42.6 49.4 0.04 98.6 103.4 0.11 
Abbreviations: MidP: mid-position; ITV: Internal Target Volume; SD: standard deviation 
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2. Dosimetric analysis for OARs 
Smaller PTVs allowed MidP to outperform the ITV by delivering less dose to each OAR 
(see Table 5.3). In the SBRT group, the differences were statistically significant for the 
mean lung dose (MLD) and V20Gy, D2 for the spinal cord, D2 and V30Gy for the thoracic 
wall, and finally D2 for the esophagus. In the SIB group, the differences were 
statistically significant for V20Gy for the lungs-GTV, V25Gy for the heart, Dmean for the 
esophagus, and D2 for the main bronchi. 
Table 5.3 Comparison of dosimetric metrics for the OARs (mean ± SD) between treatment plans 
with MidP and ITV. 
    SIB  SBRT  
OARs Parameters MidP 
(mean±SD)aa 
ITV 
(mean±SD)aa 
Δ 
(mean±SD)a 
p-value  MidP 
(mean±SD)aa 
ITV 
(mean±SD)aa 
Δ 
(mean±SD)a 
p-value 
  aaaaa        
Lungs-GTV MLD (Gy) 15.86±1.48 16.57±1.43 0.72±0.87 0.072 3.70±1.24 4.00±1.24 0.30±0.23 0.008 
Bio MLD (Gy) 14.57±1.74 15.33±1.43 0.76±0.74 0,035 - - - - 
V20Gy (%) 25.29±2.97 27.00±3.47 1.71±1.69 0.028 5.04±2.33 5.55±2.27 0.51±0.22 <0.001 
Spinal cord D2 (Gy) 28.77±5.73 33.07±7.41 4.30±8.48 0.23 7.20±3.33 7.89±3.42 0.70±0.70 0.025 
Heart D2 (Gy) - - - - 7.02±7.75 7.83±8.48 0.80±1.01 0.06 
V25Gy (%) 11.62±8.36 14.92±11.07 3.31±2.87 0.023 - - - - 
Esophagus D2 (Gy) - - - - 40.70±14.92 42.52±15.15 1.82±1.24 0.018 
Dmean (Gy) 24.47±9.32 26.33±9.47 1.86±0.63 <0.001 - - - - 
Dmax (Gy) 68.26±14.08 70.11±10.98 1.85±4.35 0.31 - - - - 
Rib cage D2 (Gy) - - - - 14.29±10.41 17.14±10.42 2.85±2.42 0.004 
V30Gy (cc) - - - - 10.91±5.58 12.14±6.16 1.22±1.12 0.013 
Vessels D2 (Gy) 70.65±9.25 71.59±8.22 0.94±1.42 0.12 - - - - 
Bronchus D2 (Gy) 75.51±9.25 76.48±9.35 0.75±0.45 0.005 - - - - 
Abbreviations: OARs, organs at risk; SIB, Simultaneous Integrated Boost; SBRT, Stereotactic Body 
Radiation Therapy; MidP, mid-position; ITV, Internal Target Volume; Δ, difference between ITV 
and MidP values; MLD, mean lung dose; VxGy, volume of the OAR receiving x Gy; Dx, dose received 
by x percent of the OAR volume 
3. Dosimetric analysis for TVs 
The MidP and ITV plans significantly differed for TVs parameters, with p-values 
ranging between 0.04 and 0.006 for Dmean, D99, D95 and D2 to the PTV. However, these 
differences were inferior to 1%, except for D95 in the SIB group, where it is inferior to 
4% due to the higher dose in the boosted sub-volume of the PTV; this higher 
difference was not clinically relevant. Notwithstanding, the mean conformity indexes 
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computed for the MidP and ITV plans were similar in the SBRT group (Paddick of 
0.84±0.05 with p=0.92, DSI of 0.92±0.03 with p=0.91), and did not significantly differ 
in the SIB group, with Paddick of 0.67±0.23 and 0.62±0.23 (p=0.20), and DSI of 
0.80±0.18 and 0.76±0.18 (p=0.24), for MidP and ITV plans respectively. This showed 
that both the ITV and MidP plans were similar enough in terms of PTV coverage to be 
further compared. 
4. MC simulations  
Figure 5.2 reports for each patient the relative difference (in percent) for D95 between 
the 3D MC planned dose distributions and the “interplay simulated” or “no interplay” 
dose distributions for the primary TVs (note that nodes and boost volumes are not 
illustrated) used to assess the plans quality.  A table compiling all the different 
metrics, i.e. Dmean, D99, D95 and D2 for primary tumors, nodes and boost volumes, is 
included in the Appendix C. 
For all SBRT patients, Dmean, D99, D95, and D2 of the 4D MC dose in  complied 
with the planning recommendations when using the ITV approach. In particular, 
tumor motion and interplay effect did not degrade the plan quality.  
In contrast, MidP failed to adequately cover  in 3 patients. For patient 5, the 
simulated interplay effect decreased D99 and D95 in   by 7.20% and 4.35%, 
respectively, compared to the planned dose distributions (Figure 5.3a). Although the 
interplay effect did not affect the two other patients, MC simulations demonstrated 
significant underdosages of  , compared to the planned doses, with Dmean, D99, 
and D95 reduced by 1.90%, 2.16%, and 2.61% for patient 4 and by 2.52%, 1.36%, and 
2.16% for patient 8, respectively (Figure 5.3b).  
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Figure 5.2 Relative difference (Δ) for D95 to the CT based primary target volume ( ) 
between the 3D Monte Carlo (MC) planned dose distributions and Interplay Simulated (IS) or No 
Interplay (NI) dose distributions calculated using a 4D MC model for mid-position and ITV 
strategies for SBRT (a) and SIB group (b). In the former case, it is important to note that ITV 
approach ensures adequate tumor coverage for all patients. In contrast, MidP strategy do not 
guarantee sufficient dose coverage to the  in 3 patients. For P5, the reduction of dose 
coverage to the  is due to the interplay effect. For P4 and P8, the significant underdosage 
to the  arises from the breathing motion alone. For the SIB group, both strategies ensure 
adequate tumor coverage for all patients. Neither tumor motion nor the interplay effect degrades 
the plan quality. 
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Figure 5.3 Dose-volume histograms (DVHs) representing the planned dose on the Planning Target 
Volume (PTV) and the actual delivered doses calculated with and without the interplay effect on 
the expanded Gross Tumor Volume ( ) for patient 5 (a) and patient 8 (b). 
For all SIB patients, Dmean, D99, D95 and D2 to the  and  computed from 
4D MC dose distributions complied with the planning recommendations when using 
both approaches. In particular, it is important to note that neither the tumor motion 
nor the interplay effect affect the plan quality. On the other hand, a significant tumor 
coverage improvement to the  was observed in 4D MC computed plans 
compared to the 3D planned MC ones when ITV approach was used in both SIB and 
SBRT groups (see Figure 5.2). 
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Discussion 
Our study confirmed that the MidP leads to significantly smaller PTVs than the ITV, 
which also translated into lower doses delivered to the OARs. Although the dose 
reduction may seem modest at first sight, it matters in the context of hypo-
fractionated RT schemes with high biologically equivalent doses.  As all plans were 
made in a similar way by the same person and showed comparable dose conformities 
to the PTV, the differences in dose distributions to OARs are believed to faithfully 
reflect volumetric changes. 
Based on these observations, the MidP appears as an appealing option for motion 
management in lung cancer treatment with TomoTherapy. A MidP volume can be 
derived for any moving structure, such as the primary tumor, lymph nodes, or even 
tumor sub-volumes. Moreover, MidP is easy to implement in clinical routine because it 
affects only the target volumes definition, and leaves all other aspects of planning 
unchanged; MidP does not require neither any additional equipment in the treatment 
room, nor complex 4D features in the TPS. It only entails the computation of the target 
volumes in their time-weighted average position, using a 4D-CT scan whose phases 
are non-rigidly registered. Unfortunately, no commercial implementation of MidP 
exists at the moment, which hinders adoption in clinical routine. 
The most innovative aspect of our study was the MC verification of the dose 
distributions in the target volumes for both the ITV and MidP. In agreement with our 
previous study [163], the 4D MC simulations confirmed that the ITV ensured adequate 
dose coverage to  in all cases. Overdosage in  observed in 4D MC 
plans was mainly attributable to the intrinsic overestimation of motion in the 
calculation of the PTV margin with the ITV. This improved D95 compared to the PTV 
without motion. For the  in the SIB group, additional overdosage may also 
stem from the use of two prescription levels on a moving target, with a substantial 
portion of the CTV entering the high dose region defined by the PTVPET, especially for 
P11, P13 and P15 with SI motion as large as 12 mm. 
In contrast, 4D MC simulations indicated that the MidP strategy did not guarantee 
sufficient dose coverage to the  in 3 out of 15 cases, all in the SBRT group. In 
the first case (P5), underdosage resulted from the interplay effect, which is specific to 
TomoTherapy and manifests in the form of undesired hot and cold spots within the 
TVs, comparable to constructive and destructive interferences. It results from a 
delivering fluence different from the planned fluence when respiratory intra-fraction 
motion and couch progression take place in TomoTherapy delivery. Kissick et al. 
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showed that these hot and cold spots are minimized when the jaw width is large and 
scanning velocity is small relatively to the breathing amplitude and frequency [213, 
214]. For this patient, we used the smallest jaw width (1.0 cm) and a couch pitch of 
0.215. Moreover, the patient breathing period was 6 s, and tumor motion was 
particularly large, with displacements of 5.16, 11.81 and 29.97 mm in LR, AP and SI 
directions, respectively. Finally, our MC simulations calculated only one fraction of the 
treatment, which maximizes the interplay effect. Previous studies showed that 
interplay effect tends to average out after multiple fractions [213, 215]. However, the 
small number of fractions, only 4 here, limits this advantageous effect. 
In both other cases (P4 and P8), the significant agreement between 4D MC dose 
distributions with and without interplay suggested that breathing motion alone was 
responsible for the degradation of the DVHs. Possible reasons are simplifications 
introduced in the PTV margin formula:  
1) Spherical GTVs were assumed while most tumors deviate from this shape. 
Moreover, the formula ignores the GTV size and shape as long as it is large 
compared to random errors (σ) [42]. However, in these two cases, the tumor 
volumes were very small with GTV of about 3 cc and 1.5 cm diameter in both 
cases, thus questioning the applicability of the model.  
2) Rotations and shape variations of the tumor have been disregarded in the 
model. Nonetheless, in these cases, we could expect that rotational errors be 
most likely of minor clinical importance given the limited size and quite regular 
shape of the considered tumors [216-218].  
3) The margin formula assumes Gaussian distributions for all geometric errors, 
on the basis of the central limit theorem [42]. If this theorem applies, 
convolving the dose with a Gaussian distribution can simulate the global effect 
of geometric uncertainties on dose distributions. However, breathing motion 
may easily depart from normality and hence invalidate the whole formula if the 
contribution of tumor motion is large compared to other source of 
uncertainties.  
The first and third hypotheses are not met in P4 and P8.  Indeed, P4 and P8 had very 
small tumors (2.48 and 3.49 cc) combined with large tumor motion (10.84 and 24.63 
mm of displacement in the SI directions, see also Table 5.1). In comparison, the 
penumbras for SBRT patients were 4.6, 4.6, and 4.3 mm in the LR, AP, and SI 
directions, thus undermining the applicability of the central limit theorem for those 
patients. In this context, P4 and P8 deviate from the formalism of Van Herk et al. and 
one might expect the MidP to underestimate the presence of the tumor at both ends of 
its trajectory, thereby jeopardizing coverage.  
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From a pragmatic point of view, simple rules based on tumor size and motion 
amplitude could be applied to choose between both margin strategies: the MidP 
should be privileged against the ITV since it allows for significant TV and dose 
reduction, except in tumors showing simultaneously small size (i.e. below 1.5 cm) and 
large motion amplitude (i.e. above 1 cm). In this scenario, the benefit of margin 
reduction should be weighted against the risk of tumor underdosage, and ITV should 
be considered as a safer option in these specific conditions.   
In conclusion, compared to the conventional ITV, the MidP strategy significantly 
reduced the PTV and the irradiated volumes in all patients, with potential room for 
dose escalation protocols. Furthermore, MidP proved to be feasible and safe in helical 
delivery for a representative set of patients commonly treated by radiation therapy 
and with lung tumors whose stage ranged from early to locally advanced. However, 
patients having very small tumors with large amplitude motions must be treated 
cautiously; the conventional ITV remains safer in this particular case.  
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Summary 
The first study has shown that FDG-PET outperforms CT for the delineation of 
primary tumor volumes in NSCLC, as previously observed in HNSCC patients. We have 
also confirmed the superiority of the gradient-based segmentation, compared to usual 
threshold-based delineation both in terms of accuracy and robustness. However, the 
added value of FDG-PET is more pronounced in cases of tumors surrounded by 
densifications of the lung parenchyma. For well-defined and peripherally located 
tumors, the CT with mediastinal windowing remains a clinically acceptable alternative 
to FDG-PET. Therefore, we suggest using the gradient-based method as the reference 
segmentation tool in the field of PET-driven delineation of lung tumors, surely when 
they are poorly identifiable on conventional CT. 
The second study demonstrated the feasibility of a non-uniform and individualized 
dose escalation based on FDG-PET in IMRT delivery for LA NSCLC patients. The dose 
can be further increased for peripheral tumors, compared to central ones. Our study 
suggests an appreciable local tumor control whereas distant recurrence remains an 
important issue. Nonetheless, randomized and larger patient cohorts are required to 
confirm our results. Although acute and late toxicities were comparable to 
conventional scheme in peripheral tumors, two patients with centrally located tumors 
died from fatal hemorrhage. Centrally located tumors with direct invasion of 
mediastinal organs must thus be treated with extreme caution to avoid late toxicities. 
Our third study confirmed that the MidP leads to significantly smaller PTVs than the 
ITV and also translates into lower doses delivered to the OARs. Furthermore, MidP 
proved to be feasible and safe in helical delivery for a representative set of patients 
commonly treated by radiation therapy and with lung tumors whose stage ranged 
from early to locally advanced. However, patients having very small tumors (<5cc) 
with large amplitude motions (>10mm) must be treated cautiously; the conventional 
ITV remains safer in this particular case. 
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Perspectives 
Locally advanced stage NSCLC comprises a very heterogeneous group of patients with 
respect to histology, tumor extent, prognosis, molecular pathology, patient 
characteristics, comorbidities, and treatment options. Up to now, all patients have 
been treated in the same way, according to conventional treatments. However, novel 
therapeutic options are investigated as part of the multimodality approach, including 
new RT strategies, optimal combination of chemotherapeutic drugs and new 
biological agents. Advances in technology and imaging might lead to a better 
prediction and selection of those patients most likely to benefit from a particular 
therapy.  
LA stage NSCLC can be considered as a model containing local and regional 
compartments in the chest and a distant compartment harboring potential micro-
metastases. Cancer cells death in each compartment is required to cure the patient.  
Since several years, many efforts have been assigned to improve the tumor local 
control and overall survival. Unfortunately, the disease tends to relapse quite 
frequently as distant metastasis or in non-irradiated lymph nodes. The survival of LA 
stage NSCLC patients seems to be related not only to the primary tumor control but 
also to the micro-metastatic disease. Consequently, we have to act on all possible 
fronts. In that regard, dose escalation combined with dose painting, adaptive RT and 
optimal motion management, as well as the use of particle therapy might improve the 
local tumor control, while development of novel therapies acting against micro-
metastases, including new chemotherapeutic agents, targeted therapy and 
immunotherapy might reduce regional and distant recurrences. Finally, decreasing 
toxicities by using robust OARs dosimetric parameters, accurate biomarkers able to 
predict toxicities, highly conformal RT and pharmacological normal tissue protection 
is of utmost importance. 
1. Improving the local control: the cornerstone of radiotherapy 
1.1. Dose painting 
Although radiation therapy is a key element in the multidisciplinary treatment of 
NSCLC and participates in improvement of local control, it is currently far from 
optimal. 
Nowadays, the conventional radiation therapy delivers a standard, homogeneous and 
static dose to the TVs along the treatment. However, from a biological point of view, a 
tumor is all except homogeneous and furthermore, it changes in shape, size and 
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metabolism during the treatment. Therefore, a heterogeneous dose distribution based 
on functional imaging might increase the tumor control probability. PET imaging has 
the potential to reveal various tumor molecular pathways, including metabolism, 
proliferation, hypoxia, and receptor or gene expressions, depending on the tracer 
used. A few years ago appeared the innovative concept of biology-guided 
radiotherapy, also called dose painting. In this concept, the tumor is considered as a 
complex cells model in which aggressiveness and sensitivity to radiotherapy can 
considerably vary. Dose painting by contours, addressed in Chapter 4, makes use of 
sub-volumes that are generated using an automated segmentation method and 
creates two or more discrete dose levels. The dose painting by numbers (DPBN), in 
contrast, considers a continuously increasing relationship between the voxel intensity 
of the image and the risk of local recurrence in that voxel. As a result, the dose is 
prescribed on a voxel-by-voxel basis as a function of the signal intensity [219, 220].  
Nonetheless, the main issues of PET-guided dose painting remain the poor spatial 
resolution, the low signal to noise ratio, especially when tracers other than FDG are 
used, and the integration of geometrical uncertainties (e.g. tumor motion). Although 
DPBN appears as an attractive approach, the PET image only represents a snapshot of 
a dynamic biological system. This raises the question of the ability of DPBN to produce 
dose distributions that really match the underlying tumor biology, as illustrated in 
Figure 6.1 [221]. 
 
Figure 6.1 Discrepancies are found between in vivo PET images (3.5 mm and 2 mm spatial 
resolution) of small animal and the microscopic reality, illustrated by autoradiography (100 μm 
spatial resolution). From Christian et al. Radiother Oncol, 2009. 
In addition to the biological relevance of heterogeneous prescription and the technical 
feasibility of matching the prescription with an actual dose distribution, the issue of 
patient-related geometrical uncertainties integration into DPBN process remains to be 
solved. These are subjects of intensive research in our laboratory.  
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Although several preclinical and clinical studies have already confirmed the feasibility 
of dose painting approaches [222-225], additional advances in imaging techniques are 
required before it can be used in practice. Afterwards, further studies will be needed 
to accurately define radio-resistant areas [225], to validate the concept in different 
anatomical sites, to assess the impact of dose escalation on these sub-areas 
considered as radio-resistant and to select the patient sub-groups that would 
beneficiate from this technique. 
Eventually, other imaging modalities could potentially be considered for dose 
painting. Image quality of MRI surpasses the other currently available imaging 
modalities. Besides the accurate anatomical representation, MRI provides functional 
and biological images required for dose painting purpose. Although some technical 
characteristics seem challenging compared to CT, MRI-guided dose painting might be 
another topic of promising research. 
1.2. Adaptive radiation therapy 
As previously discussed, a tumor is highly heterogeneous, and submitted to 
anatomical and biological changes over time. In that context, a single treatment plan 
based on the initial imaging session, performed prior to treatment, might lead to 
suboptimal treatment. The planning CT is hardly representative of the patient’s 
anatomy in all its complexity, as it does not display complex geometrical errors such 
as tumor motion, baseline shift or anatomical and tumor changes along the treatment 
course. 
It is essential to decrease these uncertainties to target tumor volumes with tighter 
margins, enabling potential dose escalation and local control improvement. IGRT is 
one of the most important advances in this field, ensuring online position correction 
through a couch shift. However, although image guidance allows repositioning of the 
patient using rigid image registration between the planning CT and the daily imaging, 
it cannot modify the initial plan for non-rigid changes, such as rotations, shape and 
size changes or the baseline shift differential between primary tumor and lymph 
nodes. This is precisely the role of adaptive radiation therapy (ART), which uses rigid 
and non-rigid registration to adapt the initial plan to the new patient and tumor 
status. Nonetheless, a particular attention has to be paid when using ART in case of 
tumor response [226]. Indeed, a decreased GTV size on the CT images or a reduced 
metabolic activity on PET images does not necessarily correlate with shrinkage of the 
CTV or with cell death within the tumor. A careful analysis of tumor regression 
patterns is required before the implementation of tumor response adaptive 
management in clinical daily use.  
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Currently, ART is at a very early stage and relies mostly on planning data. Typically, an 
off-line plan modification is applied only when significant anatomical changes (e.g. 
atelectasis disappearance, drastic weight loss or mediastinal shift after significant 
tumor shrinkage) are observed on daily imaging, usually once or twice during the 
entire treatment course. In the near future, it is expected that weekly adaptations or 
even online daily re-planning will be performed. Such treatment will require online 
automated adaptive protocols, including deformable registration tools based on image 
information from current and previous fractions, aiming to account for both inter- and 
intra-fraction variations. 
Therefore, ART is a considerable progress towards truly personalized radiation 
medicine with a potential for tumor dose escalation and/or reduced patient toxicity. 
1.3. Tumor motion management 
Tumor motion is a key issue in thoracic radiotherapy. As described in Chapter 1, 
several approaches can be used to integrate it into the treatment planning. We 
demonstrated in Chapter 5 that MidP concept outperforms the ITV in terms of 
irradiated volumes. Moreover, we showed its feasibility and safe applicability in 
helical TomoTherapy as long as motion amplitude was less than 10 mm for tumor 
diameter of 15 mm or less. Indeed, in this strategy, the tumor motion is considered as 
a random uncertainty as systematic error due to 3D sampling and hysteresis are 
eliminated. As the contribution of random errors on margin computation is much 
smaller than the systematic errors, tumor motion has actually little impact on the 
resulting PTV margin when MidP is considered. It was also demonstrated that 
margins applied for an idealized gating treatment and MidP method were similar for 
the majority of patients [113]. In addition, compared to respiratory synchronized 
techniques such as gating or tracking, margin-based MidP strategy is much easier to 
implement, and do not require any dedicated 4D planning strategy. Noteworthy, 
gating and tracking techniques suffers from a wide range of uncertainties (i.e. accurate 
determination of the tumor position, correct relationship between the target and its 
surrogate) potentially resulting in considerable and additional safety margins. 
Moreover, they involve advance equipment, education and training in the use of 
complex technology, and the implementation of a dedicated quality assurance 
program. Due to the inherent limitations of these approaches, their clinical gain in 
photon therapy appears very limited, compared to MidP strategy. 
1.4. What about the clinical target volume? 
Even though local relapse usually occurs into the GTV, some loco-regional recurrences 
might be attributed, at least partially, to a lack of microscopic disease coverage. This 
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hypothesis has been suggested in a study, in which patients at high risk of microscopic 
disease extension were more subject to develop loco-regional relapse than distant 
metastasis after stereotactic body radiation therapy (SBRT), especially if the dose 
surrounding the GTV was low [227]. It would be interesting to confirm these data in 
order to identify tumors at high risk of microscopic extension and to appraise the 
impact of adding a CTV margin for the treatment of selected early stage NSCLC 
patients. 
However, as for LA stage NSCLC patients, the next question will be the most 
appropriate CTV margin value. In the setting of LA stage NSCLC, an extension from 
GTV to CTV of 5 mm both for primary tumor and involved lymph nodes is currently 
applied.  In agreement with our first study results (see Chapter 3), several authors 
conclude that CT images using lung window lead to a large overestimation of the true 
tumor volume [87, 88, 149, 228]. It could be hypothesized that defining the tumor on 
this image (i.e. overestimating the GTV) covers a part of the microscopic tumor 
extension, offsetting the lack of CTV margin. 
Hence, an accurate assessment of the CTV margin is crucial, in particular in the era of 
dose escalation and adaptive radiotherapy, where the GTV tends to be thoroughly 
defined and geometric uncertainties are minimized. Actually, a PET-based GTV 
definition and reduced PTV margin could lead to miss part of the target if CTV margin 
is not adequately estimated. 
Nonetheless, this estimation is a challenging task, as the CTV correlation has to be 
performed between some imaging and the true microscopic tumor volume on 
pathology. Previous analyses reporting the evaluation of microscopic tumor extension 
in NSCLC were methodologically heterogeneous with resulting CTV margin values 
from 5 to up to 22.5 mm [87, 149, 228-230]. Additional assessment of microscopic 
disease extension should be investigated with a robust and reliable method. 
Finally, an appealing approach would be to image the tumor cell density in order to 
differentiate the macroscopic area from the microscopic extension. This decisive 
information combined with the integration of TCP-NTCP model parameters and 
geometric uncertainties directly into the optimization process, might lead to 
probabilistic models of 3D dose distribution and progressively replace GTV, CTV and 
PTV concepts, according to the tumor cell density.  
1.5. Particle therapy 
In recent years, particle therapy (PT) has gained increasing attention. Indeed, it 
demonstrates better dose distribution and physical properties compared to photon 
therapy together with superior biological properties (for carbons). Theoretically, PT 
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could lead to an increased therapeutic index, either escalating the dose to TVs while 
keeping isotoxic doses to OARs or decreasing toxicities while using conventional 
doses. However, the dose distribution obtained with PT is very sensitive to moving 
target and anatomical change in tumor and surrounding tissues. It is thus essential to 
properly include tumor motion, range and set-up uncertainties in treatment planning.  
The availability of 4D imaging and motion compensation techniques might be even 
more critical for PT than for photon therapy, especially in pencil beam scanning (PBS) 
delivery, where interference between dynamic beam delivery and motion of TVs and 
OARs can cause complex patterns of over and under dosage within the target. This 
interplay effect can be mitigated by using fractionated treatment and multiple 
treatment fields. Additional techniques, such as rescanning, gating or larger spot size 
scanning could also optimize the dose distribution, especially in hypo-fractionation 
treatment [231]. For moderate tumor motion, homogeneous dose distribution can be 
obtained when using conventional fractionation and rescanning, while for large tumor 
motion (>20 mm), only gating techniques combined with large spot scanning might be 
effective to reduce the breathing motion effect [231]. Although the gating approach 
requires an onboard imaging device and seems technically challenging, like in photon 
therapy, this strategy might become feasible for clinical use in the near future. By 
contrast, in addition to be technically very demanding, the tracking approach would 
not necessarily reduce the interplay effect and is not suitable for LA stages NSCLC, as 
primary tumor and positive lymph nodes can move differently.  
Eventually, besides the technical difficulties in PT, the cost effectiveness of the 
technique is questioned. Although numerous planning studies have shown the 
dosimetric benefits of protons over photons, randomized controlled trials comparing 
photons and PT are largely lacking, especially in NSCLC [232, 233]. In early stage lung 
cancer, clinical data tend to demonstrate that SBRT is comparable to protons in terms 
of survival outcome even though the latter present a highly favorable toxicity profile. 
In contrast, for LA stages NSCLC, PT might appear in the near future as a new tool to 
improve local control, at least in a subset of patients, provided that related technical 
issues will be adequately managed and well-designed and prospective trials with 
regards to current photon radiation treatments will be conducted. 
2. Improving the regional control: a multi-modality challenge 
In our dose escalation study, we observed a high rate of regional recurrence, as 
discussed in Chapter 4. Actually, 5 patients (38.5%) developed out of field recurrences 
while 1 patient (7.7%) experienced an in field recurrence.  
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NSCLC is characterized by a high risk of occult lymph node metastasis, even for early 
stages [234]. In the past, elective nodal irradiation (ENI), i.e. clinically or radiologically 
uninvolved lymph nodes, was recommended to cover the potential microscopic tumor 
invasion. Nonetheless, since the use of PET/CT for initial NSCLC staging, it is 
commonly accepted that only involved lymph nodes have to be included in the 
radiation field, given the quite low risk of out of field lymph node recurrence. Some 
consider this risk, estimated at 5-10%, as relatively low, whereas others estimate it as 
meaningful. Surprisingly, in a recent systematic review, Kepka et al. showed that the 
rate of out of field regional recurrence was substantially similar after stereotactic 
treatment for early stages NSCLC and conventional treatment for LA stages NSCLC 
[235]. Likewise, a recent study of Grills et al. demonstrated that T2 lung tumors (>3 
cm) treated by SBRT have the same LC than T1 tumors (<3 cm) but a poorer OS, 
related to a higher rate of regional recurrences [236]. These findings together with 
our trial results might lead to two observations. First, the dose gradient delivered with 
new radiation techniques, such as IMRT or even worse with proton therapy, is steeper 
than with 2D or 3D-CRT. Consequently, incidental doses to radiologically uninvolved 
(but potentially invaded by microscopic tumor cells) mediastinal, contralateral or sub-
clavicular lymph nodes are by far less than 40-50 Gy, which were doses classically 
delivered in ENI. However, it seems inconceivable to go back to this old practice 
because ENI increases toxicity and hampers delivering a high dose to the primary 
tumor, which remains the first site of relapse. Second, the initial mediastinal staging of 
the disease has to be optimal, notably using PET/CT imaging, EBUS/EUS or 
mediastinoscopy. In case of definitive radiotherapy, it appears crucial to keep the 
time-interval between the PET/CT imaging and the start of RT as short as possible to 
avoid false negative results. In that context, it might be interesting to perform a new 
planning PET/CT, as presented in our study, covering the whole LN stations, from 1 to 
2 weeks before the start of radiotherapy, as part of the simulation step. However, 
PET/CT imaging is not able to identify microscopic tumor extension and its sensibility 
decreases from 91% for enlarged LN to 75% for LN of <1cm in short axis on CT 
images [237]. It is thus important not to be overconfident on imaging and the final 
decision to selectively irradiate a PET negative lymph node suspicious on CT imaging 
remains at the radiation oncologist evaluation. Eventually, the question of a more 
aggressive mediastinal staging arises. Would it be more appropriate to perform a 
mediastinoscopy or even thoracoscopy (for station 5 or 6) with sampling of whole 
accessible nodal stations before each radical RT for early stage or CRT for LA stage 
NSCLC? 
Despite the current precautions, it is likely that regional relapse will appear in a few 
cases with the development of extremely conformal delivery radiation treatment. It 
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might be valuable to pursue research on additional molecules acting against micro-
metastasis either concomitantly or in adjuvant therapy after definitive CRT. It would 
be also interesting to identify biomarkers, predictive and prognosis indicators to 
select those patients that will most likely benefit from these molecules, including 
targeted therapy, immunotherapy or new chemotherapy agents, among others. This 
topic will be developed in the next paragraph. 
3. Improving the distant control: a key issue for the future 
Distant progression remains an issue in the treatment of NSCLC, as illustrated in our 
study (Chapter 4) and in many other trials. The local, the regional as well as the 
distant tumor control might affect overall survival. In that regard, novel 
radiosensitizing systemic cytotoxic agents and drugs targeting specific molecular 
pathways, combined with technologic progresses in RT, might decrease both loco-
regional and distant risk of relapse, thus improving the outcome of these patients.  
Since last decade, considerable investigations have been conducted in the field of 
molecular biology leading to the development of several molecular targeted therapy 
agents for NSCLC patients. Given the good results of agents directed against epidermal 
growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptors, 
tyrosine kinase inhibitors (TKI) or anti-VEGF antibodies in advanced metastatic 
disease, it might be expected that they would also prove some efficiency in combined 
modality treatment for LA advanced stage NSCLC [238]. Nevertheless, it must be 
admitted that, so far, these drugs have failed to demonstrate a gain when associated 
with concurrent chemo-radiotherapy [239, 240]. However, these disappointing 
results might stem from the lack of patient selection for the target or from a negative 
interaction in some patients when chemotherapy and EGFR TKI were prescribed 
concomitantly. These results highlight once again the importance of improving our 
knowledge on lung cancer biology. Ongoing research will precise the value of these 
new agents as part of the curative intent multi-modality treatment.  
Future areas of research encompass immunotherapy that offers exciting prospects for 
the treatment of lung cancer. Currently, ongoing studies are assessing the 
opportunities of antigen-dependent immunotherapy, including vaccines and antigen-
independent immunotherapy, targeting immune checkpoints. 
In addition to novel therapies development, the abscopal effect of radiotherapy gains 
increasing interest [241-244]. Although biological and cellular mechanisms are still 
not well understood, this immunologically mediated phenomenon reduces or inhibits 
tumor growth outside the irradiation field by stimulating the immune response, 
notably by an increased tumor antigen presentation due to the radiation-induced 
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inflammation. Consequently, it appears promising to study, among others, the 
combination of anti cytotoxic T-lymphocytes-associated protein 4 (CTLA 4), 
programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitor 
agents and radiotherapy for potentiating the anti-tumor immune response [245-248]. 
It is assumed that efficacy will be based on the association of several drugs but the 
optimal combination and sequence of chemotherapy, radiotherapy and 
immunotherapy to ensure maximum synergy remains to be determined. 
In the foreseeable future, one might expect the generalization of sequencing the whole 
genome and transcriptome. This might help to identify and study all specific 
oncogenic alterations, which would accelerate the development of agents with highly 
specific activity. 
4. Decreasing toxicities: an ambitious daily concern 
As already mentioned in Chapter 1, the first step in toxicity assessment is probably the 
standardization of OARs contours, dosimetric constraints definition and classification 
of adverse effects. 
Then, the use of highly conformal radiation delivery techniques, including IMRT, SBRT 
and PT, represents an opportunity to improve dose distribution and reduce potential 
radio-induced early and late effects.  
Nonetheless, several patients with centrally located lung tumors present, at diagnosis, 
a mediastinal involvement that precludes dose escalation, even with novel radiation 
technique, since the probability of adverse effects remains extremely high. For these 
patients, therapeutic prospects are very limited and combining RT with innovative 
systemic therapeutic agents, as discussed above, might increase tumor local control. 
In these particular cases, the choice of a sequential CRT approach with a highly 
effective drug would potentially be of interest. In selected patients with good response 
on the primary site, a dose escalation RT could be re-considered. 
Moreover, it seems crucial to develop accurate biomarkers able to predict the risk of 
early and late toxicities.  In this way, it would be easier to select patients for more 
aggressive treatment, e.g. safe and isotoxic dose escalation. 
Eventually, pharmacological normal tissue protection might be another attractive field 
of research. In that regard, investigation focused on the pathogenesis of radio-induced 
pneumonitis, esophagitis and mediastinal organ damages will be required to identify 
appropriate targets for preventive therapy. Using such molecules would allow to 
increase local tumor control, especially when OARs are dose-limiting.  
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5. Perspectives conclusion 
Survival of LA NSCLC patients depends primarily on local tumor control but also on 
the control of micro-metastases located regionally or distantly. Therefore, it is crucial 
to act at every level to improve patient’s outcome. 
Refinement of anatomical and functional imaging together with an optimal 
management of geometric uncertainties should allow the generalization of clinical 
daily use of innovative radiation techniques that are essential to ensure a better local 
tumor control. 
Additionally, combination of multiple treatments, including novel therapeutic agents, 
is a promising and active field of research, which is of particular importance to act in 
synergy on microscopic tumor cells. 
More than ever, a better understanding of lung cancer biology is a challenging but 
mandatory step towards personalized management and improved outcome of NSCLC 
patients. 
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Appendix A 
TNM classification for non-small cell lung cancer (7th edition AJCC) 
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Appendix B: Supplementary data for the dose escalation study 
(Chapter 4) 
Table 1. Measurement of SULpeak (PERCIST), SUVmax (EORTC) and longest diameter (RECIST 1.1) 
of the primary tumor for all patients 
 PERCIST SULpeak  EORTC SUVmax  RECIST 1.1 (mm)  
 t0 t1 t2 t3 t4 t0 t1 t2 t3 t4 t0 t1 t2 t3 t4 
P1 9.8 2.5 5.1 10.6 - 16.4 3.9 9.2 18.5 - 55 51 NM NM - 
P2 11.1 2.6 3.4 2.8 3.4 16.0 4.4 5.1 4.0 2.9 58 46 42 35 35 
P3 3.9 1.6 1.9 - - 6.2 2.3 2.7 - - 34 34 29 - - 
P4 8.4 2.6 - - - 12.8 4.2 - - - 50 37 - - - 
P5 5.5 3.0 1.9 1.9 2.0 10.0 5.2 2.6 2.8 2.5 46 37 29 26 31 
P6 9.6 3.5 2.9 4.0 - 16.1 5.9 4.7 6.6 - 68 54 44 42 - 
P7 4.3 1.5 1.5 1.2 0.8 12.7 4.2 5.0 4.1 4.2 57 54 44 42 NM 
P8 7.4 9.6 7.2 - - 10.5 13.1 10.4 - - 81 64 54 - - 
P9 5.1 4.3 1.8 1.3 1.4 10.3 6.2 2.8 0.7 0.7 30 30 27 21 17 
P10 10.1 1.9 2.3 2.0 - 19.4 3.1 3.3 3.3 - 49 31 31 NM - 
P11 9.9 1.2 0.8 0.8 1.3 17.2 1.8 1.1 1.3 1.4 27 14 12 9 7 
P12 3.2 1.8 1.3 0.4 0.6 7.5 2.8 6.5 1.1 1.1 35 29 26 NM NM 
P13 7.4 3.5 1.4 2.3 1.6 18.8 7.6 5.1 5.5 3.4 47 25 NM 26 26 
Abbreviation: t0, baseline; t1, 2 months post-treatment; t2, 6 months post-treatment; t3, 1 year post-
treatment; t4, 2 years post-treatment; NM, non-measurable. 
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Table 2. Overall survival 
OVERALL SURVIVAL 
Characteristics  
Total 
N=13 
Survie Number of patients alive 7 (53.8%) 
 Number of patients deceased 6 (46.2%) 
   
Kaplan Meier estimate of OS (months) median NE 
 CI95 (13.85 - NE) 
 minimum 4.9 
 maximum 46.3 
   
OS rate at 6 months 92.3% 
 12 months 84.6% 
 18 months 61.5% 
 24 months 52.8% 
 36 months 52.8% 
Note: NE = Not Estimable due to insufficient events. 
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Table 3. Overall progression free survival  
OVERALL PROGRESSION FREE SURVIVAL 
Characteristics  
Total 
N=13 
Overall progression Number of patients with overall progression 7 (53.8%) 
 Number of patients without any progression 6 (46.2%) 
   
Kaplan Meier estimate  
of Overall PFS (months) 
median 18.78 
 CI95 (4.31 - NE) 
 minimum 2.6 
 maximum 40.6 
   
Overall PFS rate at 6 months 76.9% 
 12 months 53.9% 
 18 months 53.9% 
 24 months 46.2% 
 36 months 34.6% 
Note: NE = Not Estimable due to insufficient events. 
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Table 4. Local progression free survival  
LOCAL PROGRESSION FREE SURVIVAL 
Characteristics  
Total 
N=13 
Local progression Number of patients  
with local progression 
2 (15.4%) 
 Number of patients  
without any local progression 
 
11 (84.6%) 
Kaplan Meier estimate  
of local PFS (months) 
median NE 
 CI95 (9.18 - NE) 
 minimum 4.9 
 maximum 46.3 
   
Local PFS rate at 6 months 92.3% 
 12 months 76.9% 
 18 months 61.5% 
 24 months 52.8% 
 36 months 52.8% 
Note: NE = Not Estimable due to insufficient events. 
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Table 5. Regional progression free survival 
REGIONAL PROGRESSION FREE SURVIVAL 
Characteristics  
Total 
N=13 
Regional progression Number of patients  
with regional progression 
6 (46.2%) 
 Number of patients  
without any regional progression 
7 (53.8%) 
   
Kaplan Meier estimate  
of Regional PFS (months) 
median 25.13 
 CI95 (7.20 - NE) 
 minimum 4.3 
 maximum 40.6 
   
Regional PFS rate at 6 months 92.3% 
 12 months 61.5% 
 18 months 52.8% 
 24 months 52.8% 
 36 months 31.7% 
Note: NE = Not Estimable due to insufficient events. 
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Table 6. Distant progression free survival 
DISTANT PROGRESSION FREE SURVIVAL 
Characteristics  
Total 
N=13 
Distant progression Number of patients  
with distant progression 
6 (46.2%) 
 Number of patients  
without any distant progression 
7 (53.8%) 
   
Kaplan Meier estimate  
of Distant PFS (months) 
median 18.78 
 CI95 (4.90-NE)   
 minimum 2.6 
 maximum 40.6 
   
Distant PFS rate at 6 months 76.9% 
 12 months 61.5% 
 18 months 53.9% 
 24 months 46.2% 
 36 months 34.6% 
Note: NE = Not Estimable due to insufficient events. 
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Table 7. Primary tumor response rates for PERCIST and RECIST 1.1. methods. 
FU 
interval 
2 months 6 months 12 months 24 months 
 PERCIST RECIST PERCIST RECIST PERCIST RECIST PERCIST RECIST 
Number of 
patients 
alive 
13 13 12 12 10 10 7 7 
Number of 
evaluable 
patients 
11 13 11 10 10 7 7 5 
CR 8 0 9 0 8 0 7 0 
PR 2 3 0 7 0 7 0 4 
SD 1 10 1 5 0 0 0 0 
PD 0 0 1 0 2 0 0 1 
Abbreviations:  FU, follow-up; CR, complete response; PR, partial response; SD, stable disease; PD, 
progressive disease. 
Some lesions were not evaluable on PET imaging due to radio-induced lung inflammation and on 
CT imaging due to non-measurable target lesions according to RECIST 1.1. 
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Figure 1. Evolution of the primary tumor SULpeak at each time point, with median values of 7.40, 
2.62, 1.93, 1.92 and 1.41 at baseline, 2, 6, 12 and 24 months post-treatment, respectively.  
SULpeak decreases dramatically at 2 months after CRT and remains at the background level as seen 
in SBRT series. P1 and P6 recurred locally at 6 and 12 months, respectively. P3, P4 and P8 died 
before 1-year follow-up, while P1, P6 and P10 died before 2-year follow-up. 
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Figure 2. a Kaplan-Meir curves of overall survival 
 
 
Figure 2. b Kaplan-Meir curves of overall progression free survival  
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Figure 2. c Kaplan-Meir curves of local progression free survival 
 
 
Figure 2. d Kaplan-Meir curves of regional progression free survival 
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Figure 2. e Kaplan-Meir curves of distant progression free survival 
 
 
Figure 3. Diagram of quality of life (QoL) for all patients before, during and after chemo-
radiation. QoL is presented as mean ± 1 standard deviation. As expected, it degrades during the 
treatment but improved 2 months after. The decreasing QoL at 2 years after chemo-radiation 
relies on tumor recurrences for 7 patients, who received salvage chemotherapy. 
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Appendix C : Supplementary data for the mid-position study 
(Chapter 5) 
1. Motion estimation 
1.1. Registration of the 4D CT phases 
Non-rigid registration was performed between a reference CT phase (maximum 
exhale phase in this study, as it corresponds to the trigger for both CT and PET 
reconstruction) and all other phases of the 4D-CT in order to estimate the internal 
deformations in the thorax. The registration method used in this study was a non-
parametric registration which combines the phase-based displacement field 
estimation of the Morphon algorithm with a diffeomorphic field accumulation [119]. 
The diffeomorphic accumulation allows us to define the displacement as the 
transformation resulting from a time-invariant velocity field. The operation that 
converts velocity into displacement is the field exponential, denoted Φ in the 
following, and the velocity can then be recovered using the field logarithm. The 
interest of using the velocity, i.e. working in the “log-domain”, is that it becomes 
possible to perform Euclidean operations on the vector field, which are not consistent 
when dealing with displacement fields. For instance, the averaging of two velocity 
fields can be achieved using the mean of vector components, while this does not make 
sense for displacement fields, as illustrated in Fig. 4 in the case of two diffeomorphic 
fields D1 and D2 representing equal rotations but in opposite directions. One can 
clearly see that the mean of the two displacement fields does not reflect the ``average'' 
transformation but leads to a global ``shrinking''. In the contrary, the mean of 
corresponding velocity fields V1 and V2 leads to the identity transformation, which 
reflects the ``average'' transformation.  
  
 
Figure 4. Computing the average of two invertible displacement fields D1 and D2 using a simple 
Euclidean operation (mean vector computation) on their time-invariant velocity fields V1=Φ(D1) 
and V2=Φ(D2).  
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1.2. Constrained registration of the 4D PET phases 
Once the anatomical deformations have been estimated based on the 4D-CT images, these 
deformations were used to estimate the motion between PET images by limiting the 
possible solutions. However, as the binning is different in 4D-PET and 4D CT acquisition, 
the estimated deformations of the 4D CT may not directly applied on a PET phase. Under 
the assumption that the breathing is sufficiently reproducible along several cycles, the 
possible respiratory motions are limited to the trajectory defined by all possible 
interpolations between 2 successive displacement fields resulting from CT registrations. 
This interpolation is computed in the log-domain in order to preserve diffeomorphism.  
Limiting the motion to the CT-based trajectory reduces the number of optimization 
variables from 3 times the number of voxels to only 1 variable, which is the temporal 
position on the trajectory. The registration of PET images then becomes a simple 
optimization of a metric (sum of square differences was chosen in this study) according to 
one single variable, which is the position on the trajectory.  
Let us denote V(i) the velocity field resulting from the registration between the CT phase i 
and the reference. The corresponding displacement field is given by D(i) = Φ(V(i)). For 
each PET phase j, the objective function of the registration process is then given by: 
, 
where t is the optimization variable and  denotes the deformation of the PET 
phase pj by the displacement field D(t). This field is computed using linear interpolation 
between velocity fields: 
 , 
where underscore denotes the rounding to the closest lower integer and overscore denotes 
the rounding to the closest higher integer. 
This makes the PET registration very fast, robust and physically meaningful in spite of the 
lack of reliable information in 4D PET images.  
1.3. Mid-position 3D PET reconstruction 
The time-weighted average of all inter-CT deformations, which is computed in the log-
domain for the reason explained previously, gives the displacement from the reference 
phase to the average anatomical position (i.e. mid-position). Then the difference between 
this average deformation and each inter-PET deformation was computed in the log-domain, 
resulting in a transformation from each PET phase to the mid-position.  
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The PET phases were deformed accordingly and summed to produce a mid-position 3D 
PET image. 
2. Monte Carlo (MC) simulations: detailed results 
2.1. MC results for primary tumor volumes defined on CT image 
Table reporting, for each patient, the relative difference for various dose-volume 
histograms (DVH) metrics between the 3D MC planned dose distributions and Interplay 
Simulated (IS) or No Interplay (NI) dose distributions calculated using a 4D MC model for 
both concepts, i.e. mid-position and ITV. 
 
 Patient 
no 
Parameters  PTVCT P  
IS 
Δ 
 
 
NI 
Δ 
 
PTVCT 
P 
 
IS 
Δ 
 
 
NI 
Δ 
 
   MidP MidP MidP MidP MidP ITV ITV ITV ITV ITV 
   (Gy) (Gy) (%) (Gy) (%) (Gy) (Gy) (%) (Gy) (%) 
SBRT 1 Dmean 
D99 
D95 
D2 
56.13 
51.31 
54.11 
58.14 
56.16 
52.01 
53.53 
58.39 
0.06 
1.29 
-1.07 
0.46 
56.24 
52.01 
53.55 
58.40 
0.22 
1.29 
-1.03 
0.48 
58.58 
51.54 
54.30 
61.07 
59.69 
56.16 
57.57 
61.84 
2.05 
8.55 
6.05 
1.43 
59.70 
56.09 
57.54 
61.75 
2.07 
8.43 
5.99 
1.27 
 2 Dmean 
D99 
D95 
D2 
55.89 
53.03 
54.08 
58.49 
55.42 
52.57 
53.67 
57.45 
-0.87 
-0.85 
-0.76 
-1.94 
55.48 
52.68 
53.81 
57.31 
-0.76 
-0.66 
-0.50 
-2.19 
57.78 
52.60 
54.45 
60.56 
57.94 
55.88 
56.61 
59.72 
0.29 
6.09 
4.00 
-1.55 
58.04 
55.98 
56.72 
59.91 
0.48 
6.26 
4.21 
-1.20 
 3 Dmean 
D99 
D95 
D2 
63.53 
56.93 
60.25 
66.40 
62.98 
56.36 
59.78 
65.70 
-0.91 
-0.95 
-0.79 
-1.17 
63.04 
56.42 
59.80 
65.72 
-0.83 
-0.84 
-0.76 
-1.13 
64.03 
57.01 
60.37 
67.01 
63.72 
57.43 
60.58 
66.40 
-0.52 
0.69 
0.34 
-1.02 
63.81 
57.69 
60.77 
66.48 
-0.36 
1.12 
0.67 
-0.88 
 4 Dmean 
D99 
D95 
D2 
55.87 
52.98 
54.20 
57.58 
54.84 
51.81 
52.79 
57.14 
-1.90 
-2.16 
-2.61 
-0.80 
54.67 
51.88 
52.70 
56.70 
-2.23 
-2.02 
-2.79 
-1.62 
56.48 
53.00 
54.29 
58.37 
55.73 
53.70 
54.30 
57.37 
-1.39 
1.31 
0.02 
-1.85 
55.87 
53.78 
54.41 
57.32 
-1.13 
1.45 
0.22 
-1.93 
 5 Dmean 
D99 
D95 
D2 
51.21 
46.47 
48.41 
53.19 
50.61 
43.01 
46.32 
53.61 
-1.26 
-7.20 
-4.35 
0.86 
51.57 
45.71 
48.22 
53.34 
0.75 
-1.59 
-0.40 
0.31 
51.84 
46.27 
48.58 
54.04 
52.63 
49.06 
50.41 
54.42 
1.64 
5.82 
3.82 
0.80 
52.75 
49.20 
50.63 
54.39 
1.89 
6.10 
4.26 
0.73 
 6 Dmean 
D99 
D95 
D2 
55.96 
53.26 
54.17 
57.85 
55.93 
52.98 
54.36 
57.47 
-0.06 
-0.51 
0.36 
-0.71 
55.99 
53.11 
54.34 
57.60 
0.04 
-0.28 
0.32 
-0.47 
58.57 
51.79 
54.51 
61.07 
59.36 
56.06 
57.65 
60.70 
1.47 
7.91 
5.82 
-0.70 
59.42 
56.05 
57.71 
60.80 
1.57 
7.89 
5.92 
-0.50 
 7 Dmean 
D99 
D95 
D2 
57.50 
52.16 
54.25 
60.08 
56.85 
52.41 
53.89 
59.06 
-1.21 
0.46 
-0.67 
-1.88 
56.88 
52.38 
53.87 
59.22 
-1.15 
0.40 
-0.71 
-1.58 
58.56 
52.24 
54.33 
61.56 
58.55 
55.02 
56.41 
60.79 
-0.02 
5.14 
3.85 
-1.43 
58.60 
55.05 
56.46 
60.79 
0.08 
5.20 
3.95 
-1.43 
 8 Dmean 
D99 
D95 
D2 
56.63 
52.49 
54.24 
58.43 
55.27 
51.76 
53.07 
56.80 
-2.52 
-1.36 
-2.16 
-3.01 
55.27 
51.76 
53.08 
56.80 
-2.52 
-1.36 
-2.15 
-3.01 
56.91 
52.39 
54.25 
59.03 
57.14 
54.32 
55.29 
58.72 
0.41 
3.57 
1.92 
-0.58 
57.14 
54.17 
55.27 
58.67 
0.41 
3.29 
1.89 
-0.67 
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SIB 9 Dmean 
D99 
D95 
D2 
77.62 
60.87 
63.51 
87.11 
77.60 
60.66 
63.43 
86.70 
-0.03 
-0.33 
-0.13 
-0.66 
77.75 
61.05 
63.71 
86.83 
0.21 
0.30 
0.33 
-0.46 
76.89 
59.92 
62.58 
87.60 
78.18 
61.62 
64.46 
87.33 
2.08 
2.72 
3.01 
-0.44 
78.23 
61.67 
64.41 
87.37 
2.14 
2.80 
2.93 
-0.38 
 10 Dmean 
D99 
D95 
D2 
78.48 
60.23 
62.81 
88.67 
78.51 
60.61 
63.23 
88.42 
0.05 
0.62 
0.67 
-0.39 
78.55 
60.49 
63.20 
88.47 
0.11 
0.42 
0.62 
-0.31 
77.97 
58.89 
61.62 
87.80 
79.14 
61.21 
62.80 
87.64 
1.87 
3.72 
1.89 
-0.24 
79.16 
61.12 
62.81 
87.58 
1.90 
3.58 
1.90 
-0.34 
 11 Dmean 
D99 
D95 
D2 
110.51 
68.24 
86.62 
124.64 
110.19 
69.52 
87.09 
123.93 
-0.51 
2.04 
0.76 
-1.13 
110.34 
69.42 
87.07 
124.15 
-0.28 
1.89 
0.72 
-0.77 
92.07 
54.58 
69.89 
106.50 
94.29 
59.35 
74.47 
106.22 
3.56 
7.63 
7.32 
-0.45 
94.43 
59.34 
74.46 
106.28 
3.77 
7.62 
7.31 
-0.35 
 12 Dmean 
D99 
D95 
D2 
65.88 
54.69 
61.44 
76.50 
66.15 
55.57 
61.81 
76.65 
0.45 
1.40 
0.59 
0.23 
66.23 
55.56 
61.94 
76.65 
0.56 
1.39 
0.79 
0.23 
64.57 
52.67 
60.18 
75.58 
65.36 
55.88 
60.57 
75.92 
1.25 
5.13 
0.63 
0.55 
65.43 
56.06 
60.82 
75.91 
1.37 
5.43 
1.02 
0.53 
 13 Dmean 
D99 
D95 
D2 
66.29 
58.35 
61.79 
71.99 
66.05 
57.61 
61.30 
71.81 
-0.39 
-1.18 
-0.79 
-0.29 
66.12 
57.62 
61.45 
71.51 
-0.27 
-1.16 
-0.54 
-0.78 
66.94 
58.66 
62.61 
71.41 
67.22 
62.07 
64.04 
71.50 
0.44 
5.47 
2.29 
0.14 
67.25 
62.12 
64.29 
70.91 
0.49 
5.54 
2.69 
-0.81 
 14 Dmean 
D99 
D95 
D2 
73.01 
59.66 
62.20 
84.82 
72.70 
59.46 
61.99 
84.03 
-0.49 
-0.33 
-0.34 
-1.26 
72.73 
59.63 
62.08 
84.13 
-0.44 
-0.05 
-0.20 
-1.11 
70.66 
58.03 
60.51 
85.96 
71.79 
60.22 
61.39 
85.96 
1.81 
3.51 
1.41 
-1.37 
72.09 
60.40 
61.57 
85.56 
2.29 
3.79 
1.70 
-0.64 
 15 Dmean 
D99 
D95 
D2 
70.76 
56.64 
60.81 
83.14 
70.92 
58.28 
61.18 
82.37 
0.25 
2.61 
0.59 
-1.23 
70.98 
58.30 
61.26 
82.47 
0.35 
2.64 
0.72 
-1.07 
70.59 
56.60 
60.57 
83.64 
72.60 
60.18 
61.37 
83.05 
3.21 
5.72 
1.28 
-0.94 
72.68 
60.15 
61.59 
83.06 
3.34 
5.67 
1.63 
-0.92 
Abbreviations: Patient no, PTVCT, Planning Target Volume defined on CT images; , modified 
CTV volumes expanded by all geometric uncertainties except the tumor motion; Δ, the relative 
difference for various DVH metrics between the 3D MC planned (P) dose distributions and 
Interplay Simulated (IS) or No Interplay (NI) dose distributions; SBRT, Stereotactic Body 
Radiation Therapy; SIB, Simultaneous Integrated Boost; MidP, mid-position; ITV, Internal Target 
Volume. 
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2.2. MC results for primary tumor volumes defined on PET images 
Table reporting, for each patient, the relative difference for various dose-volume 
histograms (DVH) metrics between the 3D MC planned dose distributions and Interplay 
Simulated (IS) or No Interplay (NI) dose distributions calculated using a 4D MC model for 
both concepts, i.e. mid-position and ITV. 
 
 Patient 
no 
Parameters  PTVPET P 
PET
exp
GTV
 
IS 
Δ 
 
PET
exp
GTV
 
NI 
Δ 
 
PTVPET 
P 
PET
exp
GTV
 
IS 
Δ 
 
PET
exp
GTV
 
NI 
Δ 
 
   MidP MidP MidP MidP MidP ITV ITV ITV ITV ITV 
   (Gy) (Gy) (%) (Gy) (%) (Gy) (Gy) (%) (Gy) (%) 
SIB 9 Dmean 
D99 
D95 
D2 
83.70 
77.52 
79.53 
88.12 
83.67 
77.49 
79.68 
87.72 
-0.04 
-0.03 
0.19 
-0.49 
83.81 
77.64 
79.78 
87.82 
0.13 
0.15 
0.30 
-0.37 
83.84 
77.71 
79.53 
88.59 
83.93 
78.07 
79.92 
88.14 
0.11 
0.44 
0.47 
-0.55 
84.02 
78.07 
79.96 
88.24 
0.21 
0.44 
0.52 
-0.44 
 10 Dmean 
D99 
D95 
D2 
86.19 
79.59 
82.17 
90.01 
86.06 
79.76 
82.01 
89.88 
-0.16 
0.21 
-0.19 
-0.16 
86.19 
79.92 
82.25 
89.79 
0.00 
0.40 
0.10 
-0.27 
89.58 
83.31 
85.52 
92.67 
89.68 
83.79 
85.88 
92.51 
0.11 
0.57 
0.43 
-0.19 
89.67 
83.69 
85.86 
92.42 
0.10 
0.45 
0.40 
-0.29 
 11 Dmean 
D99 
D95 
D2 
119.79 
113.95 
115.57 
124.55 
119.26 
113.19 
115.15 
123.73 
-0.44 
-0.64 
-0.35 
-0.69 
119.41 
113.37 
115.31 
123.93 
-0.31 
-0.48 
-0.22 
-0.52 
123.91 
111.98 
117.19 
130.23 
124.89 
118.34 
120.51 
129.78 
0.82 
5.31 
2.76 
-0.37 
125.04 
118.77 
120.74 
129.89 
0.94 
5.66 
2.96 
-0.28 
 12 Dmean 
D99 
D95 
D2 
75.49 
71.82 
72.76 
78.09 
75.71 
72.27 
73.08 
77.95 
0.29 
0.61 
0.43 
-0.19 
75.76 
72.45 
73.23 
78.07 
0.36 
0.84 
0.62 
-0.03 
74.67 
70.99 
71.91 
77.99 
74.95 
71.50 
72.28 
78.15 
0.38 
0.68 
0.50 
0.21 
74.99 
71.59 
72.36 
78.19 
0.43 
0.79 
0.60 
0.26 
 13 Dmean 
D99 
D95 
D2 
67.89 
63.57 
64.73 
72.09 
67.67 
63.57 
64.66 
71.91 
-0.34 
0.00 
-0.11 
-0.28 
67.77 
63.98 
64.91 
71.51 
-0.19 
0.60 
0.26 
-0.87 
67.81 
63.26 
64.74 
71.35 
67.75 
63.53 
64.60 
71.40 
-0.09 
0.40 
-0.20 
0.08 
67.80 
64.13 
65.05 
70.73 
-0.02 
1.30 
0.47 
-0.91 
 14 Dmean 
D99 
D95 
D2 
83.24 
77.80 
80.60 
85.74 
82.75 
77.93 
80.44 
84.87 
-0.60 
0.15 
-0.20 
-1.06 
82.81 
78.02 
80.41 
85.00 
-0.52 
0.26 
-0.24 
-0.89 
83.17 
77.69 
79.32 
87.00 
82.73 
78.43 
79.67 
86.00 
-0.53 
0.90 
0.42 
-1.21 
83.15 
78.98 
80.16 
86.51 
-0.03 
1.57 
1.02 
-0.59 
 15 Dmean 
D99 
D95 
D2 
80.74 
75.50 
76.94 
84.30 
80.48 
76.00 
77.50 
83.34 
-0.32 
0.63 
0.70 
-1.21 
80.57 
75.84 
77.52 
83.43 
-0.22 
0.43 
0.72 
-1.09 
80.90 
76.71 
78.00 
84.61 
80.70 
77.34 
78.38 
83.67 
-0.24 
0.78 
0.48 
-1.18 
80.79 
77.51 
78.42 
83.70 
-0.14 
0.99 
0.53 
-1.14 
Abbreviations: Patient no, PTVPET, Planning Target Volume defined on PET images; 
PET
exp
GTV  , 
modified GTV volumes expanded by all geometric uncertainties except the tumor motion; Δ, the 
relative difference for various DVH metrics between the 3D MC planned (P) dose distributions and 
Interplay Simulated (IS) or No Interplay (NI) dose distributions; SIB, Simultaneous Integrated 
Boost; MidP, mid-position; ITV, Internal Target Volume 
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2.3. MC results for lymph node volumes defined on CT images 
Table reporting, for each patient, the relative difference for various dose-volume 
histograms (DVH) metrics between the 3D MC planned dose distributions and Interplay 
Simulated (IS) or No Interplay (NI) dose distributions calculated using a 4D MC model for 
both concepts, i.e. mid-position and ITV. 
 
 Patient 
no 
Parameters  PTVCT P 
 
IS 
Δ 
 
 
NI 
Δ 
 
PTVCT 
P 
 
IS 
Δ 
 
 
NI 
Δ 
 
   MidP MidP MidP MidP MidP ITV ITV ITV ITV ITV 
   (Gy) (Gy) (%) (Gy) (%) (Gy) (Gy) (%) (Gy) (%) 
SIB 9 Dmean 
D99 
D95 
D2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 10 Dmean 
D99 
D95 
D2 
63.79 
58.66 
60.88 
74.79 
63.63 
57.27 
60.34 
73.13 
-0.26 
-2.23 
-0.86 
-2.65 
63.67 
57.87 
60.71 
72.92 
-0.20 
-1.27 
-0.28 
-3.00 
63.23 
57.02 
60.29 
76.63 
63.33 
60.37 
61.14 
73.99 
0.16 
5.36 
1.36 
-4.22 
63.42 
60.54 
61.35 
74.18 
0.29 
5.63 
1.69 
-3.91 
 11 Dmean 
D99 
D95 
D2 
62.28 
58.44 
59.63 
73.92 
62.29 
58.66 
59.75 
74.36 
0.02 
0.36 
0.20 
0.70 
62.21 
58.66 
59.70 
74.10 
-0.11 
0.36 
0.11 
0.29 
63.78 
55.29 
59.57 
79.51 
64.05 
60.39 
61.48 
76.48 
0.44 
8.15 
3.05 
-4.85 
64.01 
60.35 
61.43 
76.33 
0.37 
8.09 
2.97 
-5.10 
 12 Dmean 
D99 
D95 
D2 
63.22 
59.41 
61.18 
65.98 
63.32 
59.58 
61.21 
65.80 
0.16 
0.28 
0.05 
-0.30 
63.38 
59.47 
61.50 
65.82 
0.26 
0.10 
0.51 
-0.26 
61.57 
58.51 
59.69 
64.91 
61.77 
59.45 
60.13 
64.56 
0.33 
1.51 
0.71 
-0.56 
61.84 
59.77 
60.44 
64.45 
0.43 
2.02 
1.20 
-0.72 
 13 Dmean 
D99 
D95 
D2 
62.85 
59.33 
60.96 
65.22 
62.72 
59.16 
60.96 
65.12 
-0.22 
-0.27 
0.00 
-0.17 
62.85 
59.26 
61.12 
65.17 
0.00 
-0.10 
0.25 
-0.08 
64.12 
59.91 
62.01 
66.88 
64.11 
61.35 
62.57 
66.39 
-0.02 
2.31 
0.89 
-0.79 
64.20 
61.67 
62.73 
66.26 
0.13 
2.82 
1.15 
-1.01 
 14 Dmean 
D99 
D95 
D2 
65.13 
60.17 
61.43 
81.75 
64.58 
60.03 
61.24 
80.89 
-0.88 
-0.23 
-0.31 
-1.38 
64.63 
60.19 
61.29 
80.86 
-0.80 
0.03 
-0.23 
-1.43 
64.46 
59.62 
60.95 
83.14 
63.68 
60.35 
60.97 
79.80 
-1.25 
1.17 
0.03 
-5.34 
63.77 
60.51 
61.04 
79.93 
-1.10 
1.43 
0.15 
-5.14 
 15 Dmean 
D99 
D95 
D2 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Abbreviations: Patient no, PTVCT, Planning Target Volume defined on CT images; , modified 
GTV volumes expanded by all geometric uncertainties except the tumor motion; Δ, the relative 
difference for various DVH metrics between the 3D MC planned (P) dose distributions and 
Interplay Simulated (IS) or No Interplay (NI) dose distributions; SIB, Simultaneous Integrated 
Boost; MidP, mid-position; ITV, Internal Target Volume 
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